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SUMMARY 
 
 
 
Genetic engineering has been employed in the design of novel protein 
polymers composed of repetitive amino acid sequences or peptide blocks whose 
structural complexity imparts distinct mechanical, chemical or biological properties.  
Recently, we have reported the synthesis of elastin-mimetic multiblock copolymer 
composed of identical endblocks derived from self-associating, hydrophobic 
sequences that display plastic-like mechanical responses (Ile-Pro-Ala-Val-Gly), 
separated by a central block that is both hydrophilic and elastomeric (Val-Pro-Gly-
Glu-Gly).  Significantly, these multiblock systems afford the ability to form physical or 
virtual crosslinked networks through the self-association of chemically similar domains 
under physiologically relevant conditions (pH 7.4, 37°C).   
Recombinant synthesis of elastin-mimetic proteins has been employed for 
several decades, however, long-term biocompatibility and biostability of such proteins 
was not fully defined.  We present virtually crosslinked elastin-mimetic proteins which 
exhibit exceptional biocompatibility and long-term biostability over a period of at least 
seven months.  This report is the first evidence of a non-chemically or ionically 
crosslinked system that exhibits long-term in vivo stability.  
Although, physically crosslinked protein-based materials possess a number of 
advantages over their chemically crosslinked counterparts, physical crosslinks and 
the related domains so formed may be deformed or damaged at applied stresses 
lower than those required to disrupt covalent crosslinks.  In this regard, we have 
synthesized a new class of recombinant elastin-mimetic triblock copolymer capable of 
both physical and chemical crosslinking.  We have demonstrated that chemical 
crosslinking provides an independent mechanism for control of protein mechanical 
 xv 
 
responses.  Specifically, elastic modulus was enhanced and creep strain reduced 
through the addition of chemical crosslinking sites.   
A number of reports have described the design of synthetic genes, which 
encode elastin-like proteins for bacterial expression in Escherichia coli.  Although 
advantages with this expression system exist, significant limitations including the lack 
of eukaryotic post-translational systems, the tendency to sequester mammalian 
proteins into inclusion bodies, difficult purification protocols, and endotoxin 
contamination have been noted.  We demonstrate the expression of a recombinant 
elastin-mimetic protein from P. pastoris.  A novel synthetic strategy, monomer library 
concatamerization, was utilized in designing non-repetitive elastin genes for highly 
repetitive protein sequences.  It is likely that this strategy will be useful for creating 
large, repetitive genes for a variety of expression systems in order to more closely 
approach the genetic diversity inherent to native DNA sequences.    
All told, elastin-based protein polymers are a promising class of material 
characterized by high degree of biocompatibility, excellent biostability, and a tunable 
range of mechanical properties from plastic to elastic.  A variety of options facilitate 
the processing of these biopolymers into chemically crosslinked or non-crosslinked 
gels, films, or nanofibers for any of a number of implant applications including 
structural components of artificial organs and engineered living tissues, carriers for 
controlled drug release, or biocompatible surface coatings. 
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CHAPTER I 
INTRODUCTION 
 
 
1.1 CENTRAL HYPOTHESIS AND SPECIFIC AIMS 
The central hypothesis encompassing the work described in this manuscript 
states that recombinant elastin proteins can be engineered to exhibit enhanced 
biostability and mechanical properties that closely match those of native elastin thus 
providing a rational approach for generating the elastin component of a tissue 
engineered vascular graft.     
The Central Hypothesis was investigated by pursuing the following specific aims.  
The goal of Specific Aim 1 was to synthesize recombinant elastin-mimetic protein 
polymers that have the capacity to form both physical and chemical crosslinks.  We 
hypothesized that using genetic engineering approaches elastin-mimetic materials can 
be produced with controlled elastomeric properties and enhanced biostability through 
appropriate choice of recombinant peptide sequences that facilitate both chemical and 
physical crosslink formation.  For this aim, two novel elastin-mimetic triblock copolymers 
were engineered, LysB10 and R4.  These results are presented in Chapter 2. 
 The goal of Specific Aim 2 was to characterize the mechanical properties of 
crosslinkable elastin-mimetic triblock copolymers.  We anticipated that the presence of 
chemical and physical crosslinks would act synergistically to improve the modulus of 
elasticity and resilience of elastin films.  Target property endpoints for crosslinkable 
elastin-mimetic triblock copolymers have been defined as exhibiting a modulus of 
elasticity of 0.3-1.3 MPa and greater than 80% resilience over a strain of 30-45%.  
Additionally, we hypothesized that creep responses of elastin films can be improved with 
the incorporation of chemical crosslinks.  Target property endpoints for crosslinkable 
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elastin-mimetic triblock copolymers have been defined as exhibiting less than 10% creep 
above physiologic stresses (45 kPa).  Both LysB10 and R4 proteins were evaluated as 
water-cast films with and without glutaraldehyde (GTA) crosslinking.  Uniaxial stress-
strain responses and creep responses were evaluated.  These results are presented in 
Chapter 2.   
 The goal of Specific Aim 3 was to define the short- and long-term 
biocompatibility and biostability of crosslinkable elastin-mimetic triblock copolymers after 
in vivo implantation.  We hypothesized that elastin-mimetic crosslinked hydrogels would 
exhibit sufficient biocompatibility and enhanced biostability to be used in a vascular 
construct.  Biocompatibility was examined through histological evaluation of the fibrous 
capsule surrounding implanted materials as well as florescent activated cell sorting 
(FACS) analysis of number and type of inflammatory cells present at the implant site.  
These results are presented in Chapters 2 and 3.  Biostability was monitored using 
magnetic resonance imaging (MRI) over a period of seven months.  The methodology 
for assessing biostability was developed using a model protein system and these results 
are presented in Chapter 3. 
 
1.2 MOTIVATION 
The work presented herein was motivated by previous investigations in our 
laboratory and others.  In particular, we have developed a class of recombinant elastin-
mimetic proteins which have the capacity to form physically or virtually crosslinked 
systems [1-3].  These self-assembling triblock elastin copolymers have demonstrated 
that through selective engineering of block structure, a wide range of mechanical 
responses can be produced.  In recent studies we have demonstrated that relatively 
limited changes in chemistry, including midblock size or amino acid sequence, provide 
an additional mechanism for tailoring protein elasticity, resilience, tensile strength, or 
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strain at failure [1, 4, 5].  Specifically, an elastin-mimetic protein was designed with 
midblock and endblocks that were approximately equal in size and displayed significant 
increases in both tensile strength and creep resistance as compared to an elastin-
mimetic protein with endblocks approximately half the size of the midblock [5, 6].  We 
have demonstrated these proteins can find application as gels, films and fiber networks.   
We have demonstrated elastin-mimetic triblock coplymers can be used to 
generate a non-thrombogenic hydrogel coating on the luminal surface of an ePTFE 
vascular prosthesis, and display excellent short-term blood contacting properties of this 
material [7].  Extensive biocompatibility characterization is necessary to assess the 
behavior of these proteins in vivo.  Using a model protein which has been extensively 
characterized in vitro, the methods for assessing biocompatibility and biostability have 
been developed as presented in Chapter 3.  
Additionally, we have explored alternative expression systems for the expression 
of recombinant elastin-mimetic proteins as a method for simplifying purification 
protocols.  In particular, through genetic engineering we have developed elastin-mimetic 
proteins for expression in the methylotrophic yeast, Pichia pastoris.  Of note, we have 
developed a novel genetic engineering strategy to create repetitive elastin polypeptides 
with non-repetitive nucleotide sequences using a concatamerization strategy employing 
random ligation of a library of monomer repeat units.  These results are presented in 
Chapter 4. 
Collectively, these studies demonstrate the need for the development of 
recombinant elastin proteins capable of both physical and chemical crosslinking and 
characterization of their mechanical behaviors, biocompatibility, and biostability. 
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1.3 RATIONAL 
According to the American Heart Association Heart Disease and Stroke 
Statistics-2008 Updates, cardiovascular disease (CVD) is unmistakably a growing 
concern with statistics indicating approximately 500,000 procedures for coronary bypass 
surgery performed in over 250,000 patients each year.  Since 1900 CVD has been the 
leading cause of death in the United States, killing nearly 2,400 American each day, or 
one person every 37 seconds.  Specifically, coronary artery disease accounts for 54% of 
the CVD deaths annually [8]. 
Consequently, the need for a small diameter arterial prosthesis is apparent.  
Although employing polymers such as polytetrafluorethylene have been successful in 
the development of large diameter vascular grafts, the fabrication of a durable small 
diameter prosthesis remains an elusive goal. Biological reactions at the tissue material 
interface resulting from mechanical or compliance mismatch between native artery and 
the arterial replacement material lead to their ultimate failure.  Presently, autologous 
vessels (i.e. saphenous veins and internal mammary arteries) are choice vascular 
replacements, though even these vessels are not sufficient for long term patency.  
Significantly, of the 600,000 coronary bypass operations performed annually, 10-20% of 
patients will require a second operation within 10 years [9]. 
In response to these limitations, strategies to mimic some or all of the 
characteristics of the arterial wall have been pursued.  Current tissue engineering 
strategies provide an opportunity to circumvent maladaptive responses, though 
adequate replacements could be decades away.  Alternatively, the generation of protein 
polymers that mimic native structural proteins offers a replacement strategy to develop a 
vascular graft with clinical performance results that match or exceed those of a native 
vessel.  The reformulation of these proteins into nanofiber networks provides an 
opportunity to optimize the mechanical properties of an arterial bioprosthesis, as well as 
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other biologically related characteristics, thus creating an optimal vascular replacement 
material.  
The long-term goal encompassing this work can be divided into three areas:  (i) to 
synthesize a family of recombinant elastin-mimetic proteins capable of physical and 
chemical crosslinking  (ii) to define their structure-property relationships; and (iii) to 
characterize the capacity of these artificial proteins for the generation of biocompatible 
small diameter blood vessel substitutes with mechanical properties that closely match 
those of native blood vessels.   We anticipate that utilizing recombinant proteins based 
on consideration of the structural properties of the native matrix will lead to the creation 
of vascular conduits with better defined mechanical properties and enhanced 
biodegradation with improved clinical performance characteristics.   
 
1.4 BACKGROUND 
Current pursuits in the discipline of biomedicine, including artificial organs and 
engineered living tissues, are dependent on the ability to generate novel materials, 
fabricate or assemble materials into appropriate 2-D or 3-D structures, and to precisely 
tailor material-related properties in order to achieve a desired clinical response [10].  To 
that end, of profound importance is the development of artificial extracellular matrices 
(ECM). These structures are integral to the fashioning of microenvironments that are 
engineered for ideal mechanical and biological performance.  It is likely this design will 
require the mimicry of many, if not all, morphological or physiologic features of native 
tissues.  Decades of research have indeed demonstrated that as our ability to control the 
physical and biological properties of scaffolding materials improves, the quality of the 
tissues thus formed is enhanced.   
More specifically, molecular and supramolecular organization of Type I collagen 
and elastin fiber assemblies establishes and important paradigm for the design in the 
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development of novel scaffolds.  In the body, both tissues and organs are organized into 
3-D structures, each having specific architectures, directly dependent upon its biological 
function.  This architecture is believed to foster cellular ingrowth and proliferation by 
providing appropriate channels for mass transport and spatial cellular organization, thus 
directing new tissue formation.   
The primary focus of our investigation is to engineer a material for vascular graft 
replacements.  However, the strategies employed and materials thus generated can be 
utilized in biosynthetic design of many different artificial organs and tissues. 
 
1.4.1  Current strategies in the design of an engineered vascular graft 
Development of a small diameter vascular replacement for coronary bypass 
procedures has been described as the ‘Holy Grail’ for cardiovascular tissue engineering 
[11].  Developing an adequate replacement material has the potential to transform the 
treatment of coronary heart disease.  It is recognized that adverse events leading to 
vascular graft failure are related to destructive biological reactions at the blood-material 
and tissue-material interface.  Specifically, synthetic materials which have been 
successfully applied to large diameter replacements fail when applied to the small 
diameter with insufficient patency rates limited by thrombosis and compliance mismatch 
[12-16].  Over the past three decades, vascular graft design has adapted more of a 
tissue engineering approach with new graft design inspired by characteristics of the 
arterial wall. 
Earliest efforts endeavored to functionalize synthetic graft prostheses with a 
luminal layer of endothelial cells.  Though this strategy has several limitation; issues with 
cell sourcing, cell retention, and procoagulant tendencies, it has found success as larger 
peripheral artery replacements [17-20].  The inherent limitations of synthetic polymers 
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have motivated investigation to take a completely biological approach to the 
development of vascular grafts.  Early work explored collagen gel technology in which 
constructs were developed consisting of cell populated collagen gels [21].  This research 
has served as the foundation for subsequent innovation.  Extensions of this technology 
have incrementally enhanced the material integrity of the construct, through strategies to 
increase fiber alignment of the collagen [22-24], strength via mechanical conditioning 
[25, 26], crosslinking [27], and others, yet constructs exhibit inferior mechanical 
properties as compared to native vessels.  Other approaches have utilized native 
vascular cells in the production of ‘cell secreted scaffolds’ [28-31].  Though these tissue 
engineering strategies have reported promising results, some even progressing from 
bench to human studies [31, 32], each poses unique challenges.  Specifically, the 
duration of incubation time, immunologic challenges associated with the use of 
allogeneic cells, and suboptimal compliance has limited the application of these 
strategies to create a clinically applicable small diameter replacement.   
Decellularized allo- and xenogeneic tissue have alternatively been investigated 
as materials for vascular grafts.  These decellularized natural matrices contain the intact 
extracellular matrix and associated attachment proteins and have been used to produce 
structures with increase degradation resistance, decreased thromobgenicity, and 
decreased inflammatory reactions.  Human umbilical vein, bovine procine carotid artery 
and small intestine submucosa, chemically crosslinked using gluteraldehyde, have been 
employed in clinical application though their use has been limited due to suboptimal 
patency rates via dilation and aneurysm formation [33-40].  
Protein fiber spinning has recently been investigated for the development of 
tubular constructs for vascular applications.  It has been postulated that the versatility of 
structural proteins as a scaffold will be significantly enhanced when reformulated into 
fiber networks.  In this regard, electrospinning has been investigated as a mechanism for 
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generating fibers with diameters < 1 µm.  Briefly, the electrospinning technique relies on 
electrostatic forces to produce sub-micron diameter fibers from protein solutions.  A high 
voltage is applied to a spinneret while a protein solution is slowly being pumped through 
which induces evenly dispersed charges in a pendent drop at the tip of the spinneret, 
relaxing the fluid surface.  This surface charge and the external Coulombic forces from 
the electric field combine to form a tangential stress which results in the drop becoming 
distorted into a shape referred to as a Taylor cone.   At a threshold value, the electric 
field strength will overcome that of surface tension and the protein solution is ejected as 
a charged jet from the spinneret tip.  As the jet travels to the grounded collector it 
undergoes stretching and whipping phenomena which reduces the diameter of this fiber.  
It is then collected, usually in a random orientation, on the grounded collector, creating a 
nonwoven fiber networks.  Accordingly, a tubular construct can be fabricated using a 
rotating mandrel as a collector.  Materials such as soluable elastin, Type I and III 
collagen, collagen-elastin-PLGA blends and recombinant elastin-mimetic materials have 
fabricated into electrospun fiber conduits [1, 41-46].  Reformulating proteins into fiber 
networks provides an additional level of control over the properties of the system.  
Specifically, studies have indicated electrospun fabrics composed of small diameter 
fibers (≤ 1um) demonstrated decreased porosity, increased fiber density, increased 
mechanical strength, as well as an optimized biological environment for promoting 
endothelial cell adhesion as compared to larger diameter fibers (7um) [42, 47]. 
 
1.4.2 The aortic media, a model system for the design of a vascular graft prosthesis 
The native blood vessel is composed of three main structural layers containing 
unique cell and matrix components. The inner most layer of the blood vessel is the 
tunica intima which is composed of a single layer of endothelial cells with an underlying 
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basement membrane consisting of Type IV collagen, glycosaminoglycans, elastin and 
laminin. The outermost layer of the blood vessel, the tunica adventitia, forms a 
connective sheath around the vessel consisting of Type I and Type III collagen, elastin 
and fibroblasts. The adventitia functions to stabilize and anchor the blood vessel and 
maintain longitudinal tension.  The middle layer of the native blood vessel is the tunica 
media which is composed of concentric sheets of elastic lamellar units each composed 
of smooth muscle cells within a fibrillar matrix of Type I and Type III collagen, elastin and 
proteoglycans. The inherent elasticity of blood vessels arises from the structure of the 
medial layer.  Elastin and collagen function in a concerted action in response to imposed 
deformations.  Elastin is primarily responsible for distensibility and elastic recovery of the 
vessel in the low-strain regime while collagen responds by limiting deformation during 
excessive strain [48-52].  The elastin protein network appears to be integral to 
mechanically match the native blood vessel and for the prevention of intimal hyperplasia 
and potential graft failure.  Additionally, the pores of the elastic lamina are important for 
the exchange of nutrients and metabolites.  Thus, the lamellar unit of the aortic media 
serves as a foundation in the design of a vascular graft prosthetic [53-55].     
 
 
1.4.3 Native elastin, an introduction 
Native elastin is a highly insoluable matrix protein that is responsible for providing 
extensibility and resilience to most tissues of the body.  Insoluable elastin has a 70 year 
half-life making it one of the most stable proteins discovered [56].  In the vascular 
system, elastin fiber networks appear in large densities (over 50%) and function to 
provide resilience to the artery to absorb dynamic systolic stresses of the cardiac cycle 
and to release energy in the form of blood pressure during diastole [57]. Therefore, 
elastin networks maximize the durability of tissues that are loaded by repetitive forces by 
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minimizing the conversion of mechanical energy to heat which would ultimately result in 
tissue damage [52].  In addition to its structural role, elastin creates an environment 
which promotes proper cell function.  Specifically within the vascular system, elastin 
regulates smooth muscle cell phenotype and proliferation, and in this way is responsible 
for stabilizing arterial structure [57-60]. 
 
1.4.4 Biochemistry of native elastin 
Human elastin is synthesized as a 72 kDa soluble precursor, tropoelastin.  The 
distinctive composition of tropoelastin affords unique physical properties of this structural 
protein.  Tropoelastin is rich in glycine (33%), proline (10-13%), and other hydrophobic 
residues (44%) rendering elastin an extremely hydrophobic protein [61].   Tropoelastin 
contains distinct crosslinking and hydrophobic domains.  Crosslinking domains are 
alanine rich, containing pairs of lysine residues facilitating intermolecular crosslinking.  
Specifically, lysine residues are separated by either two or three alanine residues (eg. 
Ala-Ala-Ala-Lys-Ala-Ala-Lys-Ala-Ala) allowing for retention of an α-helical conformation 
in this region.  The sequence within the crosslinking domains appears to be conserved 
as a consequence of the conformational constraints of crosslinking [62].  Alternatively, 
the hydrophobic domains within tropoelastin are composed of three-quarters of valine, 
glycine, proline, and alanine which occur in repeat units like Gly-Val-Gly-Val-Pro, Gly-
Val-Pro-Gly-Val, and Gly-Val-Gly-Val-Ala-Pro.  The total size of the protein polymer, 
750-800 residues, is highly conserved among species, however, investigations have 
elucidated that precise sequence and size of this region are not critical for appropriate 
function [62]. 
 
1.4.5 Coacervation phenomena in native elastin and recombinant elastin proteins 
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 Coacervation is a self assembly process thought to align tropoelastin molecules 
in preparation for intermolecular crosslinking [63-65].  At ambient temperatures, 
tropoelastin is soluble in aqueous solutions.  However, as the temperature is raised, the 
molecules begin to aggregate through hydrophobic interactions.  Coacervation is a lower 
critical solution temperature (LCST) phenomenon in which the protein forms a more 
ordered system upon increasing temperature.  The same phenomena has been 
observed with recombinant elastin proteins where precise control over the temperature 
at which coacervation occurs has been correlated to amino acid sequence [66, 67].  
Recombinant elastin proteins which lack hydrophobic domains do not have the ability to 
coacervate [68]. 
 
 
1.4.6 Elastin fiber assembly 
 
Elastin fibers appear to exist as two morphologically different components, a 
highly isotropic amorphous elastin constituent within an organized microfibrilar scaffold 
primarily composed of fibrillin [69, 70].  Understanding of the complex mechanism of 
fiber assembly in native elastin is limited.  Fiber assembly appears to take place in the 
extracellular space in proximity to the cell membrane where microfibrils appear first, 
grouped in small bundles. Tropoelastin, synthesized by smooth muscle cells, is secreted 
within each fiber bundle.  Tropoelastin exhibits the ability to self-assemble under 
physiological conditions through coacervation.  It is likely that this phenomena is 
responsible for the alignment of tropoelastin in preparation of intermolecular crosslinking 
[62-65].  Intermolecular crosslinking occurs between four lysine residues from two 
tropoelastin molecules.  Briefly, crosslinks are formed through the deamination of the ε-
amino group of the lysine side chains by the enzyme lysyl oxidase.  The reaction occurs 
in two ways:  the reactive aldehyde residue condenses with a second aldehyde residue 
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to form an allysine aldol or it reacts with a lysine residue to form lysinonorleucine.  These 
two precursors condense to form desmosine and isodesmosine crosslinks [71].  
Crosslinking appears to take place every 65-70 residues [72].   
 
 
1.4.7  Biosynthetic approach to the development of an engineered vascular graft 
Allogeneic and xenogeneic strategies indicate native fiber networks can be used 
to fabricate a vascular graft prosthetic, though the inability to tailor matrix composition 
and content, fiber size and architecture, limits the applicability of these materials. As a 
result, strategies to design a prosthesis with precisely defined mechanical and biological 
properties has been pursued via a ‘ground-up’ design.   Recent developments in 
recombinant protein engineering now offer the opportunity to construct new proteins with 
near absolute control over molecular architecture [73-76].   Employing biosynthetic 
routes to the design of structural proteins for vascular prosthetics afford the ability to 
modulate material properties at the level of the primary amino acid sequence, thus 
affording the capability to engineer recombinant proteins to meet physiologic 
requirements.   Additionally, this strategy enables the elucidation of structure-property 
relationships and ultimately, control over these properties.  Currently, structural proteins 
have been generated in this way consisting of sequentially repeated amino acid blocks 
derived from analysis of native protein molecular structure [77, 78].  This strategy not 
only allows for control of sequence and size, it also facilitates incorporation of additional 
functional groups, in particular, the placement of crosslinks at well defined intervals 
along the peptide chain allowing for the additional control over material properties of the 
protein.  Thus, recombinant proteins that mimic structural matrix proteins can be 
engineered with a precisely tailored design to modulate tensile strength, elastic modulus, 
viscoelasticity, and in vivo stability, as well as desired host response.  
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1.4.7 Elastin-Mimetic Proteins 
Limitations to the use of elastin in biomedical and tissue engineering applications 
are a consequence of its intrinsic insolubility and inability to be processed.  But through 
the structural characterization of the hydrophobic domains, the ability to base synthetic 
protein polymers on native elastin sequences is feasible.  The pioneering work of Dan 
W. Urry elucidated the elastomeric pentapeptide repeat, VPGVG, from human elastin 
which now serves as the basic sequence extensively investigated by both chemical 
methodologies and recombinant technology [79, 80].  This repeat unit within found the 
hydrophobic domain of human elastin is responsible for resultant elastic properties.  
Additionally, this domain is responsible for facilitating fiber formation through 
coacervation phenomena, behaviors consistent with native elastin.  Spectroscopic 
analysis has revealed that native elastin, and likewise, protein polymers containing this 
repeat, exhibit β-turns and helical β-spiral conformations and display an inverse 
temperature transition defined by the generation of a more ordered system upon 
increasing temperature.  This loss of entropy is a consequence of protein folding into β-
spiral conformation and the subsequent reorientation of water from the elastin chain [81]. 
Studies have indicated that the amino acid in the fourth (X) position (VPGXG) 
modulates the coacervation temperature with more polar amino acids increasing 
transition temperature [66, 67, 82].  As long as glycine and proline residues are 
preserved the structure and function of elastin is maintained [83].  This discovery has led 
to the generation of recombinant elastin analogs designed for biomedical applications.  
For instance, recombinant techniques have been employed to design amphiphilic elastin 
protein polymers consisting of hydrophobic and hydrophilic domains.  Through precise 
sequence design and control of processing conditions, these elastin analogs exhibit a 
wide range of properties advantageous for biomedical applications, as micelles or 
physically crosslinked films [2-5, 84]. Additionally, groups have incorporated cell binding 
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domains, RGD or REDV, into elastin sequences to functionalize elastin matrix 
components for endothelial cell attachment [85-87].  Furthermore, incorporation of 
reactive lysine residues into recombinant elastin design provides the ε-amino moiety of 
lysine for crosslinking using a variety of approaches. Crosslinking of synthetic elastin-
mimetic protein polymers has been investigated using solution phase systems; either 
gamma irradiation [82, 88-90], chemical [91-102] , or enzymatic based approaches 
[100], as well as solid state photocrosslinking [103].   
 
1.5  SIGNIFICANCE OF PROPOSED RESEARCH 
It is proposed that employing a biosynthetic strategy, elastin-mimetic protein 
polymers can be designed to facilitate both covalent and physical crosslink formation 
thus enhancing static and dynamic material behavior.  Specifically, it is hypothesized 
that these protein polymers will exhibit improved compliance, resilience, creep, and 
biostability as compared to allogeneic or xenogeneic tissue.  Additionally, these proteins 
may be reformulated into gels, films or nano-fiber networks.  Significantly, this strategy 
can be integrated into schemes which are ultimately driven either by a desire to generate 
a cell containing arterial construct or a non-thrombogenic acellular conduit.
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CHAPTER 2 
Elastin-mimetic protein polymers capable of physical and chemical crosslinking 
 
2.1 INTRODUCTION 
 
Genetic engineering provides a facile route for the design of novel protein 
polymers composed of repetitive amino acid sequences or peptide blocks whose 
structural complexity imparts distinct mechanical, chemical or biological properties.  To 
date, the majority of recombinant multiblock protein polymers have been designed with 
relatively short block sequences that limit structural polymorphism.  As a consequence, 
opportunities to access diverse polymer morphologies are limited and the potential to 
tune a wide range of functional responses reduced [74, 104].  Recently, we have 
reported a new class of elastin-mimetic multiblock copolymer composed of identical 
endblocks derived from self-associating, hydrophobic sequences that display plastic-like 
mechanical responses (Ile-Pro-Ala-Val-Gly), separated by a central block that is both 
hydrophilic and elastomeric (Val-Pro-Gly-Glu-Gly) [1, 2].  Block sizes, typically, exceed 
35 kDa, which has allowed us to explore the production of protein-based materials that 
are structurally polymorphic [1-5, 84]. 
 Significantly, multiblock systems afford the ability to form physical or virtual 
crosslinked networks through the self-association of chemically similar domains.  In the 
case of elastin-mimetic proteins [1-5, 84], repeat peptide sequences of self-associating 
blocks are chosen such that coacervation or phase separation of these domains occurs 
in water under physiologically relevant conditions (pH 7.4, 37°C), which maximizes 
hydrophobic interactions that drive self-assembly.  In turn, the sequence of the non-
crosslinking domain is selected in a manner that precludes coacervation.  This typically 
has required the incorporation of hydrophilic residues in the fourth position of the 
pentapeptide repeat sequence (Val-Pro-Gly-Xaa-Gly), such as glutamic acid, which 
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limits the tendency for block aggregation.   Physically crosslinked protein-based 
materials possess a number of advantages over their chemically crosslinked 
counterparts, including ease of processability, the ability to avoid the addition or removal 
of reagents or unreacted intermediates needed for chemical crosslinking, and the 
capacity to incorporate biologically or chemically active agents or cells that might 
otherwise be sensitive to covalent crosslinking schemes.  Moreover, if blocks are of 
sufficient size and chemical diversity the potential to access diverse polymer 
morphologies exists.  This provides the capacity to tune a wide range of functional 
responses, such as mechanical behavior, permeability or drug elution characteristics, as 
well as the potential to design templated materials [74, 86, 91].  Notwithstanding these 
desirable features, physical crosslinks and the related domains so formed may be 
deformed or damaged at applied stresses lower than those required to disrupt covalent 
crosslinks.   
Native elastin is enzymatically crosslinked upon proper alignment of two pairs of 
lysine residues between adjacent tropoelastin chains with formation of desmosine or 
isodesmosine linkages [105, 106].  Likewise, most recombinant elastin analogues that 
have been designed to date have relied on crosslinking through available amino groups, 
albeit with most reports describing the use of chemical crosslinkers, including 
isocyanates, NHS-esters, phosphines, aldehydes, or genipin [91-102].  In this regard, we 
have previously reported the design of a synthetic elastin sequence, (Val-Pro-Gly-Val-
Gly)4(Val-Pro-Gly-Lys-Gly), in which lysine residues were chemically crosslinked using 
bis(sulfosuccinimidyl) suberate and disuccinimidyl suberate [99].  Subsequent studies 
have reported the application of transglutaminase or lysyl oxidase for enzymatic 
crosslinking [107].  In addition, we have also explored solid-state crosslinking of 
recombinant elastin-mimetic proteins using both UV and visible light activated 
photoinitiators [103].  In tropoelastin, lysine residues are often interspersed among 
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alanine repeats (eg. Ala-Ala-Ala-Lys-Ala-Ala-Lys-Ala-Ala), which has suggested that 
self-association of alanine-rich sequences facilitates crosslinking [108, 109].  Several 
elastin-like proteins have been designed in similar manner [86, 91, 110].  
The capacity of chemical crosslinks to provide an independent mechanism for 
control of protein mechanical responses and biostability is well established.  However, in 
this report we postulated that by chemically locking a multiblock protein assembly in 
place, functional responses that are linked to specific domain structures and 
morphologies may be preserved over a broader range of loading conditions that would 
otherwise disrupt microphase structure solely stabilized by physical crosslinking.  We 
report herein the synthesis of a new class of recombinant elastin-mimetic triblock 
copolymer capable of both physical and chemical crosslinking.  These investigations 
were motivated by a desire to capture features unique to both physical and chemical 
crosslinking schemes so as to exert optimal control over a wide range of potential 
properties afforded by protein-based mutiblock materials.  
 
 
 
2.2 MATERIALS and METHODS 
 
Synthetic gene construction of elastic- and plastic-like domains.  Synthetic 
methods used to produce the DNA inserts that encode the various elastin-mimetic block 
copolymers have been described previously [2-5].  Genes encoding two distinct 
chemically crosslinkable protein triblock copolymers were synthesized.  Briefly, 
oligonucleotide cassettes encoding elastic- (E) and plastic-like (P) repeat units (Table 2-
1, Appendix A) were independently synthesized and inserted into the BamH I and HinD 
III sites within the polylinker of pZErO cloning vectors.  Specifically, P1 and E1 encode 
the monomer repeat unit for plastic- and elastic-like domains designated for the triblock 
protein polymer, referred to as LysB10.  A second set of oligonucleotide cassettes, P2 
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and E2, were designed to encode monomer repeat units for plastic- and elastic-like 
domains for a second protein triblock copolymer, designated R4.  Recombinant clones 
were isolated after propagation in E. coli strain TOP10F’ and the identity of the DNA 
inserts E and P verified by double-stranded DNA sequence analysis.   DNA monomers E 
and P were liberated from the respective plasmids via sequential restriction digestion 
with Bbs I and BsmB I, respectively.  Multimerization, or self-ligation in a head-to-tail 
fashion of each DNA cassette afforded a population of multimers.  This procedure was 
repeated separately for the four multimers synthesized in this report (P1, E1, P2, and E2).   
Multimers derived from DNA monomers were inserted into the BsmB I site of 
their original plasmid containing the monomer cassette.  Multimers encoding 33 repeats 
of the P1 monomer, 16 repeats of the P2 monomer, 28 repeats of the E1 monomer, and 
15 repeats of the E2 monomer were isolated and identified via restriction cleavage with 
BamH I and HinD III.  Double-stranded DNA sequence analysis confirmed the integrity of 
the concatemers within the recombinant plasmids, which were labeled pP1, pP2, pE1, and 
pE 2, respectively.  pP1 and pE1 were utilized in the construction of the LysB10 gene, pP2 
and pE 2 for the R4 gene.  
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Table 2-1.  Coding Sequences of Oligonucleotide Cassettes Employed for the Construction of Crosslinkable 
Protein Triblocks, LysB10 (AP1IE1IP1A) and R4 (AP2IE2IP2A) 
E 1 Block (LysB10 Elastic-like Block) 
Val Pro Gly Ala Gly Val Pro Gly Ala Gly Val Pro Gly Glu Gly 
GTT CCA GGT GCA GGC GTA CCG GGT GCT GGC GTT CCG GGT GAA GGT 
Val Pro Gly Ala Gly  Val Pro Gly Ala Gly 
GTT CCA GGC GCA GGT  GTA CCG GGT GCG GGT 
 
E2 Block (R4 Elastic-like Block) 
Val Pro Gly Ile Gly Val Pro Gly Ile Gly Val Pro Gly Ile Gly    
GTT CCA GGT ATT GGC GTT CCG GGT ATC GGT GTG CCA GGC ATC GGT 
Val Pro Gly Ile Gly Val Pro Gly Ile Gly   
GTA CCG GGT ATT GGC GTT CCA GGC ATT  GGC  
 
 
P1 Block (LysB10 Plastic-like Block) 
Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly 
ATT CCG GCT GTT GGT ATC CCA GCT GTT GGT ATC CCA GCT GTT GGC 
Ile Pro Ala Val Gly Ile Pro Ala Val Gly 
ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC 
 
P2 Block (R4 Plastic-like Block) 
Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly 
ATT CCA GCT GTT GGT ATC CCA GCT GTT GGT ATC CCA GCT GTT GGC 
Ile Pro Ala Val Gly Ile Pro Ala Val Gly 
ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC 
 
 
I Block (Lysine Insert) 
Ile Pro Ala Val Gly Lys Ala Ala Lys Val Pro Gly Ala Gly 
ATT CCA GCT GTT GGT AAG GCG GCC AAG GTT CCA GGT GCA GGC 
 
 
A Block (Modified Lysine Adaptor) 
Val Pro Ala Val Gly Lys Val Pro Ala …… Ile Pro Ala Val 
GTT CCA GCT GTT GGT AAG GTT CCA GCT …… ATT CCA GCT GTT 
Gly  Lys Ala Ala Lys Ala  Stop 
GGT AAG GCG GCC AAG GCG TAA 
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Synthetic gene construction of chemical crosslinking domains.  Single 
stranded oligonucleotides encoding the sense and anti-sense strands of the Lysine 
Insert (I) and Lysine Adaptor (A) were chemically synthesized (Sigma Genosys, Inc.) 
(Appendix A, Table 2-1).  The Lysine Insert is a 60 bp DNA cassette encoding the 
crosslinking sequence, Lys-Ala-Ala-Lys, which was inserted between the plastic- and 
elastic-like domains.  The Lysine Adaptor is a 50 bp DNA cassette designed with 
restriction enzyme cut sites midway through the cassette to allow for insertion of the 
assembled triblock gene.  The Lysine Adaptor encodes for a single N-terminal lysine 
residue and two C-terminal lysine residues.  Additionally, it allows for facile cloning into 
the pET24-a expression vector within the multiple cloning region.  This ensures correct 
insertion of the gene in frame with the N-terminal polyhistidine tag.   
The following procedure detailing the protocol to generate double stranded DNA 
was implemented for both the Lysine Insert and Lysine Adaptor.  The DNA was 
suspended in 10 mM Tris buffer (pH 8) to a final concentration of 0.5 µg/uL.  A solution 
of 10 µg of each corresponding oligonucleotide, 4µL 5M NaCl, 4µL 1M MgCl2, 152 µL of 
sterile ddH2O was subjected to an annealing procedure initiated at a reaction 
temperature of 99°C with temperature decrements of 1°C every 5 minutes to a final 
reaction temperature of 30°C.  The resultant double stranded DNA cassette was 
analyzed by agarose gel electrophoresis (4% GTG NuSieve agarose, 1X TBE buffer).  
Double stranded synthetic DNA was phosphorylated through a 2-hour incubation 
with T4 Poynucleotide Kinase (New England Biolabs) in the presence of T4 DNA ligase 
buffer with 10mM ATPs (New England Biolabs).  The enzymes were removed with 
phenol/chloroform/isoamyl alcohol (25:24:1) and the double stranded DNA (dsDNA) was 
recovered through an ethanol precipitation.   
The pZErO-1 acceptor plasmid (1 µg), was prepared via BamH I and HinD III 
double digestion, followed by heat inactivation of the enzymes at 65°C and a dilution of 
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the digested plasmid to 10 ng/µL.  The Lysine Insert and Lysine Adaptor were designed 
with BamH I and HinD III overhangs to enable cloning into pZErO-1 at these restriction 
sites.  
The DNA cassette and respective acceptor plasmid were ligated together in the 
presence of T4 DNA Ligase at 16°C for 30 minutes.  A 2 µL aliquot of the ligation 
reaction mixture was used to transform 40 µL of electrocompetent TOP10F’ E. coli cells.  
A total of 100 µL of the transformation mixture was spread onto low salt (LSLB) agar 
supplemented with Zeocin (50 µg/µL).  The plates were incubated for 12 hours at 37°C.  
Five transformants were selected from each plate to inoculate individual 7 mL cultures of 
LSLB/Zeocin.  Cultures were rotary incubated for 12 hours at 37°C.  Plasmid DNA was 
isolated following a Qiagen Spin Miniprep protocol (Quiagen, Inc.).  DNA was initially 
screened by a BamH I and HinD III double digestion.  Positive transformants were 
verified by agarose gel electrophoresis (4% GTG NuSieve agarose, 1X TBE buffer).  
Automated DNA sequencing utilizing the M13 forward and M13 reverse primers 
confirmed correct DNA products.  Plasmids containing the correct sequence for the 
Lysine Insert and Lysine Adaptor are identified as pI and pA, respectively. 
 Assembly of elastin-mimetic triblock copolymers.  The proteins, LysB10 and 
R4 were designed to contain the Lysine Insert between each plastic-like and elastic-like 
blocks and to be flanked by the Lysine Adaptor (-Lysine Adaptor-Plastic-like Domain-
Lysine Insert-Elastic-like Domain-Lysine Insert-Plastic-like Domain-Lysine Adaptor-) 
(Scheme 2-1).  All subcloning steps were performed in the pZErO-1 plasmid using LSLB 
media under Zeocin antibiotic selection.  Scheme 2-1 summarizes the general cloning 
strategy employed in the assembly of these genes.
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Scheme 2-1.  General cloning strategy in the assembly of crosslinkable triblock genes.  
Plasmids have been designated by the DNA cassette they contain.  For example, the 
plasmid containing the Lysine Insert cassette is referred to as plasmid I (pI).  P = Plastic-
like cassette (blue), E = Elastic-like cassette (yellow), I = Insert cassette (black), A = 
Adaptor cassette (black). 
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Recombinant plasmids encoding the elastic-like (pE) (E1=2.1 kB, E2=1.1 kB) and 
plastic-like (pP) (P2=2.5 kB, P2=1.2 kB) domains were constructed, as described above.   
Each gene was isolated from its respective plasmid with Bbs I and BsmB I sequential 
digestion.  The gene fragment was isolated via preparative gel electrophoresis (1% 
agarose, 0.5X TBE) and purified using Zymoclean Gel Recovery (ZymoResearch, Inc).  
Preparative amounts of pI DNA was isolated for two separate reactions.  A total of 5 µg of 
pI was digested with restriction enzyme Bbs I and Shrimp Alkaline Phosphatase (SAP) 
dephosphorylated (1 U SAP per 1 pmol strand ends) to prevent re-ligation.  A separate 5 
µg of pI was digested with the restriction enzyme BsmB I and SAP dephosphorylated.  
The linearized plasmids were isolated via preparative gel electrophoresis (1% agarose, 
0.5X TBE) and purified using Zymoclean Gel Recovery.   
Similar protocols for ligation, transformation, and propagation were followed, as 
previously described.  Two separate ligation reactions were performed between Bbs I 
digested pI and P and BsmB I digested pI and P (Scheme 2-1, Cloning Step 1).  
Isolated DNA from clones were screened by a BamH I and HinD III double digestion and 
cleavage fragments analyzed by agarose gel electrophoresis.  Correct ligation was 
confirmed by automated DNA sequence analysis using M13 forward and reverse 
primers.  Plasmids containing the correct sequences are identified as pIP and pPI.   
 Analogously, 5 µg of pPI was digested with restriction enzyme BsmB I and Shrimp 
Alkaline Phosphatase (SAP) dephosphorylated (1U SAP per 1 pmol strand ends) to 
prevent relegation.  The linearized plasmid was isolated via preparative gel 
electrophoresis (1% agarose, 0.5X TBE) and purified using Zymoclean Gel Recovery.  
Linearized pPI was ligated with E, followed by transformation and propagation (Scheme 2-
1, Cloning Step 2).  Isolated DNA from transformants were screened by a BamH I and 
HinD III double digestion and cleavage fragments analyzed by agarose gel 
electrophoresis.  Correct ligation was confirmed by automated DNA sequence analysis 
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using M13 forward and reverse primers.  The plasmid containing the correct sequence 
was termed pPIE. 
 Recombinant plasmids pIP and pPIE were digested with Bbs I / Xma I and BsmB I 
/ Xma I, respectively.  The gene fragment from each of these digestions was isolated via 
preparative gel electrophoresis (1% agarose, 0.5 x TBE) and purified using Zymoclean Gel 
Recovery.  IP and PIE fragments were ligated by T4 DNA ligase, transformed into 
TOP10F’ and plated on LSLB/Zeocin plates (Scheme 2-1, Cloning Step 3).  As the Xma I 
site cuts within the Zeocin coding region, only clones containing the correctly assembled 
triblock (PIEIP), and thus, the correctly reassembled antibiotic coding region, were able to 
propagate.  Transformants were confirmed by analysis of BamH I and HinD III restriction 
digest fragments with agarose gel electrophoresis (1% agarose, 0.5 x TBE) and 
automated DNA sequence analysis using M13 forward and reverse primers.  The plasmid 
containing the correct sequence for the triblock was termed, pPIEIP. 
 pA, containing the Lysine Adaptor, was assembled, as described above.  This 
plasmid was digested with restriction enzyme BsmB I and SAP dephosphorylated.  The 
triblock, PIEIP, was excised from the pZErO-1 plasmid via sequential digestion using 
restriction enzymes Bbs I and BsmB I and purified via gel isolation.   A ligation reaction 
was performed to relocate the PIEIP gene from pPIEIP to pA (Scheme 2-1, Cloning Step 
4).  The ligation mixture was transformed into competent TOP10F’ cells and plated on 
LSLB media under Zeocin antibiotic selection.  Isolated DNA from transformants were 
screened via agarose gel electrophoresis analysis of a BamH I and HinD III double 
digestion.  Automated DNA sequence analysis using M13 forward and reverse primers 
confirmed correct insertion of the gene pAP1IE1IP1A and pAP2IE2IP2A.  pAP1IE1IP1A was 
identified as the cloning plasmid, pLysB10 and pAP2IE2IP2A as the cloning plasmid, pR4.   
 The pET24-a plasmid (1 µg, Invitrogen) was prepared via BamH I and HinD III 
double digestion, followed by gel isolation and purification.  The APIEIPA gene was 
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released from the pZErO-1 vector at analogous sites.   Adaptor and plasmid were ligated 
together in the presence of T4 DNA ligase at 16°C for 30 minutes.  A 2 µL aliguot of the 
ligation reaction mixture was used to transform 40 µL of electrocompetent TOP10F’ E. 
coli cells.  A 100 µL aliquot of the transformation mixture was spread onto LB agar 
supplemented with kanamycin (50 µg/µL).  The plates were incubated for 12 hours at 
37°C.  Five transformants were selected from each plate to inoculate individual 7 mL 
cultures of LB/kanamyacin media.  Cultures were rotary incubated for 12 hours at 37°C.  
Plasmid DNA was isolated following a Qiagen Spin Miniprep protocol (Quiagen, Inc.).  
DNA was screened by a BamH I and HinD III double digestion.  Positive transformants 
were verified by agarose gel electrophoresis (4% GTG NuSieve agarose, 1X TBE 
buffer).  Automated DNA sequencing utilizing the T7 promoter and T7 terminator primers 
confirmed the correct DNA product.  The resultant plasmid was identified as expression 
plasmids, pLysB10 (AP1IE1IP1A) and pR4 (AP2IE2IP2A).  DNA agarose gels in Figures 
2-1 and 2-2 depicts gene products at each subcloning step in the assembly of pLysB10 
and pR4, respectively. 
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Figure 2-1.   Analytical restriction digests, 1% TAE (Tris-acetate-EDTA) agarose gel, 
depicting gene and vector sizes at each stage of the LysB10 assembly process with 
corresponding digestion schemes. DNA standard used was a 1Kb DNA ladder (NEB).  A. 
Lane 1: BamHI / HinDIII digest pE1 (2.1 Kb), pZerO-2 (3.3 Kb). Lane 2: BamHI / HinDIII 
digest pP1 (2.5 Kb), pZerO-2 (3.3Kb).  Lane 3: Nsi I / Xma I digest pP1I (2.56 Kb), pZerO-1 
(1.3, 1.5 Kb).  Lane 4:  Nsi I / Xma I digest pIP1 (2.56 Kb), pZerO-1 (1.3, 1.5 Kb).  B.  Lane 1: 
Nsi I digest pP1IE1 (4.66 Kb), pZErO-1 (2.8 Kb).  C.  Lane 1: Nsi I digest pP1IE1IP1 (7.22 Kb), 
pZErO-1 (2.8 Kb).  Lane 2: Nsi I digest LysB10 (7.28 Kb), pZErO-1 (2.8 Kb).    Lane 3: 
BamHI / HinDIII digest LysB10 (7.28 Kb), pET 24a (5.3 Kb). 
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Figure 2-2.  Analytical restriction digests, 1% TAE (Tris-acetate-EDTA) agarose gel, depicting gene and vector sizes at each stage of the R4 
assembly process with corresponding digestion schemes. DNA standard used was a 1Kb DNA ladder (NEB). A. Lane 1: Nsi I digest pE2 (1.1 
Kb), pZerO-1 (2.8 Kb). Lane 2: Nsi I digest pP2 (1.2 Kb), pZerO-1 (2.8Kb).  Lane 3: Nsi I digest pE2I (1.16 Kb), pZerO-1 (2.8 Kb).  Lane 4:  Nsi 
I digest pP2I (1.26 Kb), pZerO-1 (2.8 Kb).  Lane 5:  Nsi I digest pP2IE2I (2.42 Kb), pZerO-1 (2.8 Kb).  B.  Lane 1: Nsi I digest pP2IE2IP2 (3.62 
Kb), pZerO-1 (2.8 Kb). Lane 2: Nsi I digest pR4 (3.7 Kb), pZerO-1 (2.8Kb).  Lane 3: BamH I / HinD III digest pR4 (3.7 Kb), pET24-a (5.3 Kb).   
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Isolation and purification of protein triblock copolymers.  The plasmid, 
pLysB10, encoding the protein LysB10 as a single contiguous reading frame within 
plasmid pET24-a was used to transform the E. coli expression strain BL21(DE3).   This 
afforded a protein triblock of sequence (Table 2-2):   
N-terminal endblock: VPAVGK[(VPAVG)(IPAVG)4][(IPAVG) 5]33 
Midblock: (IPAVG)KAAK(VPGAG)[(VPGAG)2VPGEG(VPGAG)2]28(VPAVG)KAAK(VPGAG)  
C-terminal endblock:  [(VPAVG)(IPAVG)4][(IPAVG) 5]33IPAVGKAAKA   
The plasmid, pR4, encoding the protein R4 as a single contiguous reading frame 
within plasmid pET24-a was used to transform the E. coli expression strain BL21(DE3).   
This afforded a protein triblock of sequence (Table 2-3):  
N-terminal endblock:  VPAVGKVPAVG[(IPAVG)5]16  (IPAVG) 
Midblock:  (IPAVG)KAAK(VPGAG)(VPGIG) [(VPGIG)5]15(VPGIG)(VPAVG)KAAK(VPGAG) 
C-terminal endblock:  (VPGAG) [(IPAVG)5]16 (IPAVG)VPAVGKAAKA 
Large-scale fermentation (100 L) was performed at 37°C in Circle Grow (Q-
BIOgene) medium supplemented with kanamycin (50 µg/mL) at the Bioexpression and 
Fermentation Facility, University of Georgia.  The fermentation cultures were incubated 
under antibiotic selection for 24 hours at 37°C.   
Cells were harvested through centrifugation in sterile tubes at 1660 RCF for 20 
minutes at 4°C.  The supernatant was carefully decanted, cell pellets were resuspended 
in cold, sterile PBS (phosphate buffered saline, 20 mL per large culture flask pellet) and 
frozen at -80°C.   Three freeze (-80°C) / thaw (25°C) cycles were employed for the initial 
cell fracture with equilibration back to cold temperatures following the cycles.  Once cells 
were completely resuspended, six cycles of sonication, consisting of 20 second bursts 
followed by a 20 second rests in an ice bath, was employed to thoroughly break the 
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cells.  To recover any unbroken cells, a preparative centrifugation step was used (1660 
RCF for 10 minutes at 4°C).  Unbroken cells, which pelleted out during the spin were 
resuspended in cold, sterile PBS and re-sonicated, as described above.   
 The cold cell lysate was centrifuged at 20,000g for 40 minutes at 4°C.  The 
supernatant was transferred to a cold, sterile tube and poly(ethyleneimine) (PEI) was 
added to a final concentration of 0.5%.  This solution was centrifuged again at 20,000g 
for 40 minutes at 4°C to remove all nucleic acids and contaminating cellular material 
precipitated by the PEI.  The supernatant was transferred to new sterile 50 mL tubes and 
NaCl was added to a 2M final concentration.  The elastin-mimetic protein was salted out 
of solution at 25°C for 30-45 minutes.  This solution was centrifuged at 9500g for 15 
minutes at 25°C to recover the protein product (‘hot-spin’).  The supernatant was 
discarded and the protein pellet was resuspended in cold, sterile PBS on ice for only 10-
20 minutes to avoid solubilizing unwanted contaminates.  The resuspended protein 
solution was then subjected to a ‘cold spin’ at 20,000g for 40 minutes at 4°C.  The 
supernatant was transferred to sterile 50 mL tubes and salting precipitation was 
repeated.  The hot (25°C) / cold (4°C) spin cycles were repeated until no contaminating 
pellet was observed after the cold spin.  The number of cycles ranged between 6 to 10 
and ended with a hot spin.  Dialysis and lyophillization afforded proteins LysB10 and R4 
as fibrous solids in isolated yield of 150 mg/L and 200 mg/L of culture, respectively. 
For in vivo studies, LysB10 and R4 proteins underwent a secondary treatment 
with sodium hydroxide (NaOH).  The protein pellets were resuspended in cold, sterile 
PBS at approximately 50mg/20mL.  Sterile NaOH was added to a 0.4N final 
concentration and mixed gently by hand.  The mixture was incubated on ice for fifteen 
minutes, after which 5M sodium chloride was added to a final concentration of 2M.  The 
protein was precipitated from solution at 25°C, centrifuged at 8500g for 20 minutes at 
25°C, and resuspended in cold PBS.  This treatment was repeated for a total of three 
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times.  Following the third treatment, the protein solution was adjusted to pH 6-8.  A cold 
spin was performed at 20,000 rpm for 40 minutes at 4°C and the supernatant was 
sterilely desalted using PD-10 desalting columns (GE Healthcare Lifesciences) with 
molecular grade water (Cellgro).  The end product was filtered through a 0.2 µm filter, 
eluted into autoclaved Lyoguard freeze drying trays (Gore), frozen at -80°C, and 
lyophilized.  This procedure afforded Lys B10 and R4 as white fibrous protein products 
with isolated yields of 75 mg/L and 100 mg/L of expression culture, respectively.   
 Lyophilized protein was resuspended in sterile molecular grade water at 1 mg/mL 
and endotoxin levels were assessed according to manufacturer instructions using the 
Limulus Amoebocyte Lysate (LAL) assay (Cambrex).  Levels of 0.1 EU/mg were 
obtained (1 EU = 100 pg of endotoxin), which corresponds to endotoxin levels for 
clinically used alginate (Pronova sodium alginate, endotoxin < 100 EU/gram).  
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Table 2-2.  Amino acid sequence of LysB10 and related nucleic acid coding sequence 
[VPAVGKVPAVG(IPAVG)4][(IPAVG) 5]33 [IPAVGKAAKVPGAG][(VPGAG)2VPGEG(VPGAG)2]28 
[VPAVGKAAKVPGAGVPAVG(IPAVG)4][(IPAVG) 5]33[IPAVGKAAKA] 
 
Val Pro Ala Val Gly Lys Val Pro Ala Val Gly Ile Pro Ala Val 
GTT CCA GCT GTT GGT AAG GTT CCA GCT GTT GGT ATC CCA GCT GTT 
Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val 
GGT ATC CCA GCT GTT GGC ATT CCG GCT GTA GGT ATC CCG GCA GTG 
Gly [Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val 
GGC ATT CCG GCT GTT GGT ATC CCA GCT GTT GGT ATC CCA GCT GTT 
Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly]33 Ile Pro Ala Val 
GGC ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC]33ATT CCA GCT GTT 
Gly Lys Ala Ala Lys Val Pro Gly Ala Gly [Val Pro Gly Ala Gly 
GGT AAG GCG GCC AAG GTT CCA GGT GCA GGC GTT CCA GGT GCA GGC 
Val Pro Gly Ala Gly Val Pro Gly Glu Gly Val Pro Gly Ala Gly 
GTA CCG GGT GCT GGC GTT CCG GGT GAA GGT GTT CCA GGC GCA GGT 
Val Pro Gly Ala Gly]28 Val Pro Ala Val Gly Lys Ala Ala Lys Val 
GTA CCG GGT GCG GGT]28GTT CCA GCT GTT GGT AAG GCG GCC AAG GTT 
Pro Gly Ala Gly Val Pro Ala Val Gly Ile Pro Ala Val Gly Ile 
CCA GGT GCA GGC GTT CCA GCT GTT GGT ATC CCA GCT GTT GGT ATC 
Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly [Ile 
CCA GCT GTT GGC ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC ATT 
Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile 
CCG GCT GTT GGT ATC CCA GCT GTT GGT ATC CCA GCT GTT GGC ATT 
Pro Ala Val Gly Ile Pro Ala Val Gly]33 Ile Pro Ala Val Gly  Lys 
CCG GCT GTA GGT ATC CCG GCA GTG GGC]33ATT CCA GCT GTT GGT AAG 
Ala Ala Lys Ala  Stop 
GCG GCC AAG GCG TAA 
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Table 2-3.  Amino acid sequence of R4 and related nucleic acid coding sequence 
[VPAVGKVPAVG[(IPAVG)5]16  (IPAVGIPAVG)KAAK(VPGAGVPGIG) [(VPGIG)5]15 
(VPGIGVPAVG)KAAK(VPGAGVPAVG) [(IPAVG)5]16 IPAVGVPAVGKAAKA] 
 
Val Pro Ala Val Gly Lys Val Pro Ala Val Gly [Ile Pro  Ala Val 
GTT CCA GCT GTT GGT AAG GTT CCA GCT GTT GGT [ATT CCG   GCT GTT 
Gly Ile  Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val 
GGT ATC  CCA GCT GTT GGT ATC CCA GCT GTT GGC ATT CCG GCT GTA 
Gly Ile Pro Ala Val Gly]16   Ile Pro Ala Val Gly Ile Pro Ala Val 
GGT ATC CCG  GCA  GTG GGC]16 ATT CCG GCT GTT GGT ATT CCA GCT GTT 
Gly Lys Ala Ala Lys Val Pro Gly Ala Gly Val Pro Gly Ile Gly 
GGT  AAG GCG GCC AAG GTT CCA GGT GCA GGC GTT CCA GGT ATT GGT 
[Val Pro Gly Ile Gly Val Pro Gly  Ile Gly Val Pro Gly Ile Gly 
[GTA CCT  GGT ATT GGC GTT CCG GGT  ATC GGT GTG CCA GGC ATC    GGT 
Val Pro Gly Ile Gly  Val Pro Gly Ile Gly]15 Val Pro Gly Ile Gly  
GTA CCG GGT  ATT GGC GTT CCA GGC ATT GGC]15 GTA CCT GGT ATT GGT 
Val Pro Ala Val Gly Lys  Ala Ala Lys Val Pro Gly Ala Gly Val 
GTT CCA GCT GTT GGT AAG GCG GCC AAG GTT CCA GGT  GCA GGC GTT 
Pro Ala Val Gly [Ile Pro Ala Val Gly Ile Pro Ala Val Gly Ile 
CCA GCT GTT GGT [ATT  CCG GCT GTT GGT ATC CCA GCT GTT GGT ATC 
Pro Ala Val Gly Ile Pro Ala Val Gly Ile Pro Ala Val Gly]16 Ile 
CCA GCT GTT GGC ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC]16 ATT 
Pro Ala Val Gly Ile Pro Ala  Val Gly Lys Ala Ala Lys Ala Stop 
CCG  GCT GTT GGT ATT CCA GCT  GTT GGT AAG GCG GCC AAG GCG TAA 
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 Identification of elastin-mimetic proteins.    Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed a single protein band 
at 250 kDa and 100 kDa corresponding to LysB10 (Figure 3A) and R4 (Figure 3B), 
respectively.  A total of 10 µg of the elastin-mimetic polypeptide along with molecular 
weight markers (Precision Plus Protein Kaleidoscope, Bio-Rad) were run on a 7.5% gel 
and negatively stained with a Copper stain (Bio-Rad).  As previously reported, molecular 
weights observed by SDS-PAGE for elastin-mimetic proteins are approximately 20% 
greater than calculated molecular weights [75, 97] .  
 
                                                  
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3.   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis of crosslinkable elastin-mimetic triblock copolymers.  A. LysB10, run on 7.5% SDS-
PAGE stained with Copper Stain (BioRad).  Expected molecular weight: 209 KDa.  B.  R4 
run on 7.5% SDS-PAGE stained with Copper Stain.  Expected molecular weight: 108 KDa.  
Marker lane: Precision Plus Protein Kaleidoscope (Bio-Rad).  C.  Assembly scheme for 
crosslinkable elastin-mimetic proteins, LysB10 and R4.  Both proteins are triblock 
copolymers with lysine-containing crosslinking domains flanking each plastic-like and elastic-
like domain.  Together, there are eight possible sites for chemical crosslinking afforded by 
the free amine moieties of the lysine residues and the N-terminal amine of the peptide chain.  
Plastic-like domain (grey), Elastic-like domain (white), Crosslinking domain (black).
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Amino acid composition analysis was performed by the Microchemical Facility at 
Harvard University.  Lyophilized protein was resuspended in HPLC grade water and 
dialyzed against the same water at 4°C with buffer changes.  Solutions of 1 mg/mL were 
submitted for analysis.  Amino acid compositional analysis of LysB10.  Calc. (mol.-%): 
Ala, 19; Glu, 1; Gly, 25.7; Ile, 13.9; Pro, 19.8; Val, 19.9. Obs. (mol.-%): Ala, 18.7; Glu, 
2.3; Gly, 23; Ile, 13.5; Pro, 18.1; Val, 18.  R4.  Calc. (mol.-%): Ala, 14.2; Gly, 26.1; Ile, 
19.2; Pro, 19.8; Val, 20.2. Obs. (mol.-%): Ala, 15.6; Gly, 24.3; Ile, 17.5; Pro, 19.4; Val, 
18.9. 
 Rheological analysis of concentrated protein polymer solutions.  
Rheological data were acquired on an Advanced Rheological Expansion System III 
rheometer (ARES III, TA instrument, NJ) in parallel plate geometry with a plate diameter 
of 25 mm.  The testing protocol for rheological analysis has been detailed elsewhere [1].  
In brief, 100 mg/mL protein solutions were prepared by adding distilled, deionized water 
to lyophilized protein at 4°C, shaking the solution for 48 hours, and then allowing the 
solution to equilibrate for 72 hours.  The gap between parallel plates was adjusted 
between 0.2 and 0.35 mm and dynamic mechanical experiments were performed in 
shear deformation mode.  An initial strain amplitude sweep was performed at 4°C and 
37°C at a frequency of 1 Hz to confirm the linear viscoelastic range for the protein 
polymer. 
 The gelation temperature was determined by heating samples from 4°C to 37°C 
at a rate of 1°C per minute.  Following temperature equilibration at 37°C, viscoelastic 
properties were examined by a strain sweep at a fixed frequency of 1Hz and a frequency 
sweep at fixed strain amplitude of 2%.  Experiments were repeated on six samples and 
representative data presented. 
 35 
 Fabrication of water cast protein films.   For mechanical property analysis, 
films were cast from protein solutions in water at room temperature.  In brief, lyophilized 
proteins were dissolved at a concentration of 100 mg/mL in water at 4°C.  The protein 
solution was then poured into Teflon casting molds and regulated solvent evaporation 
performed at 23°C for 48 hours.  After complete solvent evaporation, films were 
subjected to glutaraldehyde (GTA) vapor phase crosslinking.  Specifically, films were 
enclosed in a 2 L chamber containing a 10 mL of 25% gluteraldehyde (GTA) solution.  
Films were placed on a platform 4 cm above the GTA solution and exposed to GTA 
vapor for 24 hours.  Subsequently, the films were rinsed in PBS for 48 hours with a 
change of PBS at 24 hours.  Test samples were referred to as crosslinked or non-
crosslinked indicating whether GTA treatment was used.  Prior to testing, films were 
hydrated in PBS at 37°C, which contained NaN3 at 0.2 mg/mL to prevent biological 
contamination.  Samples were cut into a dumbbell shape using a stainless steel die with 
gauge dimensions of 13 mm x 4.75 mm.  Hydrated film thickness, as measured by 
optical microscopy, was typically 0.07 mm for non-crosslinked and crosslinked Lys B10 
films and 0.1 mm for R4 films. 
 
Evaluation of water content in protein films.  For evaluation of water content, 
200 µL of a 10 wt% protein solution was cast as a disk measuring 1 cm in diameter.  
Dried films were vapor phase crosslinked with a 25% GTA solution for 24 hours, fully 
dehydrated under vacuum, and the dehydrated weight obtained using a Mettler balance.  
Films were subsequently incubated in PBS at 37°C for 24 hours and fully hydrated 
weights were obtained. A total of six films were evaluated for each protein. The 
equilibrium water content and equilibrium swelling ratio were determined according to 
equations (1) and (2), respectively [111].  
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 weighthydrated
 weightdehydrated - weight hydratedContent Water mEquilibriu =     (1) 
 weightdehydrated
 weighthydratedRatio Swelling mEquilibriu =                                       (2) 
 
Characterization of non-crosslinked extractables.   To determine the percent 
of potentially extractable protein polymer, 200 µL of a 10-wt% protein solution was cast 
as a disk measuring 1 cm in diameter.  Dried films were vapor phase crosslinked with a 
25% GTA solution for 24 hours, rinsed in PBS and incubated at 4°C, below the inverse 
transition temperature of the protein, for a period of seven days.  Every 48 hours films 
were dehydrated and dry weight was monitored for material losses. Six films were 
investigated for each protein.  The percent extractable was determined by equation (3).  
100
 weighthydrated
 weightdehydrated-1 esExtractabl % ×=      (3) 
Mechanical analysis of hydrated protein films.  A preconditioning protocol 
was employed for LysB10 samples that consisted of a single cyclic stretch to 50% strain 
for one cycle followed by 20 cycles of 30% strain with off-loading periods of 5 minutes 
between each cycle.  Due to the plasticity of R4 protein films, preconditioning was not 
conducted.  Uniaxial stress-strain properties of protein films were determined on at least 
five to six individual specimens using a dynamic mechanical thermal analyzer (DMTA V, 
Rheometric Scientific Inc., Newcastle, DE) with a 15 N load cell in the inverted 
orientation, so that samples could be immersed in a jacketed beaker filled with PBS at 
37°C.  The maximum travel distance of the drive shaft was 23 mm, which limited 
maximum strain to 70% of engineering strain.  Given the extensibility of these materials, 
uniaxial stress-strain responses were also characterized using a miniature materials 
tester (Minimat 2000, Rheometric Scientific) in tensile deformation mode at a rate of 5 
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mm/min conducted in air at room temperature.  All samples were coated with a thin layer 
of mineral oil to prevent dehydration.  For both DMTA and Minimat testing, samples were 
cut into a dumbbell shape using a stainless steel die with gauge dimensions of 13 mm x 
4.75 mm.  In addition, to calculating Young’s modulus (E), ultimate tensile stress (UTS), 
and strain at failure (ε), resilience was determined from equation (4).  
100
curve loadingunder  area
curve unloadingunder  area-curve loadingunder  area-1 Resilience % ×=  (4) 
Creep analysis was performed on 6 to 12 specimens for each film type subjected to 
varying levels of constant engineering stress for periods of up to 11 hours.   
 In vivo evaluation of crosslinked protein gels.  Syringe casting method for 
creating cylindrical implants.  In order to minimize sample manipulation and the risk of 
cross-contamination, the following protocol was used for preparation of samples for in 
vivo implant studies. A 10 wt% cold protein solution was drawn into a chilled sterile 1 mL 
syringe (Becton Dickenson) and subsequently gelled at 37°C.  The tip of the syringe was 
removed with a sterile scalpel and the molded protein gel extruded into room 
temperature PBS.  Gel samples, 4.75 mm in diameter by 8 mm in length, were incubated 
in 0.5% GTA for 24 hours.  Following crosslinking, samples were washed in sterile PBS 
for 48 hours with 20 buffer exchanges.  
Subcutaneous and peritoneal implant models.  All animal experiments were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Emory 
University.  Eight-week-old inbred male C57BL/6 mice weighing 25–30 g were obtained 
from the Jackson Laboratory (Bar Harbor, ME).  Under ketamine (95 mg/kg, IM) and 
xylazine (5 mg/kg, IM) anesthesia, a 1 cm dorsal midline incision was performed and a 
single test sample implanted in the subcutaneous space, parallel to the longitudinal body 
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axis of each mouse.  Each implant type was implanted in at least three separate mice.  
Three weeks after implantation, animals were sacrificed and samples explanted with 
overlying skin.  For peritoneal implants, a 1 cm long midline incision was made along the 
linea alba of the abdominal wall and a single implant placed into the peritoneal cavity. 
After closing the abdominal muscle with 4-0 absorbable surgical suture (Vicryl, Ethicon, 
Inc, NJ), the skin incision was closed with wound clips.  Each recombinant protein was 
implanted in at least five mice.  Mice were sacrificed one week later and, prior to sample 
removal, a peritoneal saline lavage was performed to harvest cells for FACS analysis.   
Histological examination.  Retrieved samples were processed for histological and 
immunohistochemical evaluation to characterize the local cellular response and to 
determine the extent and thickness of fibrous capsule formation.  All samples were fixed 
in 10% neutral buffered formalin overnight and processed for parafin embedding.  
Sections were prepared at a thickness of 5 µm and stained with hematoxylin and eosin 
(H&E) or rat anti-mouse monoclonal F4/80 (CI:A3-1, Abcam) to identify infiltrating 
macrophages.  In all cases, multiple sections were examined in three to five separate 
samples for each protein polymer type.   
Fluorescent-activated cell sorting (FACS) of peritoneal lavage.   Prior to 
harvesting implants, each peritoneal cavity was initially lavaged with 10 mL of cold 
Hank’s Balanced Salt Solution containing 10 U/mL heparin and 1% BSA (Mediatech, 
Inc).  Typically, 6 to 7 mL of lavage solution was retrieved and cells immunostained for 
flow cytometry with PE-conjugated rat monoclonal anti-mouse CD11b for macrophages, 
FITC-conjugated hamster anti-mouse CD3 for total T cells, FITC-conjugated rat 
monoclonal anti-mouse CD4 for helper T cells, FITC-conjugated rat monoclonal anti-
mouse CD8 for cytotoxic T cells, FITC-conjugated rat monoclonal anti-mouse CD19 for 
B cells, and FITC-conjugated rat monoclonal anti-mouse Gr-1 for neutrophils (BD 
Biosciences Pharmingen).  Typically, antibodies were diluted to 1 µg/50 µL/106 cells in 
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PBS containing 1% BSA and 0.1% sodium azide.  Cells were incubated in the dark for 
30 minutes on ice, then washed three times in staining buffer, and fixed in 1% 
paraformaldehyde.  Analysis was performed on a FACScan using Cellquest (Becton 
Dickinson) and FlowJo software (Tree Star) [112]. Comparison between groups was 
analyzed via a Student’s t-test and p < 0.05 were considered to be significant.  Results 
are presented as mean ± SEM. Two control groups were employed; one that did not 
undergo surgery and another in which surgery was performed without sample 
implantation.   At least five mice were enrolled in each experimental and control group. 
 
2.3 Results and Discussion 
Synthesis of triblock protein copolymers capable of both chemical and 
physical crosslinking.  We have recently reported the design of a new class of 
recombinant elastin-mimetic triblock copolymer that has the capacity to form physical or 
virtual crosslinks, which stabilize protein network structure [1-3].  Moreover, through 
selective engineering of block structure, including the design of block size or sequence, 
and choice of film casting conditions, microphase structure can be manipulated and, as 
a consequence, material properties, such as drug elution characteristics and mechanical 
behavior tailored over a wide range of responses [1, 4, 5].  However, physical crosslinks 
formed as a result of hydrophobic aggregation may be deformed or disrupted under 
external stresses lower than that required to disrupt covalent crosslinks.  This feature 
may limit the capacity of physically crosslinked protein-based materials to retain material 
integrity under loading conditions operative for a number of potential applications in 
tissue engineering or regenerative medicine.  Given these considerations, we have 
postulated that chemically locking a multiblock protein assembly in place may provide a 
strategy to preserve functional responses that are linked to specific domain structures 
and morphologies over a broader range of externally applied loads. Further, it would also 
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provide an additional approach for altering material strength and compliance, as well as 
stress induced creep behavior. 
In this report, elastin-mimetic triblock copolymers were designed with endblock 
sequences, encoded by a hydrophobic repeat sequence, (IPAVG), that exhibits plastic-
like mechanical responses, and a central elastomeric block of varying amino acid 
structure.  The endblock sequence was selected to display an inverse temperature 
transition in water below 37°C, thereby mediating protein self-assembly due to endblock 
coacervation at or above this temperature.  Sites for covalent crosslinking were 
engineered at positions flanking each block.  Two target proteins were genetically 
engineered.  A 209 kDa triblock, LysB10, was designed with hydrophobic endblocks 
with a mass of approximately 75 kDa each, which contained 33 repeats of the 
pentapeptide sequence [IPAVG]5, separated by a 58 kDa hydrophilic midblock 
comprised of 28 repeats of the pentapeptide sequence [(VPGAG)2VPGEG(VPGAG)2] 
(Table 2-2).  Crosslinking sites that contained a pair of lysine residues (KAAK) flanked 
each block, such that a total of eight crosslinkable residues were potentially accessible.  
The presence of glutamic acid residues (E) was responsible for the hydrophilic character 
of the midblock. 
In addition, a 108 kDa triblock protein polymer, designated as R4, was 
synthesized with flanking hydrophobic plastic-like endblocks, each with a mass of 
approximately 37 kDa that contained 16 repeats of [IPAVG]5 , separated by a 35 kDa 
midblock comprised of 15 repeats of [VPGIG]5  (Table 2-3). Likewise, a total of eight 
potential crosslinking sites were engineered into the protein sequence; positioned 
predominantly as lysine pairs (KAAK) that flank each block. The substitution of 
isoleucine for glutamic acid in the midblock yielded a protein that was largely 
hydrophobic with little difference in block polarity.  While VPGEG and VPGIG are both 
reported to form β-spiral structures that display elastic responses when crosslinked as 
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gels, polypeptides from each sequence differ significantly in their inverse transition 
temperature.  Specifically, by incorporating the hydrophobic residue, isoleucine, into the 
fourth position of the repeat sequence, the inverse transition temperature of VPGIG is 
much lower than that associated with VPGEG [66, 67, 81-83]. 
Lysine crosslinking domains were engineered with an appreciation of the 
structure of similar crosslinking sites in native elastin and a consideration of the ‘N-end 
rule’, such that the identity of the N-terminal residue of a recombinant protein may 
influence degradation in bacterial expression systems.  In native elastin, crosslinking 
domains contain paired lysines within polyalanine repears (eg. Ala-Ala-Ala-Lys-Ala-Ala-
Lys-Ala-Ala) [108, 109], which promotes formation of an alpha-helix that has been 
reported to facilitate intermolecular crosslinking [62-65].  Thus, for both protein triblock 
copolymers, a lysine containing insert was designed encoding two lysine residues 
separated by two alanine residues (Lys-Ala-Aal-Lys) that was inserted between 
component blocks.  Additionally, lysine containing adaptor sequences were designed to 
encode for two C-terminal, as well as a single lysine residue near the N-terminus.  
Lysine was not incorporated as an N-terminal residue, as previous efforts to encode 
lysine in this position have lead to a 10-fold decrease in protein yield [74, 85, 86, 113].  
This design afforded eight free amines for crosslinking, seven from lysine and one from 
the N-terminal amine (Figure 2-3C). 
 
Rheological analysis confirms formation of viscoelastic protein gels.  The 
gelation point of protein solutions can be determined by measurement of G’ and G” as a 
function of temperature at a fixed frequency.  Above 13°C, the shear storage (G’) and 
loss (G”) modulus of concentrated aqueous solutions of LysB10 increased by a factor of 
approximately 103 and 10 (Pa), respectively, while tan δ (G’/G”) decreased, consistent 
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with the formation of a viscoelastic gel (Figure 2-4A). Above 15 °C, R4 solutions 
displayed an increase in shear storage (G’) and loss (G”) modulus to 104 and 103 (Pa), 
respectively, with only a modest reduction in tan δ (Figure 2-4C). For both LysB10 and 
R4 protein solutions at 37°C, G’ and G” were independent of frequency between 1 to 10 
rad/s at a fixed strain amplitude of 2% (Figure 2-4B, 2-4D).  In addition, the complex 
viscosity (η*) was a linear function of the logarithm of frequency with a slope of -1.  
However, as evident by a significantly higher tan δ and complex viscosity, aqueous gels 
of R4 were more viscous than those of LysB10. This difference highlights the 
significance of the midblock structure in triblock design.  Despite similar endblock 
structure and the presence of an elastomeric midblock sequence in both R4 and LysB10 
triblocks, the R4 midblock is considerably more hydrophobic and coacervates along with 
the endblock at 37°C.  Indeed, when expressed as single blocks the inverse transition 
temperatures of the R4 endblock and midblock proteins were 26°C and 16°C, 
respectively, while the comparable transition temperatures for LysB10 blocks were 21°C 
and >80°C  (data not shown).  Thus, significant mixing of the elastomeric and plastic-like 
blocks occurs only in the case of gels produced from the R4 protein polymer, which 
limits its elastomeric response.  We have previously demonstrated that selected 
changes in midblock size and amino acid sequence result in significant changes in 
viscoelastic mechanical properties.  Indeed, a more viscous response, similar to that 
observed for R4, was displayed by a protein composed entirely of hydrophobic plastic-
like endblock sequences [1].  
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Figure 2-4.  Rheological behavior of triblocks in water.  (A) LysB10 dynamic shear storage (G′), loss modulus (G″) are plotted as a 
function of temperature (γ 2%, ω 1Hz).  (B) LysB10 dynamic shear storage (G′), loss modulus (G″), and complex viscosity (η*) are 
plotted as a function of frequency (γ 2%, 37°C). (C) R4 dynamic shear storage (G′), loss modulus (G″) are plotted as a function of 
temperature (γ 2%, ω 1Hz).  (D) R4 dynamic shear storage (G′), loss modulus (G″), and complex viscosity (η*) are plotted as a 
function of frequency (γ 2%, 37°C).
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Glutaraldehyde crosslinking of elastin-mimetic triblock copolymer films. 
Investigations by our group and others have demonstrated that covalent crosslinks can 
enhance the mechanical stability of a variety of elastin analogues (Table 2-4).  Aldehyde 
crosslinking agents, such as glutaraldehyde, have been commonly used to process 
implanted tissues and proteins because of their capacity for efficient crosslink formation 
with an associated reduction in tissue antigenicity and enhanced mechanical strength 
[114, 115].  While limitations of glutaraldehyde exist [96, 107], since it remains an 
industry standard and its effects are otherwise well established, it was used in this study 
as a model crosslinking system. 
As a measure of the extent of crosslinking, the percent of extractable protein was 
examined after incubating samples at 4°C for seven days.  Below the inverse transition 
temperature, non-crosslinked films dissolved immediately due to disruption of physical 
crosslinks.  After vapor phase GTA crosslinking, films retained approximately 86% 
(LysB10) and 88% (R4) of their mass consistent with a high degree of chemical 
crosslinking, despite a relatively limited number of crosslink sites per protein species.  
The equilibrium water content observed for R4 and LysB10 films was 32.0 ± 3.7% and 
54.3 ± 3.8%, respectively; values that are similar to the 32% water content reported for 
hydrated elastin at 36°C [116].  Likewise, water swelling ratios were 1.5 ± 0.1 for R4 and 
2.4 ± 0.2 for LysB10, consistent with the higher proportion of hydrophobic amino acids 
in R4. 
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Table 2-4. Review of chemically crosslinkable elastin-mimetic systems and chemical crosslinking strategies 
 
Abbreviations:  CS5-RGD cell binding domain, GTA-glutaraldehyde, DSG-disuccinimidyl glutarate, HMDI-hexamethylene diisocyanate, BS3-bis(sulfosuccinimidyl) 
suberate, DSS-disuccinimidyl suberate, TSAT-tris-succinimidyl aminotriacetrate, THPP-tris(hydroxymethyl)phosphino-propionic acid, PQQ-pyrroloquinoline quinine, E= 
elastic modulus, σ = ultimate tensile strength, ε = elongation at break, G* = complex modulus, G = shear modulus
 
Crosslinkable Recombinant Elastin-
Mimetic Proteins 
Molecular  
Weight (kDa) 
Crosslinking 
Agent 
Fabrication 
Technique 
Mechanical 
Evaluation 
Biocompatibility 
Evaluation Reference 
Poly(KGGVG) (polydisperse) 6.5-14 (polydisperse) GTA and DSG hydrogel 
- 
 
- 
 
[94] 
 
VPGIG2VPGKGVPGIG2-CS5- 
VPGIG2VPGKGVPGIG2 
80.7 GTA film - - [93] 
E = 0.099-0.32 MPa 
σ = 0.5-0.9 MPa CS5-(VPGIG)20 [CS5-(VPGIG)20]3 
[CS5-(VPGIG)20]5 
14, 36.6, 59 GTA film 
ε = 251-393 % 
 
- [86] 
[VPGVG4VPGKG]25 80.6 BS3 and DSS hydrogel - - [98] 
E = 0.4-0.9 MPa 
G = 0.13-0.31 MPa 
CS5-(VPGIG)25 
[CS5-(VPGIG)25]3 
[CS5-(VPGIG)25]5 
14, 36.6, 59 Isocyanate hydrogel 
Ε = 340-570 % 
 
- [96] 
ELP[KV6]-102, ELP[KV16]-112 42.7, 47 TSAT hydrogel G* = 1.6-15 kPa - [97] 
ELP[KV6-112] 47.1 TSAT Hydrogel + cells G* = 0.28-1.7 kPa non-cytotoxic in vitro [107] 
KV7F-72 AND KV2F-64 31, 28.3 THPP Hydrogel G* = 5.8-45.8 kPa 
non-cytotoxic in 
vitro, 3 days [101, 102] 
E = 1.8 MPa Genipin Film 
ε = 0.68 mm/mm - 
E = 0.4 MPa 
Exons 20-24 
 10 PQQ Film 
ε = 0.90 mm/mm - 
[65, 92] 
 
E = 0.08-0.7 MPa BS3 Film G = 0.022-0.060 MPa - 
E = 0.3-0.97 MPa 
CS5-[(VPGIG)2(VPGKG)(VPGIG)2] 4 
 37 DSS Film G = 0.12-0.32 MPa - 
[100] 
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Mechanical responses of LysB10 copolymer films.  Most biomolecular 
constructs represent dynamic systems of hydrated biopolymer chains whose 
entanglements and structural interrelationships may be altered in response to an 
external load.  As a consequence, initial mechanical properties may change in response 
to repetitive loading forces until stable behavior is observed.  Thus, mechanical 
preconditioning is presumed to induce changes in microstructure that lead to fixed 
structural rearrangements of the constituent polymer chains and, as a consequence, 
stable material properties under a given loading environment [117-120]. Preconditioned, 
non-crosslinked LysB10 films were robust and elastomeric; displaying an elastic 
modulus of 0.49 ± 0.03 MPa, an ultimate tensile strength of 2.88 ± 0.71 MPa, a strain at 
failure of 463 ± 43%, and a resilience of 53 ± 2%.  In contrast, preconditioned 
crosslinked samples exhibited a three-fold increase in Young’s modulus (1.10 ± 0.45 
MPa) and a 50% decrease in strain at failure (223 ± 30%) along with no significant 
change in ultimate tensile strength compared to their non-crosslinked counterparts 
(Table 2-5, Figures 2-5, 2-6).  We speculate that these differences are largely related to 
the stabilization of semi-rigid endblocks by chemical crosslinking.  While crosslinking 
enhanced strength and modulus, a modest reduction in resilience was noted.  Since 
crosslinking was performed prior to preconditioning, the capacity of chain entanglements 
between midblock and endblock sequences to structurally rearrange in response to the 
conditioning protocol may have been restricted.  In other words, crosslinked-fixed mixing 
between rigid and elastomeric domains, in addition to restricting the mobility of the 
elastomeric phase, may have contributed to this effect.  
The approximate hoop stress of a blood vessel with an inner diameter of 4.5 mm 
and wall thickness of 0.8 mm is 45 kPa, when subjected to an intraluminal pressure of 
16 kPa (120 mmHg).  Crosslinked LysB10 films demonstrated limited creep (<10%) over 
11 hours at stress levels at or below 45 kPa. Increasing the applied stress by a factor of 
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ten increased creep to ~30% (Figure 2-7A).  In contrast, non-crosslinked films showed a 
four-fold greater level of creep strain in response to 45 kPa loading stress (Figure 2-7B). 
 
Mechanical responses of R4 copolymer films.  Hydrated R4 films revealed 
plastic-like deformation behavior.  Specifically, stress increased linearly with increasing 
strain until a yield point was observed at 1.72 MPa and 4.49 MPa in non-crosslinked and 
crosslinked films, respectively (Figure 2-8A). Corresponding values of Young’s modulus 
were 48.6 ± 0.9 MPa and 67 ± 5.14 MPa for non-crosslinked and crosslinked samples, 
respectively.  These values are four- to ten-fold greater than those noted for LysB10 
(Table 2-5).  As compared to LysB10, the more hydrophobic character of R4 is 
associated with reduced water uptake, which contributes to an increase in material 
rigidity and tensile strength.  Moreover, given the similarity of endblock and midblock 
polarity, size, and transition temperature, we speculate that a greater degree of block 
mixing occurs in films composed of R4 with rigid, plastic-like domains sustaining a higher 
level of the external load.  Crosslinking appears to have a relatively greater effect on the 
yield point (2.6-fold increase) than Young’s modulus (1.4-fold increase).  Likely, the 
effect of block mixing has a more profound effect on the mobility of the elastomeric 
phase than crosslinking, which predominantly stabilizes the semi-rigid endblocks.  
Consistent with these observed uniaxial stress-strain properties, crosslinked R4 films 
demonstrated limited creep strain (<10%) over an 11-hour period, despite applied 
stresses as high as 400 kPa.  Substantial deformation, however, was noted at stresses 
of nearly 1 MPa (Figure 2-8B). 
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Table 2-5.  Summary of mechanical parameters in crosslinked and non-crosslinked films 
Protein Treatment 
Resilience 
(%) 
Young’s Modulus 
DMTA (MPa) 
Young’s 
Modulus 
 Minimat (MPa) 
UTS 
(MPa) 
Strain at 
Failure  
(%) 
LysB10 GTA Xlinked 39 ± 1* 1.10 ± 0.45*  1.60 ± 0.48* 3.62 ± 0.98 223 ± 30* 
LysB10 Non-Xlinked 52 ± 2* 0.49 ± 0.03* 0.53 ± 0.02* 2.88 ± 0.71 463 ± 43* 
R4 GTA Xlinked - 67.4 ± 5.14* - 4.49 ± 0.27* 8 ± 2* 
R4 Non-Xlinked - 48.6 ± 0.90* - 1.72 ± 0.30* 4.9 ± 1* 
B10§ 
 
Water-25 
 
67± 1 
 
0.71 ± 0.12 
 
- 
 
- 
 
- 
 
Average values obtained from 3-10 replicates.  Resilience and Young’s Modulus determined from DMTA testing.  Young’s modulus, UTS, and % 
Strain determined from Minimat testing. *(p < 0.05 between crosslinked and non-crosslinked samples) 
§B10 Data obtained from Wu et al, Biomacromolecules, in review [6]. 
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Figure 2-5.  The influence of preconditioning on the resilience of water cast LysB10 
films with and without glutaraldehyde crosslinking (Figure A and B, respectively).  A 
sample was cyclically stretched to 50% strain and then to 30% for 20 cycles, with an off-
loading period of 5 minutes between cycles.  This figure is representative of multiple 
data sets.  
A 
B 
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Figure 2-6. A. The influence of preconditioning on the resilience of water cast LysB10 
films with (left y-axis) and without glutaraldehyde crosslinking (right y-axis).  The sample 
was cyclically stretched to 50% strain and then to 30% for 20 cycles, with an off-loading 
period of 5 minutes between cycles.  This figure is representative of multiple data sets 
and illustrates cycle 20 of 30% stretch. B. Uniaxial stress-strain analysis performed on a 
Minimat 2000.  The Young’s modulus was 1.60 ± 0.48MPa for preconditioned 
glutaraldehyde crosslinked films and 0.53 ± 0.02 MPa for preconditioned non-
crosslinked films measured from the linear region.
A 
B 
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Figure 2-7.  A.  Creep behavior of water cast LysB10 films GTA crosslinked examined 
as tensile stress was maintained at 45KPa and 450KPa.  These figures are 
representative of multiple data sets in which variability was <10%.  B. Comparison of the 
creep behaviors of water cast LysB10 films with and without gluteraldehyde crosslinking 
at applied stresses of 45 KPa.   
A 
B 
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Figure 2-8.   A.  Uniaxial stress-strain analysis.  The Young’s modulus was determined 
from the linear region of the curve as 67.4± 5 MPa for glutaraldehyde crosslinked R4 
films measured on a Minimat 2000 and 48.6± 9 MPa for non-crosslinked R4 films 
measured on a DMTA. B. Comparison of the creep behaviors of water cast R4 films 
subjected to gluteraldehyde crosslinking.  Creep was examined as tensile stress was 
maintained at 45KPa and 450KPa, and 800KPa.  This figure is representative of multiple 
data sets.  R4 samples were not preconditioned. 
A 
B 
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In vivo responses to crosslinked elastin-mimetic protein hydrogels.  Using 
a murine model, crosslinked LysB10 and R4 hydrogels were implanted into either the 
subcutaneous space or the peritoneal cavity.  FACS analysis demonstrated no 
difference in either the cell number or cell type identified within peritoneal lavage fluid, 
harvested one week after either sham surgery or protein polymer implantation (Figure 2-
9). Samples implanted within the peritoneal cavity and subcutaneous tissue were 
explanted one and three weeks after implantation, respectively (Figures 2-10, 2-11).  
Macrophages were identified along the periphery of the fibrous capsule and in the 
surrounding tissue without infiltration into the implant. The fibrous capsule thickness of 
LysB10 samples within the subcutaneous space was 25.3 ± 16.1 µm, while the capsule 
measured 14.5 ± 5.3 µm for those placed in the peritoneal cavity.  R4 implants displayed 
a similar response, with a fibrous capsule thickness of 24.2 ± 6.0 µm and 8.4 ± 1.2 µm 
for subcutaneous and peritoneal cavity implants, respectively.   
Tissue-material interactions, including biopolymer stability, are integral to 
assessing the suitability of elastin-like protein polymers for implant related applications.  
To date, reports documenting in vivo responses to elastin-mimetic protein implants have 
been limited; largely confined to studies performed 15 to 20 years ago on proteins 
synthesized chemically and subject to radiation crosslinking [82, 121].  In these 
investigations, homopolymers or copolymers composed of VPGVG, VPGKG, VPGEG, 
IPAVG, and VPAVG reportedly did not induce significant inflammatory or allergic 
reactions [121-124]. The most thoroughly characterized elastin variant, chemically 
synthesized poly(GVGVP), was subjected to in vitro toxicity and mutagenicity assays 
and was administered via intravenous, intraocular, intramuscular, intraperitoneal, and 
subcutaneous routes without toxic effect [82, 121].  A fibrous capsule was noted three 
weeks after intramuscular implantation of a radiation crosslinked sample [82].  In a more 
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recent report, elastin microparticles prepared from chemically synthesized poly(VPAVG) 
were evaluated following subcutaneous and intravitreal injection.  No inflammatory 
response was observed after 28 days.  However, tractional retinal detachment was 
noted [122].  The failure to detect an immune mediated reaction to these polymers is 
consistent with other studies that have sought to identify potentially immunogenic 
epitopes on native elastin.  While polyclonal and monoclonal antibodies can be raised 
against peptides derived from the hydrolysis of native elastin, neither VPGVG nor 
VPAVG peptides have been among the recognized sequences [124].  Moreover, 
VPGVG peptides were unable to competitively inhibit the binding of any of the antibodies 
raised against native elastin, which further supports the notion that this pentapeptide is 
not present among antigenic elastin epitopes [124]. 
Recently, genetically engineered elastin-mimetic protein polymers have been 
investigated in vivo as non-thrombogenic coatings [7, 125], targeted drug delivery 
vehicles [126-128], and as an implantable material [129].  In the latter instance, after a 
13 week implant period in the subcutaneous space, recombinant human tropoelastin 
‘sponges’, chemically crosslinked with bis(sulfosuccinimidyl) suberate, were surrounded 
by a fibrous capsule with a minimal to moderate inflammatory response [129].  Non-
chemically crosslinked recombinant elastin-like proteins have also been administered 
within the intra-articular space as a 650 µM protein solution [129].  Although the 
biological response was not evaluated, this study revealed a three hour half-life for non-
aggregating VPGVG proteins and a three day half-life for aggregating VPGXG proteins, 
where X = V:G:A at a ratio of 1:7:8.  As a related material, a 47 kDa recombinant silk-
elastin-like protein (SELP), comprised of GAGAS silk-like [S] and GVGVP elastin-like [E] 
amino acid sequences ([S]4[E]4[EK][E]3) has been studied after injection into the 
subcutaneous space.  Histological analysis revealed minimal fibrous encapsulation after 
four weeks with a mild degree of inflammation that included the presence of 
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macrophages in the surrounding tissue [130].  SELPs have been also used for 
adenoviral gene delivery and demonstrate prolonged and localized expression of 
adenoviruses for up to 15 days, suggesting the potential for cancer therapy [131, 132].  
A summary of in vivo biocompatibility studies conducted on elastin-mimetic proteins is 
presented in Table 2-6.  
The evaluation of in vivo biocompatibility is largely based on characterizing local 
tissue responses to subcutaneously implanted materials where the intensity and duration 
of inflammation and wound healing, including capsule formation, is evaluated 
histologically [133, 134].  Although histological studies of biopolymers containing elastin-
mimetic sequences have previously noted the presence of ‘mild inflammation’ [121, 122] 
and ‘a reaction that was limited to a typical cell mediated response to the presence of a 
foreign body’, the extent of fibrous capsule formation has not been reported [129].  
Fibrous capsule thickness has been investigated for a variety of polymeric and ceramic 
implants designed for tissue repair, cell encapsulation, or as drug delivery systems [135-
138].  Capsule thicknesses are dependent on implant site and material type and typically 
varies between 2 and 150 µm over implantation periods of one to three months.  For 
example, greater capsule thickness has been observed for materials within 
intraperitoneal sites compared to those in subcutaneous sites over identical implant 
durations [136].  As an illustration of the effects of surface chemistry, implants comprised 
of poly(alkyl methacrylate) (PAMA) with short alkyl side chains exhibited a thicker fibrous 
capsule than those with long side chains (140 µm vs 120 µm) [135].   Additionally, self-
assembled monolayers (SAMs) of alkanethiols on gold with different terminal functional 
groups displayed surface dependent inflammatory responses after one week with 
extremely hydrophobic methyl terminated surfaces inducing thick fibrous capsules (130 
µm) and higher recruitment of inflammatory cells compared to hydrophilic COOH- and 
OH- terminated surfaces (80 µm and 70 µm, respectively) [139].  Likewise, 
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functionalized polypropylene implants revealed similar foreign body reactions to surface 
modifications, with –OH surfaces triggering a stronger response (~100 µm) compared to 
–COOH rich surfaces (37 µm ) [140].  In contrast, surface topography does not appear to 
have a significant effect on capsule thickness, although it may influence local 
inflammatory responses [141].   In this report, there were no observable differences in 
biological responses for either chemically crosslinked triblock elastin-mimetic protein 
polymer.  Both R4 and LysB10 implants initiated limited local inflammatory activity and 
displayed relatively thin fibrous capsules. 
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Figure 9. FACS analysis of peritoneal implanted LysB10 and R4 cylindrical hydrogels one week post-implant (n=5 for each 
group).  Experimental groups showed no statistical difference in cell number from normal and sham control groups. 
 
 
 
 
 
 
Figure 2-9. FACS analysis of peritoneal implanted LysB10 and R4 cylindrical hydrogels one week post-implant (n=5 for each group).  
Experimental groups showed no statistical difference in cell number from normal and sham control groups
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Figure 2-10. Histological analysis of three subcutaneous LysB10 implants retrieved 3 weeks post-implant.  (A) H&E staining of 
formalin fixed, paraffin embedded subcutaneous LysB10 implants demonstrates the presence of a mild foreign body reaction along 
the periphery of the sample.  (B)  F4/80 staining of formalin fixed, paraffin embedded subcutaneous LysB10 implants demonstrate 
the presence of macrophages along the periphery of the fibrous capsule but no infiltration into the LysB10 implant.  Histological 
analysis of peritoneal LysB10 implants retrieved 1 week post-implant.  (C)  H&E staining demonstrates the presence of a mild 
foreign body reaction along the periphery of the peritoneal LysB10 implant .  (D)  F4/80 staining the presence of macrophages along 
the periphery of the fibrous capsule but no infiltration into the peritoneal LysB10 implant.  Images are oriented so that the LysB10 
gel is located in the bottom right corner.  
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Figure 2-11. Histological analysis of three subcutaneous R4 implants retrieved 3 weeks post-implant.  (A) H&E staining of formalin 
fixed, paraffin embedded subcutaneous R4 implants demonstrates the presence of a mild foreign body reaction along the periphery 
of the sample.  (B)  F4/80 staining of formalin fixed, paraffin embedded subcutaneous R4 implants demonstrate the presence of 
macrophages along the periphery of the fibrous capsule but no infiltration into the R4 implant.  Histological analysis of peritoneal R4 
implants retrieved 1 week post-implant.  (C)  H&E staining demonstrates the presence of a mild foreign body reaction along the 
periphery of the peritoneal R4 implant .  (D)  F4/80 staining the presence of macrophages along the periphery of the fibrous capsule 
but no infiltration into the peritoneal R4 implant.  Images are oriented so that the R4 gel is located in the bottom right corner.  
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2.4 Conclusions 
A new class of recombinant elastin-mimetic protein polymer has been designed 
that is capable of both physical and chemical crosslinking.  We have demonstrated that 
chemical crosslinking provides an independent mechanism for control of protein 
mechanical responses.  Specifically, elastic modulus can be enhanced and creep strain 
reduced through the addition of chemical crosslinking sites.  Additionally, we have 
demonstrated exceptional biocompatibility of gluteraldehyde treated multiblock systems.  
By chemically locking a multiblock protein assembly in place, unique structures and 
morphologies are preserved and stabilized, which provides the capacity to modulate a 
wide range of functional responses, such as mechanical behaviors, permeability, and 
drug elution characteristics.  We anticipate that these materials will find utility in a 
number of vascular and non-vascular biomedical applications. 
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CHAPTER 3 
Biocompatibility of Recombinant Elastin-Mimetic Proteins 
 
3.1 INTRODUCTION 
Elastin-based protein polymers, genetically engineered with or without cell 
binding motifs, crosslinking domains, or non-natural amino acids, represent a promising 
new class of biomaterial [86, 102, 107, 142, 143].  Their capacity to be processed as 
gels [2-4], films [5, 6], or nanofibers [1, 103]  demonstrate the versatility of these 
recombinant proteins with potential applications in drug delivery [2, 144-146], tissue 
engineering [86, 147-149], or as constituents of implanted medical devices [7, 125].   
The majority of these proteins have been examined as covalently crosslinked networks 
[91-103]. 
Recently, we have reported the synthesis of amphiphilic elastin-mimetic protein 
polymers composed of complex block sequences that self-assemble through the 
formation of robust physical crosslinks [1, 4, 5, 150].  The biosynthetic scheme for 
generating self-assembling recombinant proteins has been based upon a convergent 
strategy for integrating multiple blocks of concatemerized DNA cassettes by sequential 
ligation [1, 2, 98].  To date, this strategy has been used to design diblock, triblock, and 
tetrablock copolymers ranging from 100 to 200 kDa in molecular weight [1, 4-7, 84, 150].  
The segregation of protein blocks into compositionally, structurally, and spatially distinct 
domains affords ordered structures on the nanometer to micrometer size range. 
Significantly, protein polymers that are structurally polymorphic display tunable 
mechanical, chemical, and biological properties [1, 4, 5, 150]. 
We have recently synthesized a triblock copolymer, designated B9, that contains 
identical hydrophobic endblocks with [(IPAVG)4(VPAVG)] repeat sequences, separated 
by a central hydrophilic block with repeating units of [(VPGVG)2(VPGEG)(VPGVG)2] [2].  
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Phase behavior and mechanical properties of elastin-mimetic polypeptides are critically 
dependent on the identity of the residues within the pentapeptide repeat unit Val/Ile-Pro-
Xaa-Yaa-Gly.  Yaa modulates the coacervation or inverse transition temperature (Tt) in 
water in a manner commensurate with the polarity of the amino acid side chain and 
polymer-solvent interactions.  Substitution of Ala for Gly in the third position of the repeat 
results in a change in mechanical response from elastic to plastic [151].  Thus, the 
midblock of B9 displays elastic-like behavior with spectroscopic features consistent with 
structural conformations of native elastin, including a highly mobile backbone, β-turns, 
and a loose helical β-spiral.  The presence of glutamic acid in the midblock raises the 
inverse transition temperature, preventing coacervation of the midblock over a 
temperature range exceeding 75°C [152, 153]. Nonetheless, these protein polymers 
reversibly self-assemble from concentrated aqueous solution above the Tt of the 
hydrophobic endblocks (~18°C) to form a stable, water solvated, interlocking network.  
Two-dimensional Fourier transform infrared (FTIR) spectroscopy reveals that above the 
Tt, endblock secondary structure changes from helix to sheet with the assembly of 
physical crosslinks [84].  Due to the presence of Ala in the third position of the 
pentapeptide repeat, the hydrophobic endblocks form relatively rigid domains that 
display plastic-like behavior.  Prior investigations from our group have confirmed robust 
viscoelastic and mechanical responses for this, as well as for other related elastin-
mimetic triblock copolymers [1, 4-6].    
In vivo studies have demonstrated excellent blood contacting properties in a 
primate arteriovenous shunt model when the triblock copolymer, B9, is coated as a thin 
film on the lumen of a small diameter vascular graft [7].  However, long-term 
biocompatibility and biostability for any of the members of this new class of physically 
crosslinked protein-based material has yet to be fully defined.  Indeed, it is possible that 
amphiphilic protein hydrogels would display significant in vivo instability, given the 
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existence of naturally occurring amphiphiles in biological fluids, such as phospholipids, 
glycolipids, and lipoproteins [154]. Such amphiphiles could act as surfactants 
destabilizing the virtual crosslinks of protein-based material whose structural integrity is 
based on the association of hydrophobic domains [155, 156].  While structural instability 
may be acceptable for biodegradable systems, it has the potential to severely limit the 
longevity of biomaterials whose integrity is related to hydrophobic interactions.  Many 
non-covalently crosslinked self-assembled systems, such as amphiphilic peptides, 
lipopeptides, or glycolipids that form thin films or fiber networks are useful for drug 
delivery where the half-life of the system is on the order of hours.  In general, none of 
these approaches demonstrate stability beyond a few days [157-161].   
We report herein that a virtually crosslinked elastin-mimetic triblock copolymer 
exhibits exceptional biocompatibility and long-term biostability over a period of at least 
seven months.  In conducting these studies, we have employed magnetic resonance 
imaging (MRI) as a noninvasive tool to provide real-time structural information for both 
the implant and surrounding tissue, as well as insight into degradation behavior [162-
164]. To our knowledge, this is the first evidence of a non-chemically or ionically 
crosslinked protein polymer system that exhibits long-term stability in vivo. 
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3.2 MATERIALS and METHODS 
Synthesis and purification of the elastin-mimetic triblock copolymer B9.  
The recombinant protein polymer B9 was derived from concatemerization 
of elastin-mimetic peptide sequences, as previously described [2].  The structure 
consists of an ABA triblock where: 
A block:  VPAVG[(IPAVG)4(VPAVG)]16IPAVG 
B block: VPGVG[(VPGVG)2VPGEG(VPGVG)2]48VPGVG. 
Individual colonies of B9 in pET24-a in E. coli strain BL21 (DE3) were used to inoculate 
30 mL of Circle Grow liquid media (Q-BIOgene) supplemented with the antibiotic 
kanamycin (50 µg/mL) and grown overnight at 37°C with shaking.  A total of 5% vol/vol 
of the overnight culture was used to inoculate large expression flasks containing 500 mL 
Circle Grow media and antibiotic, followed by a 24 hour expression at 37°C with shaking. 
Cells were harvested through centrifugation in sterile tubes at 1660 RCF for 20 
minutes at 4°C.  The supernatant was carefully decanted, cell pellets were resuspended 
in cold, sterile phosphate buffered saline (PBS) (20 mL per large culture flask pellet) and 
frozen at -80°C.   Three freeze (-80°C) / thaw (25°C) cycles were employed for the initial 
cell fracture with equilibration back to cold temperatures following the cycles.  Once cells 
were completely resuspended, six cycles of sonication, consisting of 20 second pulses 
with 20 seconds between each pulse in an ice bath, was employed to thoroughly break 
the cells.  To recover any unbroken cells, a preparative centrifugation step was used at 
1660 RCF for 10 minutes at 4°C.  Unbroken cells, which pelleted out during the spin, 
were resuspended in cold, sterile PBS and re-sonicated, as described above.   
 The cold cell lysate was centrifuged at 20,000g for 40 minutes at 4°C.  The 
supernatant was transferred to a cold, sterile tube and poly(ethyleneimine) (PEI) was 
added to a final concentration of 0.5%.  This solution was centrifuged again at 20,000g 
for 40 minutes at 4°C to remove all nucleic acids and contaminating cellular material 
 65 
precipitated by the PEI.  The supernatant was transferred to new sterile 50 mL Falcon 
tubes and NaCl was added to a final concentration of 2M.  The elastin-mimetic protein 
was salted out of solution at 25°C for 30-45 minutes.  This solution was centrifuged at 
9500g for 15 minutes at 25°C to recover the protein product (‘hot-spin’).  The 
supernatant was discarded and the protein pellet was resuspended in cold, sterile PBS 
on ice for up to 10-20 minutes to avoid solubilizing unwanted contaminates.  The 
resuspended solution was then subjected to a ‘cold spin’ at 20,000g for 40 minutes at 
4°C.  The supernatant was transferred to sterile 50 mL tubes and salting precipitation 
repeated.  The hot (25°C) / cold (4°C) spin cycles were repeated until a contaminating 
pellet was no longer observed after the cold spin.  Typically, 6-10 cycles were required 
followed by a hot spin.   
For in vivo studies, B9 underwent a secondary treatment with sodium hydroxide 
The protein pellet was resuspended in cold, sterile PBS at approximately 50 mg per 20 
mL.  Sterile sodium hydroxide was added to a final concentration of 0.4N and mixed 
gently by hand.  The mixture was incubated on ice for fifteen minutes, after which 5M 
sodium chloride was added to a final concentration of 2M.  The protein was precipitated 
from solution at 25°C, centrifuged at 8500g for 20 minutes at 25°C, and resuspended in 
cold PBS.  This treatment was repeated three times.  Following the third treatment, the 
protein solution was adjusted to pH 6-8.  A cold spin was performed at 20,000 rpm for 40 
minutes at 4°C and the supernatant was desalted using a PD-10 desalting column (GE 
Healthcare Lifesciences) with molecular grade water (Cellgro).  The end product was 
passed through 0.2 µm filter, eluted into autoclaved Lyoguard freeze drying trays (Gore), 
frozen at -80°C, and lyophilized.  This procedure afforded B9 as a white fibrous protein 
product with isolated yields of 50 mg/L of expression culture.   
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 Lyophilized B9 was resuspended in sterile molecular grade water at 1 mg/mL 
and endotoxin levels were assessed using the Limulus Amoebocyte Lysate (LAL) assay 
(Cambrex).  Levels of endotoxin were typically 0.1 EU/mg (1 EU = 100 pg of endotoxin).  
  
Structural characterization of the elastin-mimetic triblock copolymer B9.    
Gel electrophoresis.  Protein size and purity was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).  A total of 10 µg of the elastin-mimetic 
polypeptide was run on a 7.5% gel along with Precision Plus Protein Kaleidoscope (Bio-
Rad) molecular weight markers and negatively stained with Copper (Bio-Rad).  MALDI-
TOF mass spectrometry characterized a 165 kDa protein and the sequence was 
confirmed by amino acid compositional analysis [4].   
 Rheological analysis of concentrated B9 solutions.  Rheological data were 
acquired on an Advanced Rheological Expansion System III rheometer (ARES III, TA 
instrument, NJ) in parallel plate geometry with a plate diameter of 25 mm.  The testing 
protocol for rheological analysis has been detailed elsewhere [1].  In brief, protein 
solutions were prepared at 100 mg/mL by adding distilled, deionized water to lyophilized 
protein at 4°C, shaking the solution for 48 h, and then allowing the solution to equilibrate 
for 72 h.  The gap between parallel plates was adjusted between 0.2 - 0.35 mm and 
dynamic mechanical experiments were performed in shear deformation mode.  The 
gelation temperature was determined by heating samples from 4°C to 37°C at a rate of 
1°C per minute.  Experiments were repeated on three samples and representative data 
presented. 
In vivo biocompatibility of the elastin-mimetic triblock copolymer B9.  
Subcutaneous injection.  According to a protocol approved by Emory University 
Institutional Animal Care and Use Committee (IACUC), B9 protein solutions were 
injected into the subcutaneous space of 8 week old inbred male C57BL/6 mice weighing 
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25–30 g obtained from Jackson Laboratory (Bar Harbor, ME).  Mice were sedated using 
ketamine (95 mg/kg, IM) and xylazine (5 mg/kg, IM).  A total of 200 µL of 100 mg/mL 
solution of endotoxin free B9 was injected into the interstitial fascia where it immediately 
gelled.  A set of three mice each received a single injection.  All injections were 
conducted in the cold room using chilled syringes, needles, and solutions.  Mice were 
immediately warmed following the injection.  Three weeks post implantation, mice were 
sacrificed and the hydrogel explanted along with overlying skin.   
Peritoneal injection.  According to a protocol approved by Emory University 
Institutional Animal Care and Use Committee (IACUC), B9 protein solutions were 
injected into the peritoneal cavity of 8 week old inbred male C57BL/6 mice weighing 25–
30 g obtained from Jackson Laboratory (Bar Harbor, ME).  Mice were sedated using 
ketamine (95 mg/kg, IM) and xylazine (5 mg/kg, IM) prior to protein injections.  A total of 
200 µL of 100mg/mL solution of endotoxin free B9 was injected into the peritoneal cavity 
where it immediately gelled.  A set of five mice each received a single injection.  All 
injections were conducted in the cold room using chilled syringes, needles, and 
solutions.  Mice were immediately warmed following the injection.  One week post 
implantation, mice were sacrificed, and free cells in the peritoneal cavity were harvested 
by saline lavage, as detailed below, for FACS analysis prior harvesting the hydrogel for 
histological assessment.  
Histological examination.  Retrieved hydrogel samples were processed for 
histological and immunohistochemical evaluation to facilitate identification of cell types 
present.  All samples were fixed overnight in 10% neutral buffered formalin and 
processed for parafin embedding.  Sections were prepared at a thickness of 5 µm and 
stained with hematoxylin and eosin (H&E) or rat anti-mouse monoclonal F4/80 (CI:A3-1, 
Abcam) for infiltrating macrophages.  In all cases, multiple sections for each of three to 
five samples were examined.    
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Fluorescent-activated cell sorting (FACS) of peritoneal lavage.   Prior to 
harvesting implants, each peritoneal cavity was initially lavaged with 10 mL of cold 
Hank’s Balanced Salt Solution containing 10 U/mL heparin and 1% BSA (Mediatech, 
Inc).  Typically, 6 to 7 mL of lavage solution was retrieved and cells immunostained for 
flow cytometry with PE-conjugated rat monoclonal anti-mouse CD11b for macrophage, 
FITC-conjugated hamster anti-mouse CD3 for total T cells, FITC-conjugated rat 
monoclonal anti-mouse CD4 for helper T cells, FITC-conjugated rat monoclonal anti-
mouse CD8 for cytotoxic T cells, FITC-conjugated rat monoclonal anti-mouse CD19 for 
B cells, and FITC-conjugated rat monoclonal anti-mouse Gr-1 for neutrophils (BD 
Biosciences Pharmingen).  Antibodies were diluted in staining buffer (PBS pH 7.4 
containing 1% BSA and 0.1% sodium azide) to 1 µg/50 µL/106 cells, incubated with cells 
for 30 minutes in the dark on ice, washed three times in staining buffer, and fixed in 1% 
paraformaldehyde.  Analysis was performed on a FACScan using Cellquest (Becton 
Dickinson) and FlowJo software (Tree Star) [112].  Comparison between groups was 
analyzed via a Student’s t-test and p < 0.05 were considered to be significant.  Results 
are presented as mean ± SEM. The control group employed did not undergo surgery.   
At least five mice were enrolled in each experimental and control group. 
 
Non-invasive assessment of protein polymer implants in vivo.  Fabrication 
of cylindrical protein polymer implants.  A cold solution of B9 at 100 mg/mL was drawn 
into a chilled 1 mL syringe (Becton Dickenson), equilibrated at 4°C for 30 minutes, and 
subsequently geled at 37°C. The tip of the syringe was removed with a sterile scalpel 
and the molded protein gel extruded into room temperature PBS, equilibrated overnight 
under a bio-hood, and then sectioned into 8 x 4.76 mm cylindrical test samples (Figure 
3-1). 
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Figure 3-1.  Syringe casting method for B9 hydrogel implants.  (A) 10wt% B9 
solution was drawn into syringe and allowed to gel at room temperature.  (B)  
End of syringe was removed.  (C)  B9 hydrogel was ejected from syringe into 
room temperature PBS.  (D)  Ejected sample equilibrated in PBS.  This sample 
was sectioned into 8mm implants. 
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 In vivo biostability.  All animal experiments were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Emory University.  Eight-week-old inbred 
male C57BL/6 mice weighing 25–30 g were obtained from Jackson Laboratory (Bar 
Harbor, ME).  Under ketamine (95 mg/kg, IM) and xylazine (5 mg/kg, IM) anesthesia, a 1 
cm dorsal midline incision was performed and bilateral cylindrical gels implanted in the 
subcutaneous space, parallel to the spine.  Eight mice were enrolled and serial MR 
imaging performed weekly for 6 weeks and every other week thereafter.  During 
scanning, 2.5% isoflurane inhalation was utilized for induction followed by 1.8% 
isoflurane throughout the duration of imaging.  Total scan time for each animal was less 
than one hour.  At the termination of the study, all mice were sacrificed and samples with 
surrounding tissue harvested for immunohistochemical analysis.   
1H Magnetic Resonance Imaging.  MR imaging was performed using a 
Varian/Inova 4.7T horizontal bore magnet operating at 200.56 MHz (Varian, Inc).  The 
magnet was equipped with an 11.7 cm inner diameter shelf-shielded gradient system 
with a maximum gradient strength of 25 gauss/cm.  Constructs implanted in mice were 
investigated using transmit/receive 16-element quadrature birdcage coil with an inner 
diameter of 3.8 cm.  Each anesthetized mouse was secured in a home-built cradle and 
the implant centered within the magnetic field.   
Exact positioning of the construct was determined using several fast-spin echo 
scout scans.  A final high resolution fast-spin echo image (relaxation time, TR = 2.0 sec, 
echo spacing, esp = 14 µs at number of averages, nt = 2) was collected to provide a 
more detailed image of the construct structure and surrounding microenvironment.  A 
fast-spin echo sequence with an echo train length (ETL) of 8 was utilized, which afforded 
a field of view of 3.5 x 3.5 cm with a slice thickness of 0.5 mm (Figure 3-2).  
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Figure 3-2.  A.  A coronal view through the C57BL/6 mouse showing the location of the implant.  Image is oriented with the mouse 
vertical.  The green lines shown are the planing of the 23 transverse-oblique slices through the implant.  B. MR scan slices through 
implant.  C.  Transverse MR image of the subcutaneous B9 implant.  The light region on the outer surface is a cross section of the 
B9 implant.  Implant areas were assessed from individual images and summed to assess volume of the implant.  Slice thickness of 
the scan is 500 µm. (V = verterbra, M = Psoas Major muscle, I = Intestine cross-sections, B9 = cross-section of B9 implant). 
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Characteristically, transverse images of each implant consisted of 23 slices at a 
thickness of 500 µm.  The acquired data contained 256 x 256 points and was zero filled 
to 512 points in both the read and phase encoded directions.  A 2-D Fourier 
transformation was performed, which provided a final in-plane resolution of 68 x 68 µm 
with a slice thickness of 500 µm (Figure 3-3).  Cross-sectiomal area and length 
measurements were made using the image processing program, Image J (NIH).   
 
 
 
 
Figure 3-3.  Transverse MR images of the subcutaneous B9 implant.  The light region 
on the outer surface is the cross section of B9 implant.  Slice thickness is 500 µm. 
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3.3 RESULTS  
Characterization of B9.  Gel electrophoresis of B9 revealed a single band at 
170 kDa consistent with prior studies from our laboratory (Figure 3-4A) [1, 4, 7]. 
Likewise, rheological behavior of aqueous solutions of B9 was unchanged after NaOH 
treatment with an observed sol-gel transition at 18°C.   The gel point of protein solutions 
can be detected by measurement of the shear storage (G’) and loss (G”) modulus as a 
function of temperature at a fixed frequency.  Above 18°C, G’ and G” increased while tan 
δ (G’/G”) decreased, consistent with the formation of a viscoelastic gel (Figure 3-4B).  
Biocompatibility of injectable protein polymer gels.  To assess in vivo 
responses to B9 hydrogels, protein solutions were injected into either the subcutaneous 
space (Figure 5) or the peritoneal cavity in a mouse model.  Peritoneal samples were 
retrieved one week after implantation and subcutaneous samples explanted at three 
weeks.  Retrieved hydrogel samples were irregularly shaped, but optically transparent. 
Hematoxylin and eosin staining demonstrates the presence of a mild foreign body 
reaction for B9 implants by the formation of a very thin fibrous capsule surrounding the 
implant.  Observed capsule thickness was 35.75 ± 6.14 µm for subcutaneous specimens 
and 16.42 ± 2.85 µm for peritoneal samples without evident cellular infiltration into 
implants in either subcutaneous and peritoneal locations.  Scattered macrophages were 
noted along the periphery of the fibrous capsule consistent with a mild foreign body 
response (Figure 3-6 and 3-7).  The magnitude and type of peritoneal cell response 
harvested, as determined by an analysis of saline lavage, did not reveal significant 
differences between those mice receiving B9 and control non-treated mice (Figure 3-8).   
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Figure 3-4.  Structural Characterization of the B9 protein.  A.  Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed a single 
protein band at 170 KDa corresponding to B9.  10ug of the elastin-mimetic polypeptide 
was run on 7.5% gel and negatively stained with Copper stain (Bio-Rad). Molecular 
weight markers were Precision Plus Protein Kaleidoscope (Bio-Rad).  B.  Rheological 
behavior of 10 weight percent B9 in water. Dynamic shear storage (G′) and loss modulus 
(G″) are plotted as a function of temperature (γ 2%, ω 1Hz).  The gelation temperature 
was determined by heating samples from 4°C to 37°C at a rate of 1°C per minute.  
Experiments were repeated on 3 samples and representative data presented. 
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Figure 3-5. Subcutaneous injection mouse model.  200 uL of a 10 weight percent 
solution of B9 was injected subcutaneously, which gelled instantly.  A group of samples 
were retrieved three weeks for histology. 
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Figure 3-6. H&E staining of formalin fixed, paraffin embedded B9 implants demonstrates 
the presence of a mild foreign body reaction along the periphery of the sample.  
Histological analysis of subcutaneous B9 implants retrieved 3 weeks post-implant, skin 
side (A) and muscle side (B).  Histological analysis of peritoneal B9 implants retrieved 1 
week post-implant (C).  All images were obtained at 20X magnification and are oriented 
such that the B9 hydrogel is located in the bottom right corner.   
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Figure 3-7. F4/80 staining of formalin fixed, paraffin embedded B9 implants demonstrate 
the presence of macrophages along the periphery of the fibrous capsule but no 
infiltration into the B9 implant.  Histological analysis of subcutaneous B9 implants 
retrieved 3 weeks post-implant  (A) and peritoneal B9 implants retrieved 1 week post-
implant (B).  All images were obtained at 20X magnification and are oriented such that 
the B9 hydrogel is located in the bottom right corner.   
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Figure 3-8.  FACS analysis of peritoneal implanted B9 1 week post-implant (n=5).  
Experimental group showed no statistical difference in cell number from control group, p 
< 0.05.  Cells were immunostained for flow cytometry with FITC-conjugated hamster 
anti-mouse CD3 for total T cells, FITC-conjugated rat monoclonal anti-mouse CD4 for 
helper T cells, FITC-conjugated rat monoclonal anti-mouse CD8 for cytotoxic T cells, 
FITC-conjugated rat monoclonal anti-mouse CD19 for B cells, PE-conjugated rat 
monoclonal anti-mouse CD11b for macrophage, and FITC-conjugated rat monoclonal 
anti-mouse Gr-1 for neutrophils (BD Biosciences Pharmingen). 
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Noninvasive in vivo monitoring of implanted protein gels.  MR imaging 
provides a useful means for in situ characterization of implanted biomaterials.  Adequate 
contrast was achieved between the implant and surrounding tissue, which reflected the 
high water content of the protein gel (Figure 3-2 and 3-3).  Implant cross sectional areas 
and lengths were assessed through analysis image analysis over 7 months and data is 
currently being compiled (Figure 3-9).  No evidence of calcification was observed. 
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Figure 3-9.  Biostability of B9 implants assessed by MRI.  Implant cross-sectional 
areas and lenths were obtained through image analysis over 7 months and data is 
currently being compiled.  Four month biostability data is presented in this figure.
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3.4 DISCUSSION  
Molecular self-assembly is ubiquitous in nature and has recently been exploited 
for biomaterial design.  Self-assembly is mediated by a number of weak, noncovalent 
bonds, including hydrogen bonding, as well as electrostatic, hydrophobic, and van der 
Waals interactions ultimately forming higher order structures.  One such example of 
natural molecular self-assembly is tropoelastin which coacervates to align tropoelastin 
molecules in preparation for intermolecular crosslinking [63-65].  At ambient 
temperatures, tropoelastin is soluble in aqueous solutions, however, as the temperature 
is raised, molecular aggregation occurs through hydrophobic interactions.  Coacervation 
is a lower critical solution temperature (LCST) phenomenon in which the protein forms a 
more ordered system upon increasing temperature.  The same phenomena has been 
observed with recombinant elastin proteins where precise control over the temperature 
at which coacervation occurs has been correlated with amino acid sequence [66, 67]  
and exploited for tunable control over the assembly process.   
Tissue-material responses, including the rate and extent of biodegradation, are 
integral to assessing the suitability of elastin-like biopolymers for implant related 
applications.  To date, reports documenting in vivo responses to elastin-mimetic protein 
implants have been limited; largely confined to several studies performed 15 to 20 years 
ago on proteins synthesized chemically and subject to radiation crosslinking [82, 121]  In 
these investigations, homopolymers or copolymers composed of VPGVG, VPGKG, 
VPGEG, IPAVG, and VPAVG reportedly did not induce significant inflammatory or 
allergic reactions [82, 121-123].  The most thoroughly characterized variant, chemically 
synthesized poly(GVGVP), underwent in vitro toxicity and mutagenicity assays and was 
administered via intravenous, intraocular, intramuscular, intraperitoneal, and 
subcutaneous routes without toxic effect [82, 121].  A fibrous capsule was noted three 
weeks after intramuscular implantation of a radiation crosslinked sample [82].  In a more 
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recent report, elastin microparticles prepared from chemically synthesized poly(VPAVG) 
were evaluated following subcutaneous and intravitreal injections.  No inflammatory 
response observed after 28 days.  However, tractional retinal detachment noted [122].  
The failure to detect an immune mediated reaction to these polymers is consistent with 
other studies that have sought to identify potentially immunogenic epitopes on native 
elastin.  While polyclonal and monoclonal antibodies can be raised against peptides 
derived from the hydrolysis of native elastin, neither VPGVG nor VPAVG peptides were 
among the recognized sequences [124].  Moreover, VPGVG peptides were unable to 
competitively inhibit the binding of any of the antibodies raised against native elastin, 
which further supports the notion that this pentapeptide is not present among antigenic 
elastin epitopes [124]. 
Recently, genetically engineered elastin-mimetic protein polymers have been 
investigated in vivo as non-thrombogenic coatings [7, 125], targeted drug delivery 
vehicles [126-128], and as an implantable material [129].  In the latter instance, after a 
13 week implant period in the subcutaneous space, recombinant human tropoelastin 
‘sponges’, chemically crosslinked with with bis(sulfosuccinimidyl) suberate were 
surrounded by a fibrous capsule with a minimal to moderate inflammatory response 
[129].  Non-chemically crosslinked recombinant elastin-like proteins have also been 
administered within the intra-articular space as a 650 µM protein solution.  Although the 
biological response was not evaluated, this study revealed a three hour half-life for non-
aggregating VPGVG proteins and a three day half-life for aggregating VPGXG proteins, 
where X = V:G:A at a ratio of 1:7:8 [128].  As a related material, a 47 kDa recombinant 
silk-elastin-like protein (SELP), comprised of GAGAS silk-like [S] and GVGVP elastin-
like [E] amino acid sequences ([S]4[E]4[EK][E]3) has been studied after injection into the 
subcutaneous space.  Histological analysis revealed minimal fibrous encapsulation after 
four weeks with a mild degree of inflammation that included the presence of 
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macrophages in the surrounding tissue [130].  SELPs have also been used for 
adenoviral gene delivery and demonstrate prolonged and localized expression of 
adenoviruses for up to 15 days, suggesting the potential for cancer gene therapy [131, 
132].  A summary of in vivo biocompatibility studies conducted on elastin- mimetic 
proteins is presented in Table 3-1.  
The evaluation of in vivo biocompatibility has largely been based on 
characterizing local tissue responses to subcutaneously implanted materials where the 
intensity and duration of the inflammation and wound healing, including capsule 
formation, is evaluated histologically [133, 134].  Although histological studies of 
biopolymers containing elastin-mimetic sequences have previously noted the presence 
of ‘mild inflammation’ [121, 122] and ‘a reaction that was limited to a typical cell 
mediated response to the presence of a foreign body’ [129], the extent of fibrous capsule 
thickness has not been reported.  Fibrous capsule thickness has been investigated for a 
variety of polymeric and ceramic implants designed for tissue repair, cell encapsulation, 
or as drug delivery systems [135-138, 165].  Capsule thicknesses are dependent on 
implant site and material type and typically varies between 2 and 150 µm over 
implantation periods of one to three months.  For example, greater capsule thickness 
has been observed for materials within intraperitoneal sites compared to those in 
subcutaneous sites over identical implant durations [136].  Ceramic materials, aluminum 
calcium phosphate, hydroxyapatite, and tricalcium phosphate, appeared to invoke the 
mildest inflammatory response with the thinnest fibrous capsule, approximately 2.5 µm 
and 6 µm, after 90 day implant periods in the subcutanteous and peritoneal cavities, 
respectively [136].  As an illustration of the effects of surface chemistry, implants 
comprised of poly(alkyl methacrylate) (PAMA) with short alkyl side chains exhibited a 
thicker fibrous capsule than those with long side chains (140 µm vs 120 µm) [135].  
Additionally, self-assembled monolayers of alkanethiols on gold with different terminal 
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functional groups displayed surface dependent inflammatory responses after one week 
in subcutaneous tissue.  Hydrophobic methyl terminated surfaces induced thick fibrous 
capsules (130 µm) and greater recruitment of inflammatory cells, as compared to 
hydrophilic COOH- (80 µm) and OH- (70 µm) terminated surfaces [139].  Likewise, 
polypropylene implants whose surfaces were modified with –OH groups triggered 
formation of a thicker capsule  (~100 µm) that when modified with –COOH moeities (37 
µm) [140].  In contrast, surface topography does not appear to have a significant effect 
on capsule thickness, although it may influence local inflammatory responses [141].  
Relatively inert synthetic polymers, such as, silicone, and organic biopolymers, such as 
cellulose also elicit a foreign body reaction after subcutaneous implantation with an 
observed fibrous capsule thickness of approximately 90 µm and 80 µm, respectively, at 
four weeks. [165].  In this report, FACS analysis of peritoneal lavage fluid harvested one 
week after injection of B9 demonstrated no apparent difference in either the number or 
type of inflammatory cells when compared to those mice not exposed to the polymer gel 
(Figure 3-8). Significantly, as a subcutaneous implant, B9 protein polymer gels initiated 
only a limited local inflammatory response.  Remarkably, the resultant fibrous capsule is 
among the thinnest observed to date for non-ceramic implants in comparable implant 
sites and over similar periods of implantation.   This effect may be related to the 
presence of glutamic acid residues in the hydrophilic midblock that segregate to the 
surface with an enriched concentration of –COOH groups at material-tissue interface. 
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Table 3-1.  Biocompatibility evaluation of elastin-mimetic polypeptides   
Recombinant Elastin-Mimetic Assay Reported 
Results 
Testing Comments 
Chemically synthesized Poly (VPGVG) Ames 
mutagenicity test 
Non-
mutagenic 
Test samples were determined as innocuous as 
negative controls [121] 
Chemically synthesized Poly (VPGVG) Cytotoxicity-
agarose overlay 
Non-toxic No evidence of fibroblast cell death or lysis following 
incubation for 24 hours [121] 
Chemically synthesized Poly (VPGVG) Acute systemic 
toxicity 
Non-toxic No difference in IV injections of 24 hour extracts of 
gamma irradiated sheets of poly(VPGVG) and 
control extracts [121] 
Chemically synthesized Poly (VPGVG) Intracutaneous 
toxicity 
Non-toxic No erythema or edema was observed at injection 
site after 24, 48, and 72 hours [121] 
Chemically synthesized Poly (VPGVG) Muscle 
implantation 
Favorable at 7 
days 
Needle injection of film fragments, material was a 
‘slight irritant’ as compared to the negative control 
[121] 
Chemically synthesized Poly (VPGVG) Acute 
intraperitoneal 
toxicity 
Non-toxic at 4 
weeks 
Recovered implants were reported as ‘very similar 
to pre-implant condition’ [121] 
Chemically synthesized Poly (VPGVG) Systemic 
antigenicity study 
Non-antigenic No anaphylactic signs from IP injections three times 
a week, every other day, for 14 and 21 days [121] 
Chemically synthesized Poly (VPGVG) Dermal sensitation Non-
sensitizing at 7 
days 
Intradermal injections were challenged with 
solutions to provoke a mild acute inflammation at 
injection site, but ‘showed no significant evidence of 
causing dermal sensitization [121] 
Chemically synthesized Poly (VPGVG) Pyrogenicity Non-pyrogenic IV injection into rabbit ear vein and temperature of 
the animals were monitored [121] 
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Recombinant Elastin-Mimetic Assay Reported 
Results 
Testing Comments 
Chemically synthesized Poly (VPGVG) Lee White Clotting 
Study 
Normal 
clotting time 
Used canine blood, all clotting times were within 
normal ranges for dog [121] 
Chemically synthesized Poly (VPGVG) In vitro hemolysis 
test 
Non-hemolytic 0% hemolysis reported for rabbit blood determined 
spectrophotometrically [121] 
Chemically synthesized Poly (VPGVG) Bone implantation No 
calcification or 
ossification 
Fibrous granulation tissue, no calcification or 
ossification at 3 weeks [82] 
Chemically synthesized Poly (VPGVG) IM implantation No 
calcification or 
ossification 
Fibrous tissue capsule with a medium range of 
active phagocytic cell infiltration at muscle site with 
no evidence of calcification or ossification, reported 
as ‘passive tissue reaction similar to those found for 
biodegradable suture materials at three weeks [82] 
Microbially expressed triblock  Baboon 
arteriovenous 
shunt model 
Non-
thrombogenic 
Minimal fibrin and platelet deposition over a 1 hour 
time period of elastin-mimetic impregnated PTFE 
graft [7] 
Chemically synthesized Poly (VPAVG) Subcutaneous 
injection 
Non-
inflammatory 
Oedema was measured after microparticle injection 
at 24 hours in a hind paw injection model [122] 
Chemically synthesized Poly (VPAVG) Intraocular 
injection 
Non-
inflammatory 
28 days post-injection displayed minimal signs of 
inflammation, though tractional retinal detachment 
was observed with fibroblastic activity [122]  
Microbially expressed poly VPGVG 
(aggregating) and VPGAG (non-
aggregating) 
Intra-articular 
injection 
Biodegradable Protein remained in joint for 2 (non-aggregated 
protein) to 30 days (aggregated protein) [128] 
Microbially expressed human 
tropoelastin 
Subcutaneous 
implant 
Well tolerated Uniform encapsulation with minimal to moderate 
inflammation at 13 weeks [129] 
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Elastin-mimetic proteins such as B9 and other multiblock systems afford the 
ability to form physical or virtual crosslinked networks through the self-association of 
chemically similar domains.  In the case of elastin-mimetic proteins [1-5, 84], repeat 
peptide sequences of self-associating blocks are chosen, such that coacervation or 
phase separation of these domains occurs in water under physiologically relevant 
conditions (pH 7.4, 37°C), which maximizes hydrophobic interactions that drive self-
assembly.  In turn, the sequence of the non-crosslinking domain is selected in a manner 
that precludes coacervation.  This typically has required the incorporation of hydrophilic 
residues in the fourth position of the pentapeptide repeat sequence (Val-Pro-Gly-Xaa-
Gly), such as glutamic acid, which limits the tendency for block aggregation.   Physically 
crosslinked protein-based materials possess a number of advantages over their 
chemically crosslinked counterparts, including ease of processability, the ability to avoid 
the addition or removal of reagents or unreacted intermediates needed for chemical 
crosslinking, and the capacity to incorporate biologically or chemically active agents or 
cells that might otherwise be sensitive to covalent crosslinking schemes.  Moreover, if 
blocks are of sufficient size and chemical diversity the potential to access diverse 
polymer morphologies exists.  This provides the capacity to tune a wide range of 
functional responses, such as mechanical behavior, permeability or drug elution 
characteristics, as well as the potential to design templated materials [74, 86, 91].   
Most biomaterials whose integrity is based on self-association of hydrophobic 
constituents display short-lived stability in vivo and have been utilized for drug delivery or 
wound healing applications.  The instability of these systems can be attributed to natural 
surfactants, other amphiphilic molecules, or enzymes that promote lysis and solubulize 
specific lipids and proteins.  Table 3-2 summarizes the in vitro and in vivo stability of a 
number of physically crosslinked amphiphilic systems.  Phospholipids, lipopeptides, and 
glycolipids have been extensively employed as drug carriers when formulated as 
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vesicles, liposomes, or micelles, all of which have relatively short half-lives even when 
directly injected within tissues [166].  Similarly, amphiphilic graft copolymers, such as 
alkylated carrageenan [167], poly(2-hydroxyethyl methacrylate)-g-oligolactide, or 
poly(ethylene glycol)-g-poly(DL-lactic acid-co-glycolic acid) all degrade rapidly [168, 
169].  Recently, amphiphilic peptides that self-assemble as fibrous networks have been 
described as vehicles for cell and drug delivery [160, 170].  These systems display 
relatively rapid dissociative responses, as well.  In contrast, structures that self-associate 
through electrostatic interactions, including calcium or barium crosslinked alginate gels 
or alginate-polylysine thin films [171, 172], generally exhibit greater biostability.  
A number of materials that self-assembly also require additional crosslinking for 
biomedical applications.  Collagen has been used as a scaffold for tendon, cartilage, and 
bone regeneration [173-175], as well as for drug delivery [176] and skin substitutes 
[177].  However, most collagen systems are crosslinked by a variety of chemical [178-
181] or physical [182, 183] means.  In fact, non-crosslinked collagen displays a limited 
lifetime in vivo, with significant degradation observed within three to four weeks [129, 
184].   Natural silk is also degradable, but over longer durations with a >50% loss of 
strength at 6-12 weeks [185-187].  Likewise, recombinant tropoelastin has been 
fabricated into a chemically crosslinked ‘sponge’.   Degradation was evident 13 weeks 
after implantation when formulated with an open porous surface enabling cells to 
penetrate the implant, but limited when produced with a smooth surface [129].  Similarly, 
crosslinking and chemical modification has been employed to reduce degradation rates 
of hyaluronic acid hydrogels [188].  
 Significantly, this study demonstrates the long-term durability of a self-assembled 
elastin-mimetic protein polymer hydrogel, even in the absence of covalent crosslinks.  
MRI has been previously used to monitor biomaterial degradation and swelling behavior 
of a number of polymeric materials [162-164, 189-191], including hydrogels [189-194].  
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To our knowledge, these in vivo studies are the first to demonstrate that self-assembled 
protein-based materials of any form can be designed with structural stability approaching 
that displayed by many electrostatically or covalently crosslinked biopolymers.   
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Table 3-2.  Biostability in physically crosslinked systems 
 Application Biostability 
Crosslinked by hydrophobic interactions 
 
Hydrophobized 
polysaccharides, (eg, 
Dextran and Pullan) 
 
Drug delivery Dextran-4 hours-7 days [195, 196] Pullan-in vitro, 1 week [197] 
Leucine zipper motifs N/A 
In vitro chemical denaturation studies 
indicated incorporation of fluorinated 
amino acids improved stability [198]  
 
Silk Elastin-Like 
Proteins Drug delivery 
Stability controlled by the length of silk 
block, fewer silk blocks resorbed by 1 
week, more repeats (8 blocks) 
demonstrated no evidence of resorption 
at 7 weeks [199] 
Hydrogels investigated for drug release 
stable for >30 days [130] 
 
Natural Silk Sutures 6-12 weeks, with a >50% loss of strength [185, 186]  
Crosslinked by ionic interactions 
Alginate crosslinked with 
calcium ions 
 
Drug delivery and  
encapsulation  
2-12 weeks [172] 
 
Chitosan crosslinked 
with glycerol-phosphate 
disodium salt and heat 
Drug delivery 
Days-weeks dependent upon 
deacylation, with longer residence times 
observed with higher degree of 
deacylation [200] 
Carrageenan 
crosslinked with 
potassium ion or 
metallic ions 
Drug delivery 1-2 days [167] 
Alginate-PLL multilayers Coatings for implantable devices 
Stable as a film at 4 weeks with no 
observed cellular adhesion or defects 
[171] 
 
Crosslinked by crystallization 
PVA homopolymer 
 
Drug delivery 
 
stable at 37C in vitro for 6 months 
[201] 
poly (HEMA-g-
(L)oligolactate) and poly 
(HEMA-g-
(D)oligolactate) 
Drug delivery Stable for <70 days in vitro [168] 
PEG-PL(G)A-PEG 
triblock copolymers Drug delivery 
Partial degradation observed (PLGA 
backbone and PEG grafts) and 
complete degradation (PEG backbone 
with PLGA grafts) after 7 days [169] 
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3.5 CONCLUSIONS 
Elastin-based protein polymers are a promising class of material characterized 
by high degree of biocompatibility and a tunable range of mechanical properties from 
plastic to elastic.  A variety of options facilitate the processing of these biopolymers into 
gels, films, or nanofibers for any of a number of implant applications in orthopedics, as 
well as in plastics, cardiovascular, and general surgery.  Additionally, the potential exists 
for incorporating bioactive compounds onto the polymer backbone or within the protein 
matrix.  Likewise, such materials provide a prospective vehicle for cell delivery.  In this 
report we have characterized local tissue response and long-term in vivo biostability of a 
physically crosslinked recombinant elastin-mimetic copolymer.  We predict elastin-
mimetic triblock copolymers will find utility as structural components of artificial organs 
and engineered living tissues, as carriers for controlled drug release, or as biocompatible 
surface coatings.  
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CHAPTER 4 
Recombinant Elastin Protein Expression in Pichia pastoris 
 
4.1   INTRODUCTION 
Over the past decade a number of reports have described the design of synthetic 
genes, which encode elastin-like proteins (ELP) for bacterial expression in Escherichia 
coli.  Although advantages exist, significant limitations associated with E. coli expression 
systems have been noted.  The lack of eukaryotic post-translational systems, the 
insolubility of over-expressed mammalian proteins by sequestering into inclusion bodies, 
difficult purification from a pool of cytoplasmic proteins and cellular contaminants, and 
endotoxin contamination have encouraged the use of other expression systems 
including yeast, plant, insect, and mammalian cells.  Endotoxin has been a specific 
concern for ELP expression as it becomes associated with the protein product upon cell 
lysis.  Endotoxin, an amphiphillic lipopolysaccharide, is a toxic constituent found in the 
outer cell wall of gram-negative bacteria and known to induce pyrogenic pathologies 
[202].  A number of approaches have been utilized to reduce endotoxin contamination 
including sodium hydroxide digestion [203, 204], centrifugal ultrafiltration, phase 
separations with detergents [205-208] or solvents [209], neutralizing agents [210], and 
endotoxin selective absorber matrices [211] and membranes [212].  Removal of 
endotoxin from ELPs has often required one of these secondary purification treatments 
in addition to traditional purification through temperature induced precipitation, thereby, 
reducing overall protein yields.  
Recently, yeast and plant expression systems have been explored for the 
expression of ELPs and related matrix proteins.  For example, recombinant silk-elastin 
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proteins have been successfully expressed in tobacco and potato plants [213]. 
Additionally, the expression of a variety of target proteins in transgenic tobacco has been 
enhanced by an order of magnitude when fused to elastin-like polypeptides [214-216].  
Nonetheless, while transgenic plants offer the potential for scalability, reduced costs 
[217], and inherent biosafety through a reduced risk of viral or prion contamination [215], 
high yields have largely been limited to selected antibodies, enzymes, and vaccines 
[218].   The majority of recombinant proteins accumulate in only small amounts. 
As an alternate approach, yeast expression systems have become an increasingly 
attractive host for the expression of heterologous proteins [219, 220], due to their 
capacity to be incorporated into industrial-scale fermentation schemes characterized by 
high cell densities in relatively inexpensive media.  In addition, heterologous proteins 
have been efficiently secreted into the expression medium, resulting in low-cost recovery 
of the protein.  Significantly, endotoxin is not produced by yeast, thereby simplifying 
purification and sterilization strategies.  However, overall protein expression is influenced 
by two variables,  culture cell density and the amount of recombinant protein per cell 
[221] and as a consequence of the more complex process of protein production in a 
eukaryotic organism, yields are often low as compared to E. coli expression systems.  
Nonetheless, tropoelastin, collagen, and silk-like proteins have all been expressed in 
yeast with varying degrees of success [222-225]. 
In this report, a novel strategy was devised to construct a gene with enhanced 
sequence diversity that encodes a highly repetitive elastin-like protein polymer for 
expression in P. pastoris.  Traditionally, large repetitive genes that comprise most 
protein polymers have been created using a concatemerization strategy where a 
pentapeptide repeat cassette (monomer repeat unit) is self-ligated in a head-to-tail 
fashion [2, 98].  While this strategy has proven suitable for expression of elastin-like 
proteins in E. coli, the translation of repetitive gene sequence, especially in other host 
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systems, is often associated with reduced levels of protein expression.  Moreover, 
repetitive sequences are often prone to mutational events. Given these potential 
limitations, we designed a modified concatemerization strategy in which seven dissimilar 
monomer repeat units, encoding identical pentapeptide repeat sequences, served as a 
monomer library for the concatemerization reaction.  In this manner, a protein polymer 
gene was generated through random incorporation of distinct monomer repeat units.  
DNA monomers encoding identical amino acid sequences were synthesized in a manner 
that accounted for the preferred codon usage of P. pastoris, but in which the third 
nucleotide for proline, glycine and valine codons was degenerate.  Thus, 
concatamerization of the monomer library produced a genetically nonrepetitive DNA 
sequence for the pentapeptide repeat [(VPGVG)2VPGEG(VPGVG)2].  By limiting genetic 
repetition, the risk of genetic deletions, rearrangements, or premature termination errors 
during protein synthesis was minimized [220, 226, 227].  
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4.2   MATERIALS and METHODS 
Synthetic gene construction of Yeast ELP monomer library.  A collection of 
distinct single-stranded oligonucleotides corresponding to a monomer repeat unit was 
chemically synthesized (Sigma Genosys, Inc).  This was accomplished through use of 
degenerate bases incorporated into the design of the Yeast ELP coding sequence.  
Specifically, W encoded for A or T in proline and glycine and H for A, T, or C in valine.  
When chemically synthesized, equal molar amounts of the assigned nucleotides were 
used when synthesizing the degenerate position affording random incorporation of 
bases at those designated positions (Table 4-1B).  The lyophilized sequences were 
resuspended in elution buffer (10mM tris-HCl, pH 8.5) to a final concentration of 0.5 
µg/uL.  DNA Polymerase I Klenow fragment (New England Biolabs) was utilized in a 
primed extension of the oligonucleotide template for the second strand synthesis yielding 
the double stranded cassette of the monomer repeat unit.  An aliquot of the reaction 
mixture was analyzed via gel electrophoresis (4% GTG NuSieve, 1 X TBE buffer) to 
verify a single band corresponding to the size of the monomer repeat unit (~75bp).  
Subsequently, a preparative gel was used to isolate DNA and the corresponding band 
was purified via Amicon Ultrafree Centrifugal Filter Units (Millipore) and isolated via 
ethanol precipitation.  A total of 20 µg of the DNA cassette was digested with BamH I 
(10U/µg) and HinD III (10U/µg) restriction enzymes, extracted with phenol/chloroform, 
and isolated via ethanol precipitation.  
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Table 4-1.  Amino acid sequence and related nucleic acid coding sequence for the Yeast ELP 
gene in E. coli (A) and P. pastoris (B) expression systems.   
 
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly 
GTA CCT GGT GTT GGC GTT CCG GGT GTT GGT GTA CCA GGC 
 
Glu Gly  Val Pro Gly  Val Gly Val Pro Gly Val Gly  
GAA GGT GTA CCG GGT GTT GGC GTA CCA GGC GTA GGC 
 
 
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly 
GTT CCA GGW GTH GGW GTH CCW GGW GTH GGW GTH CCW    GGW 
 
Glu Gly  Val Pro Gly  Val Gly Val Pro Gly Val Gly  
GAA GGW GTH CCW GGW GTH GGW GTH CCW GGW GTH GGW  
 
 
A 
B 
 
A.  CCG is a high usage codon encoding proline in E. coli (24.5%), but extremely low in P. pastoris (3.9%) 
B.  Degenerate base W encodes for A or T while H encodes for A, T, or C (Sigma Genosys) 
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The pZErO-1 (Invitrogen) acceptor plasmid (1 µg) was prepared via BamH I and 
HinD III double digestion, followed by heat inactivation of the enzymes at 65°C and a 
dilution of the digested plasmid to 10ng/µL.  Yeast ELP monomers were designed with 
BamH I and HinD III overhangs to enable cloning into pZErO-1 at these restriction sites.  
The DNA cassettes and respective acceptor plasmids were ligated together in 
the presence of T4 DNA ligase (New England Biolabs) at 16°C for 30 minutes.  A 2 µL 
aliquot of the ligation reaction mixture was used to transform 40 µL of electrocompetent 
TOP10F’ E. coli cells (Invitrogen).  A total of 100 µL of the transformation mixture was 
spread onto low salt Luria Broth (LSLB) agar (5 g tryptone, 2.5 g yeast extract, 2.5 g 
NaCl, 7.5 g agar, 200 mL ddH2O, pH 7.5) supplemented with Zeocin (50 µg/µL).  The 
plates were incubated for 12 hours at 37°C.  Twenty transformants were selected from 
each plate to inoculate individual 7mL cultures of LSLB/Zeocin media.  Cultures were 
rotary incubated for 12 hours at 37°C.  Plasmid DNA was isolated following a Qiagen 
Spin Miniprep protocol (Quiagen, Inc.).  Miniprepped DNA was initially screened by a 
BamH I and HinD III double digestion.  Positive transformants were verified by agarose 
gel electrophoresis (4% GTG NuSieve agarose, 1X TBE buffer).  Automated DNA 
sequencing utilizing the M13 forward and M13 reverse primers confirmed correct and 
unique DNA products for seven separate monomer repeat unit cassettes, yielding the 
Yeast ELP monomer library (Table 4-2).
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A. Nucleic acid sequence of the seven unique Yeast ELP monomer units created using the wobble base system and employed in 
multimerization of the Yeast ELP gene. 
B.  Recognition (underlined) and cleavage sites (arrows) for restriction enzymes within the representative monomer, M1, repeat unit. 
C. Monomer repeat unit, M1, with cohesive ends generated from a Bbs I / BsmB I sequential digestion and used in the multimerization 
reaction.  Note that Bbs I / BsmB I are type II restriction enzymes and cleave the DNA downstream of their recognition sites. 
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Concatamerization of the Yeast ELP monomer library.  Concatamerization 
reactions utilized a total of 3.2 µg (0.4 µg of each monomer) of the Bbs I / BsmB I 
digested DNA.  Monomers were then ligated randomly end-to-end via T4 DNA ligase.  
The multimerization mixture was separated by size using agarose gel electrophoresis 
(1% agarose, 1 X TBE buffer) (Figure 4-2A).  Concatemers were excised in blocks, 
<500 bp, 500-1000 bp, 1000-3000 bp and purified using Zymoclean Gel DNA Recovery 
protocol (Zymo Research, Inc).  Concatamers of 1000-3000bp in size were ligated into 
the acceptor plasmid at the Bbs I site at 16°C for 16 hours.  The acceptor plasmid was 
prepared from the pZErO-1 plasmid containing a single monomer repeat unit, digested 
with Bbs I, and dephosphorylated with SAP (Shrimp Alkaline Phosphatase, Roache) to 
prevent self ligation.  Ligation mixtures were used to transform competent TOP10F’ cells 
and 100 µL of the transformation mixture was plated on LSLB/Zeocin agar plates.  DNA 
from positive clones were isolated via MacConnell automated miniprep and screened 
through double digestion using BamH I and HinD III restriction enzymes.  Clones of 
predetermined size (approximately 1.5 kB) were isolated and sequences confirmed with 
automated DNA sequencing.   
Construction of the modified pPICZα-A expression plasmid.  Single stranded 
oligonucleotides encoding the sense and anti-sense strands of the Yeast ELP adaptor 
were chemically synthesized (Sigma Genosys, Inc.) (Table 4-3).  The Yeast ELP 
adaptor is a ~50 bp DNA cassette designed to contain restriction enzyme cut sites 
midway through the cassette to allow for insertion of the Yeast ELP concatamer and 
allow for facile cloning into the pET24-a expression vector within the multiple cloning 
region.  This ensures correct insertion of the gene in frame with the N-terminal α-factor 
secretion signal sequence and the C-terminal polyhistidine tag and c-myc epitope.  The 
DNA was suspended in 10mM Tris buffer (pH 8) to a final concentration of 0.5 µg/µL.  A 
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solution of 10 µg of each corresponding oligonucleotide, 4 µL 5M NaCl, 4 µL 1M MgCl2, 
152 µL of sterile ddH2O was subjected to an annealing procedure initiated at a reaction 
temperature of 99°C with incremental temperature decrements of 1°C every 5 minutes to 
a final reaction temperature of 30°C.  The resultant double stranded DNA cassette was 
analyzed by agarose gel electrophoresis (4% GTG NuSieve agarose, 1X TBE buffer).  
Double stranded synthetic DNA was phosphorylated through a 2 hour incubation 
with T4 poynucleotide kinase (New England Biolabs) in the presence of T4 DNA ligase 
buffer with 10mM ATPs (New England Biolabs).  The enzymes were removed with 
phenol/chloroform/isoamyl alcohol (25:24:1) and the dsDNA was recovered through an 
ethanol precipitation.   
The pPICZα-A plasmid (1 µg, Invitrogen) was doubly digested with Xho I and 
Xba I, followed by heat inactivation of the enzymes at 65°C, and dilution to 10ng/µL.  
The adaptor was designed with Xho I and Xba I overhangs to enable its cloning into 
pPICZα-A.  Adaptor and plasmid were ligated together in the presence of T4 DNA ligase 
at 16°C for 30 minutes.  A 2 µL aliquot of the ligation reaction mixture was used to 
transform 40 µL of electrocompetent TOP10F’ E. coli cells.  A total of 100 µL of the 
transformation mixture was spread onto low salt LB (LSLB) agar supplemented with 
Zeocin (50 µg/µL).  The plates were incubated for 12 hours at 37°C.  Five transformants 
were selected from each plate to inoculate individual 7mL cultures of LSLB/Zeocin 
media.  Cultures were rotary incubated for 12 hours at 37°C.  Plasmid DNA was isolated 
following a Qiagen Spin Miniprep protocol.  DNA was initially screened by a Xho I and 
Xba I double digestion.  Positive transformants were verified by agarose gel 
electrophoresis (4% GTG NuSieve agarose, 1X TBE buffer).  Automated DNA 
sequencing utilizing the AOX1 5’ and AOX1 3’ primers confirmed the correct DNA 
product.  
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Table 4-3.  Nucleic acid sequence of Yeast ELP adaptor with related amino acid coding sequence and restriction enzyme 
cut sites.   
 
                                                                Val   Pro    Ala   Val    Gly     Val   Pro                  Pro   Ala    Val    Gly  
CTCGAGAAAAGAGAGGCTGAAGCT  GTT  CCA  GCT  GTT  GGT  GTT  CCA AGAGACGGTACCCGTCTCTT CCA  GCT  GTT  GGT CTAGA 
  Xho I                                                  BsmBI                 BsmBI                                  Xba I 
 
 
 
Adaptor was inserted at XhoI and Xba I sites within the pPICZα-A expression vector.  The Yeast ELP gene was inserted within the adaptor at the double 
BsmB I sites. 
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 Cloning the Yeast ELP gene into the modified pPICZα-A expression plasmid.  
The modified pPICZα-A plasmid was digested with restriction enzyme BsmB I and SAP 
dephosphorylated.  The Yeast ELP gene was excised from the pZErO-1 plasmid via 
sequential digestion using restriction enzymes Bbs I and BsmB I and purified from an 
agarose gel.  A ligation reaction was performed to relocate the Yeast ELP gene from 
pZErO-1 to pPICZα-A.  The ligation mixture was transformed into electrocompetent 
TOP10F’ cells and plated on LB media under Zeocin antibiotic selection.  Isolated DNA 
from transformants was screened via agarose gel electrophoresis using Xho I and Xba I 
double digestion.  A product of 1575bp was observed (Figure 4-2B).  Automated DNA 
sequence analysis using AOX1 5’ and AOX1 3’ primers confirmed correct insertion of the 
Yeast ELP gene in frame with the N-terminal α–factor secretion signal and the C-terminal 
peptide containing the c-myc epitope and the polyhistidine tag.   
 Preparation of P. pastoris for chemical transformation.  The preparation of 
chemically competent X-33 P. pastoris cells was performed following the EasyComp 
Transformation (Invitrogen) protocol.  Briefly, a YPD (Yeast Extract Peptone Dextrose) 
agar plate was streaked with the X-33 strain of P. pastoris such that isolated individual 
colonies grew after an incubation at 30°C for 2 days.  A total of 10mL of YPD media was 
inoculated with a single colony and grown overnight at 30°C in a shaking incubator (250 
rpm).  The cells were diluted from the overnight culture to an OD600 of 0.1 in 10mL of YPD.  
Cells were pelleted by centrifugation at 500g for 5 minutes at 25°C and resuspended in 
1mL Solution 1 (EasyComp), yielding competent X-33 cells.  A total of 50 µL of competent 
cells were aliquoted into 1.5mL sterile screw-cap tubes and stored at -80°C. 
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Scheme 4-1.  Cloning strategy in the construction of the Yeast ELP gene.  The seven 
unique double stranded DNA monomer cassettes were ligated together to form 
concatamer of random sequence.  A target multimer of 1575bp was selected, cloned into 
the recombinant plasmid, pPICZα-A and integrated into the P. pastoris host DNA. 
Cloning into P. pastoris expression
Expression of Recombinant Yeast
Transformation of P. pastoris
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 Transformation of the Yeast ELP gene into P. pastoris.  E. coli was utilized to 
propagate the plasmid containing the Yeast ELP gene.  A total of 5 to 10 µg of plasmid 
carrying the Yeast ELP gene was isolated and was linearized within the 5’ AOX1 region 
through digestion with restriction enzyme Pme I to promote integration into the P. pastoris 
host.  A vector linearized within the 5’ AOX1 region will integrate by gene insertion into the 
host’s 5’ AOX1 region.  The linearized plasmid was isolated via preparative gel 
electrophoresis (1% agarose, 0.5X TAE) and purified using Zymoclean Gel Recovery.   
 Transformation was performed following the EasyComp transformation protocol.  
One tube of competent X-33 cells was thawed at room temperature.  A total of 3 µg of 
linearized Yeast ELP DNA was added to the thawed cells.   A total of 1mL of Solution II 
(EasyComp) was added to the DNA-cell mixture, vortexed, and incubated for 1 hour at 
30°C in a water bath.  The mixture was mixed every 15 minutes to increase transformation 
efficiency.  Following the incubation, cells were heat shocked at 42°C for 10 minutes.  
Cells were split into two centrifuge tubes with 1mL of YPD medium added to each tube 
and incubated at 30°C for 1 hour to allow for expression of Zeocin resistance.  Cells were 
pelleted by centrifugation at 3000g for 5 minutes at 25°C and the pellet resuspended in 
150 µL of Solution III (EasyComp).  The entire transformation was spread on YPDS (Yeast 
Extract Peptone Dextrose with Sorbitol)/Zeocin agar plates and incubated at 30°C for 4 
days.   
 PCR screening for correct gene insertion into the P. pastoris host.  All 
polymerase chain reaction (PCR) screening was performed using the Qiagen Taq PCR, 
which includes the Q-solution to assist in the amplification of difficult to amplify G-C rich 
DNA.  According to the manufacturer’s instruction, a 50 µL reaction mixture using the 
AOX1 5’ and AOX1 3’ primers (5 µM) and Q-solution was subjected to a PCR cycle that 
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employed 25 cycles of a one minute fifteen second denaturation at 94°C, one minute 
fifteen second primer anneal at 57°C, and a three minute primer extension at 72°C.   
 Expression of Yeast ELP in P. pastoris.  A single colony of the transformants 
was used to inoculate 25mL of BMGY, a buffered glycerol complex medium, in a 250mL 
baffled flask, grown at 30°C with shaking until and OD600 of 2 was reached.  Cells were 
harvested by centrifugation at 3000g for 5 minutes at 25°C and resuspended in 100mL 
BMMY, a buffered methanol complex medium, for induction of expression in a 1L flask.  
To maintain induction, 100% methanol was added to a final concentration of 0.5% 
methanol every 24 hours for 4 days.  After 4 days, cells were harvested and supernatant 
collected.  Both the cellular fraction and supernatant was analyzed for protein expression.   
 Purification of Yeast ELP from P. pastoris.  Prior to protein purification, the 
supernatant was concentrated using an Amicon Ultra centrifugal filter with a molecular 
weight cut off of 30,000 kDa.  Metal affinity chromatography was used for purification of 
Yeast ELP, which isolated the protein by the polyhistidine tag, according to manufacturer 
instructions.  Briefly, a cobalt based TALON metal affinity resin (Clontech) was equilibrated 
with equilibration buffer (50mM sodium phosphate, 300mM NaCl, pH 7.0).  The 
concentrated supernatant was run through the column by gravity flow followed by 
extensive washes with equilibration buffer.  The bound protein was eluted with Elution 
buffer (50 mM sodium phosphate, 300mM NaCl, 250mM imidizole, pH 7.0) and desalted 
using PD-10 desalting columns (GE Healthcare Life Sciences).  Lyophilization afforded 
protein Yeast ELP as fibrous solid in an isolated yield of 2.5 mg/L.  Efforts to optimize 
yields are underway [228]. 
 Additionally, as observed with other structural protein expression, some protein 
was isolated from both the cytosolic and membrane fractions, though most of the protein 
was found to be secreted into the media.  It has been noted that some higher eukaryotic 
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proteins are not compatible with the yeast secretory apparatus and these proteins remain 
trapped at some point along the secretory pathway [228, 229].  To isolate this protein, the 
harvested cells were resuspended in breaking buffer (20mM Tris-Cl, pH 7.5, 1 mM EDTA, 
5% glycerol) and then disrupted through vortexing cycles.  An analytical spin was used to 
assess breaking efficiency.  Cell lysates were centrifuged at 40,000g for 40 minutes at 4°C 
and the cytosolic fraction was collected and His-purified.  The membrane fraction was 
detergent extracted with 0.5% Triton X-100 overnight at 4°C.  The lysate was centrifuged 
at 40,000g for 40 minutes at 4°C and the soluble membrane fraction collected and His-
purified.  Isolated yields of less than 1 µg were obtained from both cytosolic and 
membrane fractions, which confirmed that the ELP was not trapped in the secretory 
pathway. 
 Identification of the recombinant elastin protein, Yeast ELP.  Sodium dodecyl 
sulfate (SDS) polyacrylamide gel electrophoresis was performed.  Samples were 
separated on a 4-20% gradient acrylamide-SDS gel and total protein was visualized with 
Coomassie G250 (BioRad).  Western blot analysis was performed by transfer to an 
Immobilon PSQ (Polyvinylidene fluoride) (PVDF) membrane (Millipore) and probed with 
either mouse His-tag monoclonal antibodies (Novagen) or anti-c-myc mouse monoclonal 
antibodies followed by a goat-anti-mouse HRP (horseradish peroxidase) secondary 
antibody.   Bands were visualized by using the ECL Western blotting detection kit 
(Amersham Biosciences).  Both antibodies stained a band at 65 kDa, corresponding to the 
Yeast ELP protein.   
Edman degradation was used to identify the repeat unit of Yeast ELP to confirm 
expression.  Briefly, the protein was electroblotted on a PVDF membrane and stained 
with Amido Black (BioRad).  The Yeast ELP protein negatively stained using this stain.  
Approximately 0.5 to 2.0 pmol of protein obtained from the membrane was used for N-
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terminal sequence analysis using automated sequencers at the Microchemical and 
Proteomics Facility at Emory University.   
 
4.3  RESULTS and DISCUSSION 
Conceptual framework for the design of Yeast-expressed ELP.  The elastin-
like protein, Yeast ELP, was employed as a test substrate for assessing the efficacy of 
monomer library concatamerization in the design of a nonrepetitive ELP gene for 
expression in yeast.  The Yeast ELP protein comprises a concatenated series of 
pentapeptide repeat units yielding 21 repeats of the pentapeptide monomer sequence 
[(VPGVG)2VPGEG(VPGVG)2].  Our group has investigated this repeat sequence as a 
constituent of multiblock protein copolymers expressed by E.coli.  As a consequence of 
its high transition temperature (>> 37°C), this sequence affords a conformationally 
flexible protein segment under physiologically relevant conditions [1-4].    
In order to express a highly repetitive elastin-like protein in P. pastoris, a novel 
strategy was employed to reduce primary DNA sequence repetition without altering the 
recurring 21-mer peptide sequence.  This was accomplished through the design of a 
DNA monomer library.  Protein engineering has frequently used protein libraries that 
include defined amino acid mixtures at certain positions of interest [230, 231]. Two of the 
most commonly used methods for library generation are random mutagenesis and 
cassette mutagenesis.  Random mutagenesis introduces random point mutations 
throughout the entire protein.  The most common method for creating such a library is 
PCR.  This method has been utilized in studies, for example, aimed to identify amino 
acids integral to enzymatic function and protein-protein interactions [232].  Cassette 
mutagenesis is a method of library creation where a region of interest is targeted for 
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mutagenesis through the use of degenerate oligonucleotides.  We have used 
degenerate oligonucleotides in the design of our DNA monomer repeat unit to create a 
library of monomers, which were subsequently ligated together to create our target ELP 
gene. 
The genetic code is degenerate in that the protein biosyntheic machinery utilizes 
61 sense codons to encode the 20 amino acids.  Due to this degeneracy, different 
nucleotide sequences code for the same amino acid.  These coding differences are 
restricted to usually one position in the codon triplet and allow for multiple nucleotides to 
encode the same amino acid, thereby increasing variability of the primary DNA 
sequence of the protein.  For example, the third position of the glycine codons (GGA, 
GGG, GGC, GGT) is a fourfold degenerate site because all nucleotide substitutions at 
this site are synonymous, in that the coded amino acid is unchanged.  Degenerate 
bases allow for the incorporation of multiple nucleotides into the specified site within a 
codon.  As detailed in Table 4-1B, the monomer repeat unit for the Yeast ELP gene was 
designed through chemical synthesis based on the degenerate bases, W, encoding for 
either A or T, and H, encoding for A, T or C.  While the primary genetic sequence for the 
Yeast ELP was based on the midblock sequence of a previously reported triblock 
protein expressed in E. coli [1, 2], the sequence was modified in accordance with the 
preferred codon usage of P. pastoris (Figure 4-1).  The codon triplet encoding proline 
residues was determined to be critically important in the successful expression of this 
protein.  CCG, a high usage codon in E.coli and used extensively for encoding proline in 
the pentapeptide repeat is not adequately translated in P. pastoris.  Therefore, in the 
design of the Yeast ELP gene, only CCA and CCT codons were employed to code for 
proline residues (Table 4-1). 
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Pichia pastoris [gbpln]: 66 CDS's (38158 codons)  
 
fields: [triplet] [frequency: per thousand] ([number])  
 
UUU 23.6 (901)   UCU 23.9 (911)   UAU 14.7 (561)   UGU  8.3 (318) 
UUC 18.9 (721)  UCC 16.3 (621)   UAC 18.3 (698)   UGC  4.4 (168) 
UUA 14.5 (553)   UCA 15.4 (587)   UAA  0.9 (35)   UGA  0.3 (13) 
UUG 31.9 (1218)   UCG  6.8 (258)   UAG  0.5 (18)   UGG  9.8 (375) 
 
CUU 16.1 (614)   CCU 15.3 (584)   CAU 10.4 (395)   CGU  6.7 (256) 
CUC  7.6 (291)   CCC  6.5 (249)   CAC  9.1 (346)   CGC  2.3 (87) 
CUA 11.4 (435)   CCA 17.5 (668)   CAA 24.1 (918)   CGA  4.3 (163) 
CUG 15.5 (591)   CCG  3.9 (150)   CAG 14.5 (554)   CGG  1.8 (70) 
 
AUU 31.0 (1184)   ACU 23.7 (903)   AAU 22.9 (875)   AGU 12.2 (464) 
AUC 19.0 (725)   ACC 14.0 (533)   AAC 25.5 (974)   AGC  7.3 (279) 
AUA 11.3 (432)   ACA 14.2 (541)   AAA 30.0 (1145)   AGA 19.9 (760) 
AUG 19.2 (734)   ACG  6.0 (230)   AAG 34.8 (1328)   AGG  6.7 (254) 
 
GUU 27.0 (1032)   GCU 29.9 (1141)   GAU 36.8 (1405)   GGU 27.1 (1035) 
GUC 14.7 (561)   GCC 17.0 (649)   GAC 26.5 (1012)   GGC  8.5 (326) 
GUA 10.0 (381)   GCA 16.4 (624)   GAA 40.6 (1550)   GGA 20.0 (762) 
GUG 12.8 (487)   GCG  3.5 (134)   GAG 29.9 (1141)   GGG  6.0 (230)  
 
 
Figure 4-1. Codon Usage Table for P. pastoris (Codon Usage Database, NCBI 
GenBank) 
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Design of a library of nonrepetitive DNA monomers.  Chemically synthesized, 
single-stranded oligonucleotides designed with degenerate bases at the specified 
locations, were obtained from SigmaGenosys.  At each degenerative base location, 
equal molar amounts of each base were introduced.  For example, at a W site, equal 
amounts of A and T were available during synthesis.  Through primed extension, double 
stranded cassettes of the monomer repeat units were generated.  The cassettes were 
digested with restriction enzymes BamH I and HinD III to enable cloning into the pZErO-
1 cloning plasmid at the complementary sites within the multiple cloning region.  Multiple 
transformants were screened and automated DNA sequencing confirmed correct and 
unique DNA products for seven separate monomer cassettes, comprising the Yeast 
ELP monomer library (Table 4-2A). 
The literature reports that gene locations enriched in repetitive sequences are 
‘hot spots’ for mutational events such as insertions, deletions, and frame shifts [233, 
234].   DNA sequences with GC and CA/GT repeats have been reported to undergo 
spontaneous deletions [235, 236], while regions rich in AT have been reported as ‘hot 
spots’ for frame shifts and deletions [237].  Additionally, long repetitive sequences have 
been found to be less stable than shorter ones [238].  Specifically, in P. pastoris, the 
expression of foreign genes with high A and T content can be affected by premature 
transcription termination [239, 240], therefore, care was taken in the genetic design to 
limit such ‘hot spot’ motifs.   
Concatamerization and identification of the Yeast ELP gene.  Since 
automated DNA synthesis is currently limited to the production of oligonucleotides of 
lengths corresponding to approximately 100 bases, sequences encoding larger proteins 
cannot be directly synthesized.  DNA cassette concatamerization is a commonly 
employed method for assembling genes encoding large, repetitive proteins (Scheme 4-
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1) [2, 98].  The genes composing the monomer library were designed with non-
palindromic cohesive ends.  This was accomplished through the use of type II restriction 
enzymes, Bbs I and BsmB I, which recognize and cleave non-palindromic sequences as 
detailed in Table 4-2B, creating the digested cassette in Table 4-2C.  Consequently, 
random ligation of the seven DNA monomers proceeds in a head-to-tail fashion to 
generate concatamers of varying lengths by increments of a monomer repeat unit.  
Concatamers were separated by size, or degree of concatamerization, on an agarose 
gel (Figure 4-2A) and concatamers of 1000 to 3000bp in size were isolated and ligated 
back into the acceptor plasmid.  A clone of 1575bp was identified and was denoted as 
Yeast ELP (Figure 4-2B).       
        
                       
 
       
 Figure 4-2.  A. 1% TAE (Tris-acetate-EDTA) agarose gel.  Ladder of concatamerization 
products, each band indicates different sized concatamers, differing by 75 bp (addition of 
one monomer cassette).  Seven unique monomer units were pooled in equal amounts in 
the concatamerization reaction for random incorporation of the monomer units in the 
concatamerization of the Yeast ELP gene.  B. 1% TAE (Tris-acetate-EDTA) agarose 
gel.  Xho I / Xba I digested Yeast ELP (1575bp), pPICZα-A (3.6 kb).  DNA standard 
used was a 1Kb DNA ladder (NEB). 
- 3.0 
- 2.0 
- 0.5 
- 1.0 
kilobases 
- 3.0 
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Expression system employed for Yeast ELP.  Recombinant elastin proteins 
have traditionally been expressed through microbial expression in E. coli [241].  
Nonetheless, recognized drawbacks exist.  In particular, purification of the expressed 
protein products is labor intensive as isolation from a pool of cytoplasmic proteins and 
cellular contaminants is required.  Additionally, endotoxin, an amphiphillic 
lipopolysaccharide found in the wall of gram-negative bacteria, is released upon cell lysis 
and can become associated with the target protein [202].   As an alternative, the 
methylotropic yeast, P. pastoris was investigated for elastin expression and secretion.  
Notably, P. pastoris secretes very low levels of native proteins, which simplifies 
purification protocols [1, 242].  Moreover, endotoxin is not present as a potential 
contaminant.   
 Recent reports have described the expression of structural proteins in yeast.  
Spider dragline silk-like proteins have been expressed in both E. coli and P. pastoris at 
high levels [223, 243].  Likewise, full length tropoelastin has been expressed in 
Saccharomyces cerevisiae using a fusion peptide for targeted secretion into the 
endoplasmic reticulum with enhanced biostability [222].  P. pastoris has also been 
employed for co-expression of Type-I, -II or -III collagen with prolyl 4-hydroxylase 
yielding collagen fibrils that display D-periodic banding [224, 225].  However, issues 
related to gene rearrangement have been observed with these highly repetitive proteins.  
For example, a 101 amino acid spider dragline silk-like protein, derived from the major 
dragline protein of Nephila clavipes [244], produced multiple sized protein products, 
each an integral number of repeats of the 101 amino acid sequence encoded by the 
gene.  It was speculated that different sized products were the result of expansion or 
deletion of the DNA repeat sequence [223].  Additionally, the importance of genetic 
sequence diversity is noted among patients with trinucleotide repeat associated disease 
where sequence divergence between repeated sequences reduce the severity of the 
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disease and likelihood of inheritance [245, 246].  In fact, studies examining spontaneous 
deletions demonstrate that alteration of a single base pair within homology regions 
reduces the deletion incidence by an order of magnitude [247]. 
 In this report, P. pastoris was employed as the host for expression of the 
recombinant protein Yeast ELP.  The methylotrophic yeast strain X-33 was selected.  
Without glucose present, P. pastoris uses methanol as a carbon source.  The alcohol 
oxidase promoter (AOX 1) controls the expression of alcohol oxidase, which is integral to 
the initial step in methanol metabolism [228, 248].  The expression vector pPICZα-A 
(Figure 4-3 and 4-4), takes advantage of the AOX 1 promoter and uses methanol to 
induce protein expression of the Yeast ELP protein.  
 The 5’ AOX1 gene within the pPICZα-A vector allows for targeted integration of the 
expression construct through homologous recombination into the P. pastoris genome, 
creating a stable host able to generate high levels of protein expression (Figure 4-5).  The 
pPICZα-A vector also contains a Zeocin resistance gene that allows for antibiotic 
screening of transformed cells. Additionally, this vector includes the C-terminal fusion tags, 
c-myc epitope and polyhistidine (6xHis) sequences, that facilitate purification and analysis 
of expressed proteins.  Finally, pPICZα-A contains an α-factor secretion signal, which 
targets the protein product for secretion into the growth media.   
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Figure 4-3.  pPICZα-A expression vector (Invitrogen).  The Yeast ELP gene was 
cloned into the vector at the Xho I and Xba I restriction sites within the multiple 
cloning region.  Vector was linearized with Pme I digestion for integration into the 
P. pastoris genome at the AOX1 crossover sites.  The expressed elastin product 
has an α-factor signal sequence for secretion which is subsequently cleaved.  
Additionally, the protein retains a 5’ c-myc epitope and 5’ 6XHis-tag which can be 
used for purification or identification via Western blotting. 
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Figure 4-4.   pPICZα-A expression vector multiple cloning region (MCR) (Invitrogen).  
The Yeast ELP gene was cloned into the vector at the Xho I and Xba I restriction sites 
(  ) within the multiple cloning region.  Verification of gene insertion through PCR 
amplification employed the 5’ and 3’ AOX1 primers.   
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Figure 4-5.  Plasmid integration in P. Pastoris.  pPICZα-A vector containing the Yeast 
ELP gene of interest was linearized within the 5’ AOX1 region through digestion with 
restriction enzyme Pme I.  Linearized plasmid was integrated by gene insertion into the 
host AOX1 region. 
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 The 1575 bp Yeast ELP concatamer was inserted into a specially designed 
adaptor at the double BsmB I sites (Table 4-3) for cloning into the pPICZα-A expression 
vector at Xho I and Xba I restriction sites within the multiple cloning region.  This allowed 
for correct in frame insertion of the gene with the N-terminal α-factor secretion signal and 
the C-terminal c-myc epitope and polyhistidine tag.    
Confirming Integration by PCR.  Polymerase Chain Reaction (PCR) was used 
to analyze P. pastoris integrants to determine successful introduction of the expression 
cassette into the yeast chromosome.  The Yeast ELP gene was amplified using the 
AOX1 5’ (5´-GACTGGTTCCAATTGACAAGC-3´) primer paired with the AOX1 3’ (5´-
GCAAATGGCATT-CTGACATCC-3´) primer.  Using this method, two bands were 
expected in positive transformants, one corresponding to the Yeast ELP gene (1575bp 
gene + 588bp from the pPICZα-A parent plasmid) and the other to the AOX1 gene within 
the chromosome (approximately 2.2 kb).   All PCR screening was performed using the 
Qiagen Taq PCR, which includes Q-solution to assist in the amplification of G-C rich 
DNA.  The PCR product obtained was suggestive of incomplete amplification as multiple 
product bands were observed (Figure 4-6A), most likely as a result of both its repetitive 
nature and its G-C rich DNA.  PCR products were run on a preparative agarose gel.  
Amplification of the positive control, Yeast ELP miniprep DNA from E. coli propagation, 
appeared as a smear and ladder product (Figure 4-6A, Lane 1).  Empty X-33 cells were 
analyzed as a negative control and amplification of only the AOX1 gene from the yeast 
chromosome at 2.2 kb was evident (Figure 4-6A, Lane 2).  A screen of colonies 
indicated a possible transformant where a smear and ladder product was observed 
(Figure 4-6A, Lane 3). 
Confirmation of Yeast ELP gene integration was accomplished through 
amplification using Yeast ELP 3’-2 (5’-CTCCGACTCCTGGAACAC-3’) primer paired with 
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the AOX1 5’ (5´-GACTGGTTCCAATTGACAAGC-3´) primer.  The Yeast ELP 3’-2 primer 
was designed to amplify only a 400bp product between the regions of the AOX1 5’ 
priming site within the pPICZα-A vector and into the 5’ terminus of the Yeast ELP gene.   
This product was present in the positive control and the putative transformant, but not 
observed in the negative control (Figure 4-6B, Lane 1, 2, and 3, respectively).  DNA 
sequencing verified the identity of the 400bp PCR product as the expected region from 
the AOX1 5’ priming site into the 5’ segment of the Yeast ELP gene; confirming insertion 
of Yeast ELP into the P. pastoris chromosome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. A. 1% TAE (Tris-acetate-EDTA) agarose gel of PCR products using 
AOX1 5’ and AOX1 3’ primers.  Note incomplete amplification of the Yeast ELP gene as 
observed with the smear and ladder product (Lane 1).  Lane 1: Positive Control, Yeast 
ELP miniprep DNA.  Lane 2: Negative Control, empty X-33 colony stab, note the yeast 
chromosome has PCR product of 2.2 kb.  Lane 3:  Colony PCR product of X-33 
transformed cells containing Yeast ELP, note that the smear and ladder product is also 
observed.  B. 1.5% TAE (Tris-acetate-EDTA) agarose gel of PCR products utilizing the 
Yeast ELP 3’-2 primer and AOX1 5’ primer.  Target product, approximately 400bp in 
size, was excised from the gel, purified, and correct sequence verified through DNA 
sequence analysis using the AOX1 5’ primer.  Lane 1:  Positive control, Yeast ELP 
miniprep DNA, 400bp PCR product observed.  Lane 2:  Colony PCR product of X-33 
transformed cells containing Yeast ELP, 400bp product observed.  Lane 3: Negative 
Control, empty X-33 colony stab, no 400bp product observed.   
 
Western blot analysis.  Yeast ELP was isolated and affinity purified from the 
growth media with non-optimized yields of 2 mg/L.  Small amounts of the protein were 
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identified in the membrane and soluble cytosolic fractions, but in low amounts and were 
not utilized in protein analysis.  The expected molecular mass for the Yeast ELP protein 
was approximately 56 kDa.  As the expressed protein product did not stain with 
Coomassie, Western blot analysis was utilized to confirm the identity.  An anti-His 
primary antibody revealed the protein band migrating at approximately 65 kDa and was 
confirmed as the band corresponding to Yeast ELP using the anti-myc antibody (Figure 
4-7 A and B).  Elastin proteins tend to migrate approximately 20% higher than the 
theoretical molecular weight in a PAGE gel [75, 97].  To confirm the product was not 
migrating at a higher mass due to glycosylation, the purified protein was treated with N-
glycosidase F (Prozyme), an enzyme which catalyzes the release of all N-linked 
oligosaccharides added by yeast during secretion.  A 65 kDa product was observed 
before and after treatment with the enzyme [229, 249] (Figure 4-7C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7.  Western blotting of elastin-mimetic protein Yeast ELP run on a 4-20% SDS-
PAGE gel.  A. c-myc primary antibody, goat-anti-mouse secondary antibody.  B. anti-His 
primary antibody, goat-anti-mouse secondary antibody.   C.  Deglycosylation of Yeast 
ELP.  Western blotting of elastin-mimetic protein Yeast ELP run on a 4-20% SDS-PAGE 
gel, anti-His primary antibody, goat-anti-mouse secondary antibody.   Marker lane:  
Precision Plus Protein Kaleidoscope (Bio-Rad).  Lane 1:  Purified Yeast ELP, Lane 2:  
Purified and deglycosylated Yeast ELP.  Analysis indicates no deglycosylation of the 
Yeast ELP protein.
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4.4  CONCLUSION 
In this report, we have demonstrated the expression of a 56 kDa elastin-like 
protein from P. pastoris.  We have employed a new strategy, monomer library 
multimerization, in designing non-repetitive ELP genes for highly repetitive protein 
sequences.  This was accomplished through the synthesis of seven unique monomer 
cassettes utilizing degenerate bases.  The monomer cassettes were randomly ligated in 
a concatamerization reaction, thereby creating the target gene with varying genetic 
sequences throughout, which, nonetheless, encode identical repetitive amino acid 
sequences.  We anticipate that this strategy will be useful for creating large, repetitive 
genes for a variety of expression systems; in order to more closely approach the genetic 
diversity inherent to native DNA sequences.   Additionally, the potential exists to 
generate glycosylated ELPs through incorporating appropriate glycosylation sites.  
Indeed, several approaches such as genomics, combinatorial libraries, and synthetic 
chemistry have been employed for sugar chain remodeling of human proteins in P. 
pastoris and other expression systems [250-252].     
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CHAPTER 5 
 
CONCLUSIONS and FUTURE DIRECTIONS 
 
 
 
With over 500,000 coronary bypass surgeries being performed each year, the 
need for an adequate vessel replacement material is apparent [8].  The generation of 
protein polymers that mimic native structural proteins offers a replacement strategy to 
develop a vascular graft with clinical performance results that match or exceed those of 
a native vessel.  The elastin protein component, which is responsible for distensibility 
and elastic recovery, appears to be critical in the development of mechanical properties 
that match the native blood vessel [48-52].  The work presented in this dissertation 
describes the design of novel protein polymers composed of repetitive amino acid 
sequences based on the primary sequence of native elastin.  These studies are the first 
evaluation of in vivo biocompatibility and long-term biostability of these protein polymers.  
Additionally, these studies are the first to report the monomer library concatamerization 
strategy in the synthesis of recombinant elastin-mimetic genes for protein expression in 
Pichia pastoris.  The methodologies established can serve as a framework for the 
design, evaluation, and characterization of the next generation of recombinant elastin-
mimetic protein polymers.    
As these studies provide the foundation work for the long-term goal of creating a 
vascular graft substitute which mechanically matches native vasculature, several 
recommendations for future investigations are proposed for each of the previous 
chapters.   
Chapter 2.  Elastin-Mimetic Protein Polymers Capable of Physical and 
Chemical Crosslinking.  We have employed genetic engineering in the design of novel 
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protein polymers composed of repetitive amino acid sequences or peptide blocks whose 
structural complexity imparts distinct mechanical, chemical or biological properties.  
Previously, our group has reported the synthesis of elastin-mimetic multiblock copolymer 
composed of identical endblocks derived from self-associating, hydrophobic sequences 
that display plastic-like mechanical responses (Ile-Pro-Ala-Val-Gly), separated by a 
central block that is both hydrophilic and elastomeric (Val-Pro-Gly-Glu-Gly) [1, 2].  
Significantly, these multiblock systems afford the ability to form physical or virtual 
crosslinked networks through the self-association of chemically similar domains under 
physiologically relevant conditions (pH 7.4, 37°C).   
Although, physically crosslinked protein-based materials possess a number of 
advantages over their chemically crosslinked counterparts, physical crosslinks and the 
related domains so formed may be deformed or damaged at applied stresses lower than 
those required to disrupt covalent crosslinks.  In the present study, we have synthesized 
a new class of recombinant elastin-mimetic triblock copolymer capable of both physical 
and chemical crosslinking.  We have demonstrated that chemical crosslinking provides 
an independent mechanism for control of protein mechanical responses.  Specifically, 
elastic modulus and tensile strength were enhanced and creep strain reduced through 
the addition of chemical crosslinking sites.  Additionally, we have demonstrated 
exceptional biocompatibility of gluteraldehyde crosslinked multiblock systems.   
Although the incorporation of chemical crosslinking sites improved the elastic 
modulus, ultimate tensile strength, and creep responses of these protein polymers, a 
moderate decrease in resilience was observed.  The targeted resilience criterion for 
crosslinked systems was greater than 80% at a 35-40% strain.  We suggest that 
crosslinking stabilizes the semi-rigid endblocks beyond the effects of physically 
crosslinking alone.  Since crosslinking was performed prior to preconditioning, the 
capacity of the chain entanglements between the midblock and the endblock domains to 
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structurally rearrange in resonse to the conditioning protocol may have been restricted, 
in particular, limiting the response of the elastomeric midlbock.  Future experiments 
could explore the effect of preconditioning prior to crosslinking and its subsequent 
effects on resilience.   
These protein polymers were designed for acellular as well as cell based 
technologies.  Gluteraldehyde was employed as a model crosslinking system but 
because of the cytotoxicity associated with this crosslinker, it is not adequate for 
crosslinking cell containing systems.  In this regard, other groups have investigated 
crosslinking agents which are non-toxic to cells, including THPP [101, 102] and a natural 
crosslinker, genipin [65, 92].  Future experiments could explore the efficiency of these 
crosslinkers for the LysB10 and R4.  Presently, a research thrust in our laboratory is to 
modify the LysB10 protein to include cell binding domains.  In such systems, it might be 
advantageous to crosslink proteins in the presence of cells, therefore biocompatible 
crosslinking systems will have to be investigated.   
The versatility of these materials has been displayed through the capacity to 
process triblock protein polymers into a variety of forms, including films, gels, and fiber 
networks [1, 5, 7, 253, 254].  The fabrication of artificial organs and engineered living 
tissues is dependent on the ability to generate and assemble novel materials into 
appropriate 2-D or 3-D structures and to precisely tailor material-related properties to 
achieve a desired clinical response [10].  It is likely that the design of artificial matrices 
will require the emulation of many, if not all, of the morphological and physiologic 
features of native tissues, thus reformulation of recombinant proteins into fiber networks 
has been investigated.  In this regard, electrospinning technology has been employed in 
the fabrication of elastin-mimetic fiber networks.  Specifically, in the late 1990s, our 
group was the first to demonstrate that electrospinning could be used to fabricate native 
and recombinant collagen and elastins into non-woven fiber networks comprised of 
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nanometer scale fibers that more closely mimic native scaffolds [41, 103, 255-257].  
Future experiments could explore using LysB10 and R4 in the generation of nonwoven 
fiber networks.  The ability to chemically crosslink LysB10 and R4 fibers has the 
potential to enhance mechanical responses.  A complete description of the science of 
electrospinning and the current pursuits of electrospinning elastin and recombinant 
elastin proteins can be found in Appendix B.     
As an example, electrospinning of the B9 protein polymer demonstrated 
promising results in the development of a protein scaffold for tissue engineering with 
mechanical behaviors approaching those of the elastin fiber network component of a 
blood vessel (unpublished data).  It is likely that mechanical behaviors and biostability of 
electrospun fiber networks can be enhanced with chemical crosslinking, thus LysB10 
and R4 afford the potential to create superior scaffolding materials.   
  Alternative methods to modulate mechanical behaviors of fiber networks, 
specifically thermal annealing, have been investigated.  Thermal annealing takes place 
in the hydrated state well above the protein’s inverse transition temperature (60°C).  
Thermal annealing has been employed as a processing strategy to alter the 
microstructure of polymeric materials, most often to increase the crystallinity or to 
modulate microphase separation in order to improve material or application dependent 
properties, including strength or stiffness [258-260], hardness [259], viscoelastic 
properties [261, 262], water absorptive properties [261, 263], or photoluminescence 
[263].   
Thermal annealing of B9 fiber networks showed encouraging results for 
improving network mechanical responses.  This treatment appears to induce a 
temperature triggered phase mixing of midblock and endblock regions over this thermal 
transition as determined from solid-state NMR, which has substantial impact on the 
hydration levels of fiber networks.  Significantly, a ~50% decrease in equilibrium swelling 
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ratio was assocated with thermal annealing.  Thermally induced enhancement to 
mechanical properties was observed as an increase in ultimate tensile strength and 
elastic modulus, and likely is a consequence of both thermally induced interpenetration 
of hydrophobic and hydrophilic domains and the resultant decrease in water content 
(unpublished data).  It is likely that we can exploit tunable control over these properties 
through thermal annealing in both fiber networks and film based systems therefore 
serving as a potential method of modulating mechanical responses of LysB10 and R4 
proteins processed as films, gels or fiber networks.   
Chapter 3.  Biocompatibility of Recombinant Elastin-Mimetic Proteins.  The 
triblock copolymer, designated B9, contains identical hydrophobic endblocks with 
[(IPAVG)4(VPAVG)] repeat sequences, separated by a central hydrophilic block with 
repeating units of [(VPGVG)2(VPGEG)(VPGVG)2] [2] and reversibly self-assembles from 
concentrated aqueous solution above the Tt of the hydrophobic endblocks (~18°C) to 
form a stable, water solvated, interlocking network.  In vivo studies have demonstrated 
excellent blood contacting properties in a primate arteriovenous shunt model when the 
triblock copolymer, B9, is coated as a thin film on the lumen of a small diameter vascular 
graft [7].  However, long-term biocompatibility and biostability for any physically 
crosslinked protein-based materials has yet to be fully defined.   
Specific reports documenting in vivo responses to elastin-mimetic protein 
implants have been limited; largely confined to several studies performed 15 to 20 years 
ago on proteins synthesized chemically and subject to radiation crosslinking [82, 121]  In 
these investigations, homopolymers or copolymers composed of VPGVG, VPGKG, 
VPGEG, IPAVG, and VPAVG reportedly did not induce significant inflammatory or 
immune mediated reactions [82, 121-123].   
The evaluation of in vivo biocompatibility has largely been based on 
characterizing local tissue responses to subcutaneously implanted materials where the 
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intensity and duration of the inflammation and wound healing, including capsule 
formation, is evaluated histologically [133, 134].  In this report, B9 implants initiated 
limited local inflammatory activity and displayed among the thinnest fibrous capsule 
observed for comparable implant sites and period of implantation [135-141].  FACS 
analysis of peritoneal lavage fluid harvested one week after injection confirms 
biocompatibility with no apparent difference in either the number or type of inflammatory 
cells observed in control non-injected mice and those implanted with a B9 gel.  These 
data suggest that this biopolymer does not induce a significant inflammatory reaction. 
To assess biostability of B9 hydrogels, we have employed magnetic resonance 
imaging (MRI) to monitor implant volume changes for the duration of the experiment 
[162-164].  To date, B9 hydrogel implants have been surprisingly stable, retaining 
greater than 60% of their original volume at seven months.  Most biomaterials whose 
integrity is based on self-association of hydrophobic constituents display short-lived 
stability in vivo and have been utilized for drug delivery or in wound healing applications.  
To our knowledge, these in vivo studies are the first to demonstrate that self-assembled 
protein-based materials of any form can be designed with structural stability approaching 
that displayed by many electrostatically or covalently crosslinked biopolymers.  This 
study is ongoing.  When significant biodegradation is observed, the implant and 
surrounding tissue will be excised and examined histologically.  
The work presented in Chapter 3 serves as a preliminary study to define 
protocols necessary for in vivo evaluation of these materials, including, endotoxin 
removal from amphiphilic recombinant elastin-mimetic proteins, fabrication of uniform 
hydrogel implants, histological evaluations of those hydrogels, and in vivo evaluation 
using the MRI, in addition to establishing methodologies for data analysis.   
Given the biostability of physically crosslinked systems, it would be interesting to 
evaluate the biostability of physically and chemically crosslinked systems and thus, the 
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impact that crosslinking has on the stability of these proteins in vivo.  Chemically 
crosslinked LysB10 and R4 hydrogels can be employed for these studies.  It is likely 
these proteins will exhibit enhanced biostability characteristics when crosslinked with 
gluteraldehyde or other chemical agents as compared to physically crosslinked B9 
proteins.   Given the longevity of these materials in vivo and their hemocompatibility, it is 
likely they will find utility as structural components of artificial organs and engineered 
living tissues, as carriers for controlled drug release, or as biocompatible surface 
coatings.   
Chapter 4.  Recombinant Elastin Protein Expression in Pichia pastoris.  
Recombinant elastin proteins have traditionally been expressed through microbial 
expression in E.coli [241].  Nonetheless, recognized drawbacks exist, specifically, 
difficult target protein purification and endotoxin contamination during protein extraction.  
As an alternative, the methylotropic yeast, P. pastoris was investigated for elastin 
expression and secretion.  Notably, P. pastoris secretes very low levels of native 
proteins, which simplifies purification protocols [1, 242].  Moreover, endotoxin is not 
present as a potential contaminant.  Tropoelastin, collagen, and silk-like protein have all 
been expressed in yeast with varying degrees of success [222-225]. 
In the present study, we have demonstrated the expression of a 56 kDa elastin-like 
protein, Yeast ELP, from P. pastoris based on the pentapeptide repeat 
(VPGVG2)VPGEG(VPGVG)2.  A novel strategy was devised to construct a gene with 
enhanced sequence diversity that encodes a highly repetitive elastin-like protein polymer 
for expression in P. pastoris.  Traditionally, large repetitive genes that comprise most 
protein polymers have been created using a concatemerization strategy where a 
pentapeptide repeat cassette (monomer repeat unit) is self-ligated in a head-to-tail 
fashion [2, 98].  While this strategy has proven suitable for expression of elastin-like 
proteins in E. coli, the translation of repetitive gene sequence, especially in other host 
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systems, is often associated with reduced levels of protein expression.  Moreover, 
repetitive sequences are often prone to mutational events. Given these potential 
limitations, we designed a modified concatemerization strategy in which seven dissimilar 
monomer repeat units, encoding identical pentapeptide repeat sequences, served as a 
monomer library for the concatemerization reaction.  We anticipate that this strategy will 
be useful for creating large, repetitive genes for a variety of expression systems; in order 
to more closely approach the genetic diversity inherent to native DNA sequences.    
The expression of Yeast ELP served as a model system evaluating the efficacy 
of the monomer library concatamerization strategy in the synthesis of repetitive elastin 
genes for expression in P. pastoris.  The ultimate goal of this work is to create an 
alternative expression system for multiblock elastin-mimetic protein polymers.  Yeast 
ELP was a model protein based upon the sequence of the elastomeric midblock domain 
(E) of the B9 protein [2, 4].  In order to construct a triblock (P-E-P), plastic-like domains 
(P) encoding the pentapeptide repeat, IPAVG, were constructed in an analogous 
manner using the modified concatamerization strategy described in Chapter 4.  This 
work has been conducted in collaboration with the laboratory of Vincent Conticello, PhD 
at Emory University.  Future work for this project includes assembling these elastic-like 
and plastic-like genes into a gene encoding the P-E-P triblock.  This assembly strategy 
for such triblock copolymers has been extensively detailed in Chapter 2.   
Yeast expression systems have become an increasingly attractive host for the 
expression of heterologous proteins [219, 220], due to their capacity to be incorporated 
into industrial-scale fermentation schemes characterized by high cell densities in 
relatively inexpensive media.  In addition, heterologous proteins have been efficiently 
secreted into the expression medium, resulting in low-cost recovery of the protein.  
Significantly, endotoxin is not produced by yeast, thereby simplifying purification and 
sterilization strategies.   However, Yeast ELP yields must be optimized for large-scale 
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expression.  There are a variety of variables which can be modulated to improve 
expression.  Fermentation will likely improve expression levels as higher cell densities 
can be achieved [228].  Additionally, it has been noted that induction levels increase 
three to five times in cells which are fed methanol at growth-limiting rates relative to 
growing cells in excess methanol.  A fermenter would allow for the controlled feeding of 
methanol and enable monitoring of methanol feed rate and dissolved oxygen levels 
within the culture [228].   Other alternatives which can be explored for optimizing protein 
expression including switching expression vector, employing alternative signal 
sequence, or utilizing a different P. pastoris expression strain.   
Additionally, the potential exists to generate glycosylated ELPs through 
incorporating appropriate glycosylation sites.  The synthetic strategy we employ in the 
genetic design allows for incorporation of glycosylation recognition sequences to be 
incorporated into the elastin gene, for example, Asn-X-Ser/Thr, the recognition sequence 
for N-glycosylation in P. pastoris.  Indeed, several approaches such as genomics, 
combinatorial libraries, and synthetic chemistry have been employed for sugar chain 
remodeling of human proteins in P. pastoris and other expression systems [250-252].  
Glycoengineering recombinant elastin molecules with strategically placed carbohydrates 
has the potential to increase molecular stability, solubility, and reduce immunogenicity 
[264].   
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Table A-1.  Coding sequences for DNA monomer repeat units of individual blocks of Lys B10 
Elastin Monomer (E1)             
                             Val    Pro   Gly    Ala   Gly    Val    Pro   Gly   Ala   Gly    Val    Pro    
AGCTTGAAGAC GTT CCA GGT GCA GGC GTA CCG GGT GCT GGC GTT CCG  
HinD III                   Bbs I 
Gly   Ala   Gly     Val    Pro   Gly   Ala   Gly     Val    Pro   Gly   Ala   Gly    Val    Pro   
GGT GAA GGT GTT CCA GGC GCA GGT GTA CCG GGT GCG GGT GTT CCA AGAGACGG 
     BsmB I                   BamH I  
Plastin Monomer (P1) 
                              Ile     Pro    Ala   Val   Gly   Ile     Pro    Ala   Val   Gly    Ile    Pro    Ala   Val   Gly       
AGCTTGAAGAC ATT CCA GCT GTT GGT ATC CCG GCT GTT GGT ATC CCA GCT GTT GGC  
HinD III                    Bbs I 
Ile     Pro    Ala   Val   Gly     Ile     Pro    Ala   Val   Gly   Ile   Pro 
ATT CCG GCT GTA GGT ATC CCG GCT GTT GGT ATT CCA AGAGACGG  
BsmB I              BamH I      
Lysine Insert (I) 
       Ile    Pro    Ala   Val   Gly    Lys    Ala   Ala    Lys   Val   Pro   Gly  Ala    Gly   Val    Pro    
AGCTTGAAGAC ATT CCA GCT GTT GGT AAG GCG GCC AAG GTT CCA GGT GCA GGC GTT CCA AGAGACG 
HinD III                     Bbs I                                                                                                               BsmB I                 BamH I 
Lysine Adaptor 
               Val   Pro    Ala   Val   Gly   Lys    Val   Pro                                                      Pro 
GATCC GTT CCA GCT GTT GGT AAG GTT CCA AGAGACGGTACCCGTCT CTT CCA 
BamH I                                                           BsmB I                                                      BsmB I  
Ala   Val   Gly   Lys    Ala    Ala   Lys    Ala    Stop 
GCT GTT GGT AAG GCG GCC AAG GCG TAA 
     HinD III 
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Table A-2.  Coding sequences for DNA monomer repeat units of individual blocks of R4 
Elastin Monomer (E2)               
                              Val    Pro   Gly    Ile   Gly    Val    Pro   Gly   Ile   Gly    Val    Pro    
AGCTTGAAGAC GTT CCA GGT ATT GGC GTT CCG GGT ATC GGT GTG CCA  
HinD III                   Bbs I 
Gly   Ile     Gly     Val    Pro   Gly   Ile   Gly     Val    Pro   Gly   Ile   Gly    Val    Pro   
GGC ATC GGT GTA CCG GGT ATT GGC GTT CCA GGC ATT GGC GTT CCA AGAGACGG 
     BsmB I                   BamH I 
Plastin Monomer (P2)               
                  Ile     Pro    Ala   Val   Gly   Ile     Pro    Ala   Val   Gly    Ile    Pro    Ala   Val   Gly       
AGCTTGAAGAC ATT CCA GCT GTT GGT ATC CCA GCT GTT GGT ATC CCA GCT GTT GGC  
HinD III                    Bbs I 
Ile     Pro    Ala   Val   Gly     Ile     Pro    Ala   Val   Gly   Ile   Pro 
ATT CCG GCT GTA GGT ATC CCG GCA GTG GGC ATT CCA AGAGACGG  
BsmB I                    BamH I              
Lysine Insert (I) 
       Ile    Pro    Ala   Val   Gly    Lys    Ala   Ala    Lys   Val   Pro   Gly  Ala    Gly   Val    Pro    
AGCTTGAAGAC ATT CCA GCT GTT GGT AAG GCG GCC AAG GTT CCA GGT GCA GGC GTT CCA AGAGACG 
HinD III                     Bbs I                                                                                                               BsmB I                 BamH I 
Lysine Adaptor 
               Val   Pro    Ala   Val   Gly   Lys    Val   Pro                                                      Pro 
GATCC GTT CCA GCT GTT GGT AAG GTT CCA AGAGACGGTACCCGTCT CTT CCA 
BamH I                                                           BsmB I                                                      BsmB I  
Ala   Val   Gly   Lys    Ala    Ala   Lys    Ala    Stop 
GCT GTT GGT AAG GCG GCC AAG GCG TAA 
     HinD III     
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Electrospun Elastin and Collagen Nano-Fibers  
* Modified from Sallach RS and Chaikof EL. Electrospun Elastin and Collagen Nano-Fibers. 
Submitted as a Chapter to Handbook of Natural-based Polymers for Biomedical Applications 
 
B.1 Introduction 
Current pursuits in the discipline of biomedicine, including artificial organs and 
engineered living tissues, are dependent on the ability to generate novel materials, 
fabricate or assemble materials into appropriate 2-D or 3-D structures, and to precisely 
tailor material-related properties in order to achieve a desired clinical response [10].  To 
that end, of profound importance is the development of artificial extracellular matrices 
(ECM). These structures are integral to the fashioning of microenvironments that are 
engineered for ideal mechanical and biological performance.  It is likely this design will 
require the mimicry of many, if not all, morphological or physiologic features of native 
tissues.  Decades of research have indeed demonstrated that as our ability to control the 
physical and biological properties of scaffolding materials improves, the quality of the 
tissues thus formed is enhanced.   
More specifically, molecular and supramolecular organization of type I collagen 
and elastin fiber assemblies establishes and important paradigm for the design in the 
development of novel scaffolds.  In the body, both tissues and organs are organized into 
3-D structures, each having specific architectures, directly dependent upon its biological 
function.  This architecture is believed to foster cellular ingrowth and proliferation by 
providing appropriate channels for mass transport and spatial cellular organization, thus 
directing new tissue formation.  The use of electrospinning technology in the arena of 
biomedicine has expanded the capacity of native and recombinant proteins to be 
fabricated into artificial extracellular matrices that more closely mimic native scaffolds.  
This chapter will review efforts in the development of novel structural protein materials, 
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fabrication of nanofiber networks using electrospinning technology, and applications of 
subsequent structures in biomedicine. 
 
B.2 Electrospinning as a biomedical fabrication technology 
Tissue and organ systems can be considered in general terms as a fiber-
reinforced composite material with associated mechanical properties largely a 
consequence of protein fiber networks.  Electrospinning has been applied in this regard 
as a mechanism for generating protein nanofibers and nanofiber networks. 
  
B.2.1 The science of electrospinning 
Electrospinning is a technique which relies on electrostatic forces to produce 
nanometer to micrometer sized fibers from polymer solutions or melts.  The generation 
of fibers by electrospinning was first patented in 1934 by Anton Formhals for textile and 
polymer science [265].  It was not until 1977 that a revived interest in electrospinning 
technology emerged within the field of biomedicine for applications of wound dressings 
[266].  Traditionally, engineering plastics and conducting polymers have been 
electrospun, but recently, with emphasis on tissue engineering and microelectronics, 
electrospinning protein polymers and carbon precursors have been explored.    
Electrospinning is essentially a drawing process utilizing electrostatic interactions 
in the creation of exceptionally long fibers with uniform diameters.  This process is 
different from traditional methods of fiber formation as it is based on elongation of a 
viscoelastic jet of polymer solution or melt.  Since elongation is achieved without contact, 
as with other drawing processes, this method is optimal for the development of delicate 
nanofibers.   
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Electrospinning is a variant of the electrospraying technique.  Both involve the 
use of voltage to create a jet of polymer solution.  Electrospray involves the development 
of small droplets of low concentration solutions, a result of varicose break-up, and has 
been employed in areas such as mass spectrometry and ink jet printing.  Alternatively, 
electrospinning results in the development of a small diameter fiber from highly viscous 
solutions. Fibers with large surface to volume ratios are produced through stretching as 
a consequence of the repulsion of surface charge and evaporation of the solvent [267]. 
There are three basic components to an electrospinning apparatus; a voltage 
supply, a spinneret connected to a syringe containing the polymer solution or melt, and a 
grounded collector.  A high voltage is applied to the spinneret while the polymer solution 
is slowly being extruded.  This induces evenly dispersed charges in a pendent drop at 
the tip of the spinneret, relaxing the fluid surface.  This surface charge and the external 
Columbic forces from the electric field combine to form a tangential stress [268].  This 
causes the drop to become distorted into a shape known as a Taylor cone.  At a critical 
threshold value, the electric field strength will overcome that of surface tension and the 
polymer solution will be ejected as a charged jet from the spinneret tip.  As the jet travels 
to the grounded collector it undergoes a stretching and whipping phenomena which 
substantially reduces the diameter of this fiber.  It is then collected on the grounded 
collecting apparatus creating a randomly oriented nonwoven fiber network [267]. 
 It was initially considered that the nanometer sized fibers created by 
electrospinning were the result of splitting and splaying of the jet due to the repulsion of 
surface charges [269].  However, with high-speed photography the ability to capture 
images of jet instabilities revealed that it was rapid oscillations within the jet that were 
responsible for stretching the fibers [268].   The jet was seen to travel only a few 
centimeters in a straight path thereupon it entered into a conical envelope and was 
continuously bent and whipped into a spiraling loop.  As the perimeter of the loops 
 136 
 
increased, the diameter of the jet decreased [270].  Thinning of fiber diameters as much 
as 3 orders of magnitude have been noted [271].  
 
B.2.2 Generation of nanofibers with controlled structures and morphology 
Fiber morphology and diameter of fibers generated using the electrospinning 
technique is controlled by the experimental design and dependent on both formulation 
and operation parameters.  Critical formulation parameters include solvent selection and 
protein concentration while operation parameters comprise applied voltage, gap 
distance, and flow rate.  Through the modulation of these parameters, distinct fiber 
morphologies are observed.  Many groups have investigated and optimized spinning 
conditions to produce desirable electrospun fibers.  The formation of beaded fibers has 
been a concern and as a result of investigations by Reneker and others options for 
eliminating beads have been characterized [41, 272].  Most fibers produced by optimized 
electrospinning conditions have circular cross-sections while some exhibit a ribbon-like 
morphology, a physical difference dependent on solution concentration.  For example, 
reports describing electrospinning of recombinant elastin proteins reveal solution 
concentration and flow rate to be most critical in controlling fiber morphology, as 
determined by high resolution microscopy.  At low concentrations of recombinant elastin 
protein, Lys-25, (5 wt %) short, fragmented fibers were formed with a triangle- or spindle-
shaped beaded morphology.  At higher concentrations (10 wt %) uniform fibers were 
generated with diameters ranging between 300-400 nm with little variation in morphology 
with infrequent exception of fiber splitting at triangle-shaped bifurcation points.  At 20 wt 
% a new morphological pattern was noted, defined by the emergence of flat or ribbon-
shaped fibers, which appeared twisted during deposition [41].   
Controlling the diameter of circular fibers has been widely discussed in literature.  
It has been determined that certain parameters are critical in influencing the diameter, 
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including polymer concentration, electric field strength, and flow rate.  The following plots 
summarize the experimental evidence of the relationship of electrospinning parameters 
to fiber morphology (Figure B-1) [271, 273, 274]. 
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Figure B-1. Experimental evidence summary plots of the relationship of electrospinning 
parameters to fiber morphology.  (A) Fiber diameter as a function of deposition distance 
at constant applied voltage, flow rate and protein concentration, (B) Fiber diameter as a 
function of applied voltage at constant flow rate, depositon distance, and protein 
concentration, (C) fiber diameter as a function of flow rate at constant applied voltage, 
deposition distance, and protein concentration, (D) Fiber diameter as a function of 
protein concentration at constant applied voltage, deposition distance, and flow rate.   
(adapted from Bowlin, VCU, http://www.egr.vcu.edu/bme/faculty/bme-bowlin.html) 
 
 
B.3 Generation of collagen and elastin small diameter fibers and fiber networks 
It is as integrated fiber networks that collagen and elastin constitute the 
fundamental structural elements of tissue. Thus, whether matrix proteins are produced 
 138 
 
synthetically or extracted from native tissue, it is likely that their versatility as scaffolds 
for tissue engineering applications will be significantly enhanced when reformulated into 
fiber networks. 
 
B.3.1 Native collagen and biological function 
As a principle constituent of the extracellular matrix, collagen is ubiquitously 
present in all connective tissues. The most abundant form of collagen isolated from adult 
connective tissues, such as skin, tendon, and bone, is type I collagen. Characteristically, 
it is composed of two α 1(I) chains and one α 2(I) chain, each slightly more than 1000 
amino acids long, and organized as a triple helix and stabilized primarily by hydrogen 
bonds [275].  A single molecule of type I collagen has a molecular mass of 285 kDa, a 
width of ~14 Å, and a length of ~3000 Å. In native connective tissues, type I collagen 
molecules form fibrillar elements twenty to several hundred nanometers in diameter that 
are organized into protein networks of varying architecture. Functionally, collagen fiber 
networks act to resist high strain deformation and in the process transmit forces, 
dissipate energy, and prevent premature tissue mechanical failure [276]. 
Collagen’s tensile strength, its stability in a biological environment, and its 
capacity to present specific ligands for cell surface receptors are properties that are in 
large measure dependent on the integrity of collagen’s characteristic triple-helical 
conformation [275, 277-279]. For example, the energy requirement for collagen 
degradation by collagenase I (MMP-1) is reduced by a factor of two if native fibrillar 
(multimeric) collagen is in a monomeric form, but by a factor of ten if the triple helix is 
denatured [280]. Thus, while the self-assembly of monomeric collagen into an ordered 
supramolecular system is an important physiologic mechanism for fibril formation, the 
uniquely coiled-coil triple helix is the dominant structural feature.  This structure dictates 
collagen stability and defines its mechanical properties. Consequently, the generation of 
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a robust load-bearing fiber network with appropriate mechanical integrity and biological 
function mandates maximal preservation of the collagen triple helix during the process of 
fiber formation. 
 
B.3.2 Collagen as a biomaterial 
Collagen is a biodegradable, biocompatible, and non-immunogenic structural 
protein, which makes it a suitable component for a variety of biomedical applications.  As 
a biomaterial, collagen has been predominantly used after processing into a dry powder 
or slurry, a hydrogel after solution phase cross-linking, or as a porous matrix with or 
without the addition of other components after freeze-drying [281]. For example, 
collagen has been used in cosmetic and urological surgery as an injectable compound 
for tissue augmentation [282]; in orthopedic surgery as an implantable matrix to promote 
bone growth [283-285]; and in plastic and general surgery as a topical agent for the 
treatment of both chronic non-healing wounds and burn injuries or as a template for 
tissue regeneration [286, 287].  However, it is as a native protein network that the 
versatility of collagen as scaffolding material could have the most profound impact in the 
area of tissue engineering.  Notably, collagen fiber networks constitute the principle 
structural elements of a variety of acellular bioprosthetic tissue substitutes, such as 
porcine heart valves and bovine artery heterografts, as well as other tissue derived 
matrices, including porcine subintestinal submucosa and bovine pericardium.  
 
B.3.3 Electrospun collagen nanofibers 
The production of collagen fibers has been reported, and has traditionally relied 
upon wet spinning processes that involve the extrusion of a protein solution through a 
spinneret into an acid-salt coagulating bath, which usually contains aqueous ammonium 
sulfate, acetic acid, isopropanol, or acetone. Further treatments in ethanol and acetone 
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solutions are often required for fiber dehydration. For example, Hirano et al. [288] 
described the production of chitosan-collagen fibers (d > 30 µm) produced by wet 
spinning from an aqueous acetic acid-methanol solution into an ammonia solution 
containing 40-43% ammonium sulfate. Likewise, Fofonoff and Bell [289] have reported a 
method for forming collagen fibers (d > 100 µm) by wet spinning from an aqueous acetic 
acid solution into a heated coagulating bath containing alkaline alginic or boric acid. The 
collagen fiber is formed by polymerization when the acid in the collagen is neutralized 
upon contact with the neutralizing solution and the fibers are subsequently dehydrated in 
acetone and ethanol baths. An additional example is provided by Furukawa et al. [290] 
in which solubilized collagen is spun into a coagulating bath containing an inorganic salt, 
such as sodium, aluminum, or ammonium sulfate.   Nonetheless, limitations of these 
approaches are recognized, including: (i) the use of conditions which likely induce 
significant conformational changes in native protein structure, including protein 
denaturation; (ii) the generation of fibers that range from tens to hundreds of microns in 
diameter and are much larger than those observed in native tissues [291-293]; and (iii) a 
reliance on biologically toxic solvent systems.  Although research in the area of wet 
spinning collagen has advanced and significant improvements have been achieved, an 
alternate approach for submicron collagen fiber formation, electrospinning, has recently 
been investigated [42, 45, 256, 294-297]. The architecture generated from this process 
is similar to that found in most native extracellular matrices, thus underscoring the 
electrospinning technique for design of novel scaffolds.   
The first report of electrospun collagen fibers employed a weak acid solution to 
electrospin type I collagen-polyethylene oxide (PEO) blends at ambient temperature and 
pressure.  High resolution microscopy was employed to resolve the influence of critical 
electrospinning parameters, specifically, solution viscosity, conductivity, and flow rate on 
subsequent fiber ultrastructure and size.  A variety of fiber microstructures were 
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observed: beaded, round, and ribbon-like filaments.  Ultimately, fibers of uniform 
morphology and ultrastructure, with average diameters of 100-150 nm, were generated.  
Significantly, this procedure outlined a non-toxic and non-denaturing approach for the 
generation of collagen containing nanofibers and nonwoven fiber networks (Figure B-2) 
[256].   
 
Figure B-2. SEM micrographs of PEO-collagen blended fibers spun from 2 wt% acid 
solution (34 mM NaCl) at a flow rate of 100 µl min-1 and at different collagen–PEO 
weight ratios: (A) 30 : 1, 50 000x magnification, (B) 10 : 1, 50 000x magnification (C) 5 : 
1, 50 000x magnification, (D) 2: 1, 50 000x magnification, (E) 1 : 1, 20 000x 
magnification, (F) 1 : 2, 50 000x magnification.  Fibers of uniform morphology and 
ultrastructure, with average diameters of 100-150 nm, were generated (adapted from 
[256]). 
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Similarly, other approaches have investigated various collagen sources and 
isotypes in the production of collagen nanofibers.  Typically, acid soluble type I collagen 
from rat tail tendons or calf skin have been utilized.  Type I and Type III collagen from 
human placenta has also been investigated [294]. Results indicate that identity and 
source of collagen are significant to the morphological, mechanical, and biological 
properties of the electrospun collagen networks. Additionally, solvent such as HFIP 
(1,1,1,3,3,3 hexafluoro-2-propanol)  have been used for electrospinning  of collagen.  
While some investigators have claimed preservation of native collagen structure, studies 
in our own laboratory demonstrate complete loss of triple helical structure when 
examined by circular dichroism spectroscopy, differential scanning calorimetry, or x-ray 
diffraction  [256, 297, 298]. 
 
B.3.4 Biological role of elastin 
Native elastin is a highly insoluble matrix protein which functions to provide 
extensibility and resilience to most tissues of the body. Elastin networks are responsible 
for maximizing the durability of tissues that are loaded by repetitive forces by minimizing 
the conversion of mechanical energy to heat which ultimately results in tissue damage 
[52]. In addition to the structural role, elastin creates an environment, which promotes 
proper cell function and modulates cellular attachment, growth, and responses to 
mechanical stimuli.   
Elastin fibers appear to exist as two morphologically different components, a 
highly isotropic amorphous elastin constituent within an organized microfibrilar scaffold 
[69]. Understanding of the mechanism of fiber assembly in native elastin is limited; 
however, it appears to take place in proximity to the cell membrane where microfibrils 
emerge as fiber bundles. Amorphous elastin is synthesized by smooth muscle cells as a 
soluble monomer, the 72 kDa precursor tropoelastin, and is secreted within each fiber 
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bundle. Reminiscent of natural rubber, it is organized into insoluble networks reminiscent 
through enzymatic crosslinking via oxidation by lysyl oxidase [71]. 
The distinctive composition of tropoelastin affords unique physical properties of 
this structural protein. Tropoelastin is rich in glycine (33%), proline (10-13%), and other 
hydrophobic residues (44%) rendering elastin an extremely hydrophobic protein [61].  
Tropoelastin contains distinct crosslinking and hydrophobic domains. Crosslinking 
domains are alanine rich, containing pairs of lysine residues thereby facilitating 
intermolecular crosslinking.  Alternatively, the hydrophobic domains within tropoelastin 
are composed of three-quarters valine, glycine, proline, and alanine. Investigations have 
elucidated that the precise sequence and size of this region are not critical for 
appropriate function; however, the total size of the protein polymer, 750-800 residues, is 
highly conserved among species [62]. 
 
B.3.5 Elastin as a Biomaterial 
 A failure of current acellular bioprostheses is the inability to exhibit mechanical 
properties that match those of native tissues, primarily a result of the loss or degradation 
of the elastin protein networks, thereby reinforcing the importance of elastin fiber 
networks is bioprosthetic design.  Isolated elastin matrices from acellular allo- and 
xenogenic tissues have been investigated as scaffolding materials with these studies 
confirming that native protein fiber networks can be used to fabricate an artificial 
scaffold.  However, these scaffolds often require the addition of structural proteins or 
must be seeded with cells to demonstrate proper biochemical and biomechanical 
function [40, 299].   Despite successes, recognized drawbacks, including tissue 
heterogeneity, incomplete cell extraction, the generation of ill-defined chemical 
crosslinks, progressive biodegradation, and the potential risk of viral transmission from 
animal tissue, continue to dampen enthusiasm for this approach. As a promising 
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alternative in the generation of biomimetic scaffolds, soluble elastin, derived either as 
fragmented elastin, in the form of alpha- or kappa-elastin, or as the natural monomer 
tropoelastin [42], have been successfully electrospun.  Additionally, through genetic 
engineering of synthetic polypeptides, novel elastin proteins have been created for such 
applications.  Utilizing these strategies affords the ability to tailor matrix composition and 
content, fiber size and architecture, or other features that may influence 3-D hierarchical 
tissue structure, thus enabling the ability to design a scaffold with precisely defined 
mechanical and biological properties. 
 
B.3.6 Recombinant elastin technologies 
It has been postulated that the generation of protein polymers that mimic native 
structural proteins and the assembly of these recombinant proteins either alone or in 
combination with naturally occurring matrix proteins provides an opportunity to optimize 
the mechanical properties of artificial tissues.  In this way, recombinant technologies 
have been pursued in the generation of elastin-mimetic protein polymers.  Through the 
structural characterization of the hydrophobic domains, the ability to base synthetic 
protein polymers on native elastin sequences is feasible. The pioneering work of Urry 
elucidated the elastomeric pentapeptide repeat, VPGVG, from human elastin, which now 
serves as the fundamental sequence extensively investigated by both chemical 
methodologies and recombinant technology [79, 80].  VPGVG is a common repeat unit 
within the hydrophobic domain of human elastin and is responsible for resultant elastic 
properties. Additionally, this domain is responsible for facilitating fiber formation through 
coacervation phenomena, behaviors consistent with native elastin. Spectroscopic 
analysis has revealed that native elastin, and likewise, protein polymers containing this 
repeat, exhibit β-turns and helical β- spiral conformations and display an inverse 
temperature transition defined by the generation of a more ordered system upon 
 145 
 
increasing temperature.  This loss of entropy is a consequence of protein folding into β -
spiral conformation and the subsequent reorientation of water from the elastin chain [81].  
Studies have elucidated the amino acid in the fourth (X) position (VPGXG) modulates 
the coacervation temperature with more polar amino acids increasing transition 
temperature [66, 67, 83]. Preservation of the glycine and proline residues maintain the 
structure and function of elastin analogs [83]. This discovery has led to the generation of 
recombinant elastin analogs designed for biomedical applications. For instance, this 
technology has been employed in the design of amphiphilic elastin protein polymers 
consisting of hydrophobic and hydrophilic domains. Through precise sequence design 
and control of processing conditions, these elastin analogs exhibit a wide range of 
properties advantageous for biomedical applications, as micelles, physically crosslinked 
hydrogels, or nanofiber networks [1-3, 5, 83]. Additionally, groups have incorporated cell 
binding domains, RGD or REDV, into elastin sequences to functionalize elastin matrix 
components for endothelial cell attachment [85, 86].  Genetic engineering strategies 
afford the ability to modulate macroscopic properties on the molecular level. Therefore 
the potential exists to generate synthetic polypeptides that mimic native proteins.  In this 
regard, there is an inherent opportunity to precisely engineer recombinant sequences to 
targeted design criteria such as tensile strength, elastic modulus, viscoelasticity, and in 
vivo stability, as well as the optimization of a desired host response.   
 
B.3.7 Generation of elastin and elastin-mimetic small diameter fibers and fiber 
networks 
As material for tissue engineering applications, elastin is intended to provide both 
mechanical support and potentially act as a scaffold for cellular repopulation. As such, it 
is likely when reformulated into fiber networks that the versatility of elastin as a 
scaffolding material will be significantly improved. In this regard, electrospinning has 
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been investigated as a mechanism for generating fibers with diameters < 1 µm.  When 
proteins are reformulated as fiber systems desired mechanical and biological properties 
can be achieved for biomedical applications. For instance, flexibility of a fibrous system 
can be controlled by either a decrease in fiber diameter or an increase in fiber number 
[300]. Thus, reformulating elastin proteins into fiber networks provides an additional level 
of control over the properties of the artificial matrix designed. Specifically, studies have 
indicated electrospun fabrics composed of small diameter fibers (<1µm) were found to 
have decreased porosity, increased fiber density, increased mechanical strength, as well 
as an optimized biological environment for promoting cell adhesion as compared to 
larger diameter fibers (7µm) [42, 47] 
Previous reports have demonstrated the feasibility of electrospinning soluble 
elastin as a single component system as well as in collagen-elastin blends.  
Concentrated solutions of soluble elastin produced fibers with average diameters from 
ranging from 100 nm to 3 µm have been generated with fiber diameter being highly 
dependent upon solvent systems utilized [42, 45, 46, 297].  Additionally, collagen-elastin 
blends produced fibers with diameters ranging from nanometers to micrometers [297, 
301].  Subsequent work has endeavored to improve the mechanical properties, 
specifically the compliance and mechanical strength of these elastin based matrices, 
through the addition of synthetic polymeric materials such as PLGA, poly (D,L-lactide-co-
glycolide).  Notably, compliance testing of collagen-elastin-PLGA electrospun scaffolds 
demonstrated behavior consistent with in vivo mechanical behavior of bovine arteries.  
Specifically, controlling the ratio of collagen, elastin, and PLGA facilitated the modulation 
of electrospinning characteristics as well as the strength and stability of the electrospun 
scaffold, as a burst pressure of nearly 12 times normal systolic pressure was observed 
[295]. 
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Recently, attempts to electrospun human tropoelastin have been undertaken.  
Interestingly, electrospinning of these materials produced ribbon-shaped fibers, several 
microns in diameter, which appeared to retain a unique periodicity, controlled by 
modulating the solution flow rate.  Morphology of these fibers is reminiscent of the 
topology of elastin in native tissues, for instance, the architecture of the elastic lamina 
within blood vessels [42]. 
Notwithstanding reports with promising results, important limitations remain 
associated with native elastin electrospinning strategies.   In consideration, significant 
investigation in the design of recombinant elastin proteins, microbial expression of these 
proteins, and reformulation into protein fiber networks by means of electrospinning has 
been explored.  The first report of fiber formation from an elastin-like analog was 
described utilizing a 81 kDa recombinant elastin peptide polymer, Lys-25, comprised of 
the repeat sequence (Val-Pro-Gly-Val-Gly)4(Val-Pro-Gly-Lys-Gly).  Electrospinning of a 
15-wt% solution afforded a fabric with a unimodal distribution of fiber diameters (Figure 
B-3). Moreover, in the absence of high rotational or translational speeds on a collecting 
mandrel, fiber orientation was random. Interestingly, pulsed field gradient NMR 
spectroscopy was utilized to access network porosity and pore size distribution in 3-D 
fabrics and revealed Lys-25 electrospun matrices as physiologically ideal for cellular 
seeding in that regard (Fig 4)  [41, 103].  While a number of elastin-mimetic protein 
polymers can be fabricated as fibers and covalently crosslinked, a family of recombinant 
elastin triblock copolymers containing chemically distinct midblocks have been 
investigated in the generation of virtually crosslinked fibers and fiber networks.  
Specifically, these studies demonstrate that self-assembling triblock elastin analogues 
have the capacity to form stable fibers, but without a requirement for chemical 
crosslinking [1]. As an example, electrospinning was used to produce tubular conduits 
from a triblock copolymer.  Mechanical properties were assessed in PBS at 37°C. 
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Hydrated samples displayed an elastic modulus of 0.29 ± 0.03 MPa, a strain to failure of 
151 ± 29%; values comparable to the elastin component of the arterial wall (Young’s 
modulus ~ 0.3 MPa) [30, 302]. 
 
 
 
Figure B-3.  First reported fiber formation from an elastin-like analog utilizing a 81 kDa 
recombinant elastin peptide polymer.  SEM micrographs of elastin-mimetic peptide fibers 
spun from 15 wt % solution at 50 (A), 100 (B), 150 (C), and 200 µl min-1 (D) flow rate.  
Electrospinning of a 15-wt% solution afforded a fabric with a unimodal distribution of 
fiber diameters (adapted from [41]). 
 
B.4 Generation of crosslinked fibers and fiber networks 
It is generally understood that crosslinking is necessary for the maintenance of 
biostability in engineered collagen and elastin scaffolds.  In native tissues, lysyl oxidase, 
a specific amine oxidase, catalyzes the formation of aldehyde cross-link intermediates in 
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the solid state providing intermolecular crosslinking within collagen and elastin networks. 
Presumably, the incorporation of various degrees of crosslinking can be used to further 
tailor and control the material properties of the scaffold to specific applications.   
 
B.4.1 Crosslinking collagen networks 
Glutaraldehyde is the traditional crosslinking agent for bioartificial devices.  While 
it has been shown to enhance stability and further reduce immunogenicity, it does exhibit 
potential cytotoxicity and late induction of collagen calcification.  Therefore, alternative 
crosslinking approaches have been reported, including chemical (carboiimide, 
diisocyanates, and polypoxy compounds) and solid state photocrosslinking.  For 
example, Chaikof and colleagues described the derivitization of type I collagen with 
methacrylate groups [103, 303] and cinnamate groups for photocrosslinking [304] while 
preserving collagen’s triple helical structure.  
 
B.4.2 Crosslinking elastin networks 
Crosslinking of native elastin, as well as synthetic elastin-mimetic protein 
polymers has most often been investigated using solution phase systems; either gamma 
irradiation [88, 90], chemical [95-97, 103], or enzymatic based approaches [305], as well 
as solid state photocrosslinking [303]. Nevertheless, for most biomedical applications of 
synthetic scaffolds, vapor phase glutaraldehyde crosslinking is currently the system 
utilized, with successful in vitro and in vivo biocompatibility results.  Directed efforts in 
alternative chemical crosslinking strategies, in which no additional chemical entities are 
introduced and stable amide linkages are formed, have also been investigated.  For 
example, mixed solutions of EDC (N-(3-dimethylaminopropyl)-N’-ethylcarboiimide 
hydrochloride) and NHS (N-hydroxysuccinimide) were employed to crosslink electrospun 
collagen-elastin scaffolds with no apparent alteration to fiber morphology as determined 
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my microscopy analysis.  Scaffold stability and biocompatibility was assessed in vitro 
through cell seeding of smooth muscle cells with promising results [297]. 
Alternatively, incorporation of reactive lysine residues into recombinant elastin 
design provides the ε-amino moiety of lysine for crosslinking using a variety of 
approaches. This strategy affords the ability to achieve precise control over the nature 
and degree of crosslinking, and facilitates spatial and temporal control over the reaction 
process.  Specific investigations into reactive group spacing as well as crosslinking 
strategies on the modulation of important biological behaviors of elastin analogs has 
been conducted with the general conclusion that the placement of well defined 
crosslinks enhance the biostability of elastin and improve biologically relevant properties.  
For example, methacrylate groups were incorporated into the protein polymer backbone 
in order to facilitate site-specific solid-state photocrosslinking using either UV or visible 
light activated photoinitiators [103]. Mechanical analysis confirmed superior biologically 
relevant behaviors comparable to the elastic behavior comparable to native elastin.  
Significantly, in response to deleterious effects of chemical crosslinking reagents, 
a new class of recombinant proteins have been investigated, self-assembling triblock 
elastin copolymers, which have the capacity to form stable fibers, but without a 
requirement for chemical crosslinking [1-3].   Due to the nature of the copolymer design, 
they form physically or virtually crosslinked systems.  Notably, nanofiber formation was 
influenced by solvent conditions with nanofibers in the diameter range of 100-400 nm 
generated utilizing a solvent which identically solvates both blocks of the copolymer 
while nanofibers with diameter ranging from 800 nm-3 µm generated from an aqueous 
solution which preferentially solvates only the midblock.  Subsequent mechanical 
evaluation indicates that modulation of elastic and plastic behavior of the triblock protein 
is directly dependent on the solvent systems used in fabrication.  In particular, 
mechanical evaluation of the triblock elastin protein fibers under physiological conditions 
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revealed elastic modulus and ultimate tensile strength comparable to that of native 
tissues such as the elastin component of the arterial wall (Young’s modulus ~ 0.3 MPa) 
[30, 302].   
 
B.5 Multicomponent electrospun assemblies 
It is likely that the molecular structure and supramolecular organization of 
collagen and elastin fiber assemblies within native tissues establishes an important 
paradigm for the design of a biomimetic scaffold.  Therefore, the hierarchal assembly of 
these protein fiber networks is essential for generating constructs with both enhanced 
biostability and blood contactability, as well as mechanical properties that closely match 
those of the native tissue.  As such, the potential of electrospinning multicomponent 
systems in the design of biomimetic scaffolds is substantial since it affords an additional 
level of control in vitro to recreate native architectures.      
In this regard, two electrospinning techniques have been employed to create 
nanofibrous bicomposites, multilayering electrospinning and multicomponent (mixing) 
electrospinning [306].  Multilayering electrospinning requires sequential deposition of two 
unique materials onto the same collector, such that a hierarchal ordered structure is 
obtained.  This method has been employed to fabricate constructs composed of 
synthetic polymers lined with biocompatible native proteins such as collagen, fibrin and 
laminin. 
As an alternate technique, mixing electrospinning, in which two unique materials 
are simultaneously electrospun from different syringes, ultimately yields a fiber network 
of mixed identity.  This method is of particular interest in creating tubular constructs for 
tissue engineering of blood vessels.  For instance, a bilayered construct can be 
engineered with an outer layer of circumferentially oriented fibers mimicking the tunica 
media and an inner layer of randomly oriented fibers acting as the elastic lamina of the 
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blood vessel [307].  This method has also been employed to modulate porosity and 
microvoid spaces within an electrospun scaffold through fiber-leaching.  Several such 
studies involving simultaneous spinning of PEO and other synthetic or natural polymers, 
followed by dissolution of the PEO component in water have been investigated in the 
modulation of scaffold architecture [256, 306]. 
Additionally, blended solutions have been investigated, specifically collagen-
elastin blends, which yield a fiber matrix in which singular components are 
indistinguishable.  These types of matrices have exhibited enhanced mechanical and 
biological behaviors compared to matrices composed of the individual components [45, 
46].  Collagen-glycosaminoglycan scaffolds have also been electrospun from blended 
solutions with a pore structure (mean diameter of 260 nm) similar to that found in native 
matrices. Upon vapor phase crosslinking, these scaffolds exhibited biostability and 
resistance to collagenases along with increased cellular proliferation when seeded with 
cells [295]. 
 
B.6 Electrospun nanofiber networks and the potential for the incorporation of 
living cells 
 
  Both collagen and elastin matrix proteins provide a useful physiological starting 
point for the creation of a biochemical and biomechanical environment that is optimized 
for enhanced cell adhesion, migration, proliferation, and differentiation.  Fabrication of 
these proteins into nanofiber networks provide the  potential to incorporate various cell 
types; endothelial cells, SMC, fibroblasts, stem cells, chondrocytes, osteoblasts, human 
or animal cells which have been genetically engineered to produce a protein of interest 
(eg, growth factor, peptide hormone, antiangiogenic protein). 
In vitro investigations indicate the architecture of electrospun networks supports 
mass transport and spatial cellular organization.  Specifically, as a consequence of the 
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fiber nano-dimensions, the surface-to-volume ratio, and the unique three-dimensional 
architecture within these electrospun matrices, movement of signaling molecules, 
nutrients, and metabolic waste is likely enhanced and cell-cell and cell-matrix 
interactions are facilitated [308].  Specifically, collagen and elastin scaffolds have been 
shown to promote cell adhesion, migration and proliferation of a variety of cell types in 
vitro, with promising results concerning biocompatibility and biostability. 
 
B.7 Future Trends: Biomedical applications for electrospun collagen and 
elastin nanofiber networks 
 
There is a long felt need for durable materials for medical and veterinary use in 
organ and tissue substitutes.  Such materials must be compatible with human and 
animal physiologies such that thromboses, inflammation and other harmful physiological 
reactions are not induced.  Furthermore, durable and biologically compatible materials 
which do not require lengthy preconditioning periods prior to implantation are required. 
Over the past decade, considerable effort has been directed towards developing 
scaffolds using both synthetic and natural polymers.  As the majority of human tissues 
and organs originate from hierarchically organized fibrous structures, electrospinning 
fiber networks is of particular interest in the development of these unique matrices.  
Importantly, scaffold geometry can be modulated for a variety of tissue engineering 
applications, simply by the shape of the collector, such that seamless and complex 
scaffold geometries can be fabricated.  Additionally, from a commercial distribution 
perspective, the electrospinning technique is a rapid and efficient technology which can 
easily be conducted utilizing a sterile technique to generate a material which will likely 
have a long shelf life. 
The many diverse areas of research in which electrospinning is being employed 
within biomedicine underscores the range of applications for which this technology can 
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be utilized.  These matrices not only mimic native ECM architecture, which ultimately 
reproduce native mechanical and biological performance, but also provide the 
opportunity to further tailor biological responses.   Additionally, the electrospinning 
technique provides enormous flexibility to tissue engineering of biocompatible matrices 
for a variety of applications.  These matrices have potential in drug delivery [304], 
vascular bioengineering of blood vessels and heart valves [44, 309], hard and soft tissue 
reconstruction, load bearing prosthetic materials, materials to facilitate wound closing 
and/or healing and stem cell delivery [310].  
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